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ABSTRACT  
EARLY HOST RESPONSES AND IMMMUNE SIGNALING TO 2009 PANDEMIC INFLUENZA A (H1N1) VIRUSES IN PRIMARY CELL CULTURE MODELS  
Rachael Lask Gerlach 
March 18, 2015 
Influenza A virus (IAV) subtypes and even genotypes within subtypes can 
show differences in tropism (host, cell type), magnitude of infection, immune 
response and progression of illness.  My dissertation focused on the 
development and use of two in vitro physiologically-relevant human cell culture 
models, well-differentiated normal human bronchial epithelial (wdNHBE) cells 
and human monocyte-derived macrophages (MDM) for the study of early IAV-
host interactions. These models have given new insight into early host responses 
to seasonal H1N1 (BN59) and two pandemic A(H1N1)2009 viruses or H1N1pdm 
herein. The H1N1pdm are clinical isolates from a fatal (A/KY/180/10) and 
nonfatal (A/KY/136/09) case. In the wdNHBE model, KY180 showed a 
significantly higher titer as compared to the other two viruses at 24 hpi (hours 
post-infection).  Interestingly, by microarray analysis, there were no significant 
differences in the host genome-wide expression intensity profiles of each virus 
following infection. Soluble cytokine measurements revealed increased apical 
and basal pro-inflammatory cytokine secretion overtime.  A key finding from our 
vii 
data was greater basolateral secretion of cytokines (IL6, CCL5, CCL4 and CCL2) 
by KY180-infected wdNHBE cells. This finding suggests that the basolateral 
signals from infected epithelial cells may differ in their potential for recruitment 
and responses elicited by recruited monocytes/macrophages.  
In the second model, I used an in vitro model of recruited “resting” MDMs 
to study virus-host interactions of the clinical H1N1pdm isolates. These viruses 
replicated in MDM albeit inefficiently. While titers were similar and remained 
relatively low for all isolates, pro- and anti-inflammatory expression levels differed 
markedly between KY180 as compared to KY136 and BN59. KY180 had delayed 
expression at 8 hpi of pro-inflammatory genes (CCL5, TNF, IFN, CXCL10). This 
apparent delay in response to KY180 depended on the mode of viral entry. For 
KY180, this occurred primarily through macropinocytosis, mapping to the HA1 
gene. In summary, my studies reveal subtle, yet important differences in IAV-host 
interactions that result in alterations of immune signaling in epithelial and 
macrophage cell culture models. Continued advancement of the in vitro human 
cell culture models for the study of IAV is important as they will allow mechanistic 
insight into the intricate biology of these viruses.  
viii 
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CHAPTER 1  
INTRODUCTION 
INFLUENZA VIRUSES, PAST, PRESENT, AND FUTURE 
Influenza viruses, family Orthomyxoviridae, are important respiratory 
pathogens in humans that circulate in a variety of hosts including humans, birds, 
water mammals, horses, dogs and pigs [1-4]. Influenza viruses are transmitted 
between and across species primarily by respiratory secretions and fomites [5]. 
Annual seasonal influenza virus epidemics in humans present a significant public 
health burden resulting in millions of infections and hospitalizations each year. 
Moreover, the highly associated morbidity and mortality impose an extensive, 
annual economic impact resulting from illness amounting to 10-16 billion dollars 
[6-10]. The annual global attack rate of seasonal influenza is estimated at 5 – 
10% in adults and 20 – 30% in children, with more than 200,000 hospitalizations 
and 41,000 deaths each year in the United States alone [7, 11]. Secondary 
bacterial pneumonia is a frequent complication of influenza infection [12, 13]. Co-
infections occur in approximately 25% of all influenza-related deaths with the 




The 2013 report from the International Committee on Taxonomy of 
Viruses show the Orthomyxoviridae comprise of five genera of which three are 
influenza viruses (influenzavirus A, influenzavirus B and influenzavirus C). Each 
genus has one viral species, respectively, Influenza A virus (IAV), Influenza B 
virus (IBV) and Influenza C virus (ICV).  All three genera cause human disease, 
with the best recognized and most pathogenic being IAV.  The viruses are 
grouped according to their antigenic relatedness which is driven from differences 
between the two main surface glycoproteins hemagglutinin (HA) and 
neuraminidase (NA) (Figure 1A) [19, 20]. IAV are the most common of the 
Orthomyxoviridae genera. IAV infect a range of mammalian and avian species 
and can cause pandemics, whereas, IBV circulate among in human populations 
and have not been associated with any pandemic [4, 20].  Similar to IBV, ICV has 
a limited host range and has been isolated from humans, pigs and dogs. Cases 
of ICV each year are very rare and have a minimal public health impact [21].  
In 1936, Smith, Andrews and Laidlaw isolated IBV from patients by 
infection of human nasal secretions in the ferret [22].  Subsequently, in 1983 
IBVs diverged into two antigenically and genetically distinct lineages 
B/Victoria/2/87-like and B/Yamagata/16/88-like viruses [23-26]. IBV resembles 
IAV when evaluated by electron microscopy [27]; however, there are key 
differences between the two viruses. First, the antigenic properties, which 
describe the immune response triggered by antigens on a virus, were shown to 
be different by serological assays (Figure 1A) [20, 28]. Where IAV has three 
membrane proteins, IBV has four proteins in the envelope: HA, NA, NB, and B 
3 
matrix protein 2 (BM2) [20, 29]. NB and BM2 are integral membrane proteins that 
are unique to IBV and function proton channels important for viral entry but are 
not necessarily important for viral replication [30, 31].    
Secondly, they differ in the length of the open reading frames and non-
coding regions [20, 32, 33]. As mentioned previously, the reservoir of IBV is 
humans, however, water mammals such as seals can become infected via 
human sewage released into the ocean [4, 26]. IBV can cause severe disease in 
humans and are responsible for an average of 24% of all laboratory-confirmed 
influenza cases annually [20, 34]. 
Compared to IAV and IBV, ICV infections cause a mild respiratory illness 
and are not thought to cause epidemics or pose any public health concern to 
humans [35]. From 1997-1998, two cases of ICV were reported throughout the 
entire season highlighting the rarity of these cases occurring during yearly 
outbreaks of IAV/IBV [36]. In contrast to IAV and IBV, ICV has only one surface 
glycoprotein, giving it only seven genomic vRNAs [20]. Further, while IAV and 
IBV have two major surface glycoproteins, HA and NA, ICV has only one, HEF 
(hemagglutinin-esterase fusion) [37]. Based on comparative sequencing studies 
using the HA protein, it was estimated that IAV HA gene diverged from the IBV 
HA gene more recently than from HEF gene (HA equivalent) in ICV [19].The 
seven vRNA segments encode three RNA dependent RNA polymerase (RdRp) 
proteins (PB2, PB1, PA),  hemagglutinin esterase-fusion (HEF) glycoprotein, 
nucleoprotein (NP), matrix (M1) and CM2 (membrane protein), and the 
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nonstructural proteins (NS1 and NS2) [20]. Like IBV, ICV does not have an 
animal reservoir minimizing the chance for reassortment across species.  
In this introduction, I review the current state-of the IAV structure and life 
cycle, the host immune response to infection in humans, and what is currently 
known regarding the historical emergence of new epidemic and pandemic 
influenza strains. 
INFLUENZA A VIRUS STRUCTURE 
 Classified as  enveloped viruses, the IAV virion is formed from a lipid 
bilayer derived from the host plasma membrane during assembly and budding 
(Figure 1A) [38]. The envelope consists of two glycoproteins, HA and NA, and a 
tetrameric proton channel protein matrix 2 M2 (Figure 1A). The HA and NA are 
commonly referred to as spike proteins based on their shape. Underneath the 
lipid bilayer of the viral envelope is a structural layer composed of matrix protein 
(M1) (Figure 1A). The virion contains eight vRNA segments which are single-
stranded and in the negative-sense; hence these viruses are further classified as 
negative-strand, single-stranded RNA viruses. The genomic segments are 
coated with NP (Figure 1A). The NP encapsidated vRNAs and the polymerase 
proteins form the viral ribonucleoprotein (vRNP) complex (Figure 1A). IAVs are 
primarily spherical viruses but some filamentous forms have been reported [39]. 
The filamentous phenotype has been mapped to specific genomic segments and 
genotypic differences in amino acid sequences within HA, NA, M1, and M2 [39-
44].The functions of each of the viral proteins are summarized in Table 1. The 
viral morphology will be described in further detail in the section on the life cycle.  
5 
NOMENCLATURE 
IAVs are divided into subtypes based on antigenic variations of their 
surface glycoproteins HA and NA [20]. At present, 18 different HA subtypes and 
11 different NA subtypes have been identified (H1 through H18 and N1 through 
N11 respectively) [3, 45]. Of those HA subtypes, six are associated with human 
disease (H1, H2, H3, H5, H7, and H9). The standard nomenclature system for 
IAV includes the following information: genus, host of origin, geographic origin, 
case/strain number and year of isolation (Figure 1B).  Additionally, the subtype 
for each of the glycoproteins is given in parentheses for type A.  
INFLUENZA A VIRUS LIFE CYCYLE  
ATTACHMENT AND BINDING 
The respiratory epithelium is a primary target for influenza virus infection 
and replication [20, 46]. The infectious cycle (Figure 2) begins with the binding 
and penetration of the plasma membrane, which is mediated by the HA [47].  
This surface glycoprotein is translated as a precursor, HA0, which is cleaved into 
HA1 and HA2 subunits by extracellular host cell proteases. Cleavage is required 
for HA1 to bind sialic acid (SA) receptors and HA2 to fuse with susceptible cells 
within the host respiratory tract [48]. HA2 is a transmembrane subunit that 
mediates membrane fusion between viral and endosomal membranes during 
endocytosis [20, 49, 50]. The cleavage (or activation) site lies close to the 
external face of the virion membrane and mutations within this site are a key 
determinant of IAV pathogenesis [51, 52]. Mutations within the HA cleavage of 
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H5 and H7 avian influenza viruses have been linked to pathogenicity of IAVs [53, 
54].  
Changes in the external loop of the HA0 cleavage site, which links the 
HA1 and HA2 together, alters the structure of HA molecules and can alter their 
sensitivity to host extracellular proteases [55]. Specifically, the HAO cleavage site 
has either a single or several Lys or Arg forming either a monobasic or multi-
basic cleavage site [55]. IAVs having a monobasic HAO cleavage site can utilize 
trypsin (or other trypsin-like serine proteases) for activation, with the tissue 
distribution of these protease typically restricted to the respiratory tract [56, 57]. 
IAVs having multi-basic HAO cleavage sites  can be cleaved by ubiquitous host 
proteases, such as furin, which can result in viruses that are able to infect and 
replicate systemically, and ultimately lead to more severe disease [48, 58].  
 For IAV, the HA show differences in their binding specificity for different 
two main SA receptors within the respiratory tract, alpha-2,3 and alpha-2,6 SA 
(Figure 3A) [20]. These binding preferences drive the location for virus replication 
in the upper and/or lower tract epithelial [59-61]. Further, the receptor-binding 
specificity of the HA is a major determinant of the host range, tissue tropism, 
pathogenicity, and transmissibility [62-64]. SA was first identified as being 
responsible for binding of influenza viruses more than 50 years ago [65]. In 
humans, the epithelial cells lining the respiratory tract have different distributions 
of alpha-2,6-SA (mainly upper) and alpha-2,3-SA (mainly lower) receptors 
(Figure 3A) [66]. Therefore, IAVs vary in their ability to infect upper or lower 
respiratory tract as depending on the binding affinity for the receptors.  For 
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example, the HA of the avian H5N1 influenza viruses preferentially bind to alpha-
2,3-SA [67, 68], while H1N1 preferentially bind to alpha-2,6-SA that predominate 
in the human upper respiratory tract [69-71]. Amino acids mutations that switch 
binding specificity from alpha-2,3-SA to alpha-2,6-SA are generally thought to be 
necessary, but not a completely sufficient requirement for the adaptation of IAVs 
for efficient growth in the upper respiratory tracts of mammals and permit 
airborne transmissibility [63, 72, 73].  
Most seasonal IAV strains infect the upper respiratory tract with limited 
lower respiratory tract involvement. Patients hospitalized due to the recent 2009 
pandemic influenza A (H1N1) virus (H1N1pdm) showed both upper and lower 
respiratory tract involvement [74]. While a number of the adult patients had pre-
existing comorbidities, many did not. Moreover a large percentage of children 
without pre-existing comorbidities presented with upper and lower respiratory 
tract involvement. This led some researchers in the influenza field to ask whether 
the HA had a broader specificity for human receptors since the HA of this virus 
had an avian origin [66, 74-76]. One avian signature of the HA is at the G 
position 222 in the HA [77, 78]. In the context of H1N1pdm, this specific mutation 
in the HA1 shows dual receptor specificity for both alpha-2,3-SA and alpha-2,6-
SA, with an affinity to macrophages and type II pneumocytes in the alveoli and to 
both ciliated and goblet cells in both the tracheal and bronchial portions of the 
respiratory tract [79, 80].   
The respiratory epithelium is a highly complex environment composed of a 
heterogeneous cell population, including secretory (Clara), goblet (mucus), 
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ciliated, and basal cells that differ in frequency and distribution depending on 
location in the lung (Figure 3B) [81]. In the small airways, additional cell types, 
alveolar type 1 and 2, dominate. These cell types differ in their expression of 
alpha-2,3-SA and alpha-2,6-SA receptors (Figure 3B) [66, 82]. Currently there 
are mixed conclusions reported regarding what cell type is preferred by seasonal 
IAV with data supporting binding to ciliated and/or non-ciliated (goblet) cells [61, 
66]. Seasonal and H1N1pdm IAVs enter and replicate efficiently in ciliated cells 
that line the epithelial cell layer in the large and small airways of the respiratory 
tract, while H5N1 enters and replicates more efficiently in non-ciliated cells (type 
II pneumocytes) within the small lower airways (Figure 3B) [74, 75, 83-87].  
Hence, the spatial distribution and concentration of potential receptors 
associated within different areas of the respiratory tract and/or different cell types 
are integral in the study of IAV infection and disease [75, 88-91].  
INTERNALIZATION 
Once bound to the SA receptor, IAV may enter via clathrin-dependent 
endocytosis however internalization of IAV also may occur via caveolae, non-
clathrin and non-caveolae pathways and by macropinocytosis (Figure 4) [92-96]. 
However, clathrin-mediated endocytosis has long been identified as the major 
route of IAV cell entry [95, 96]; and is by far, the best characterized endocytic 
pathway. Early insights into the pathways of entry of IAV in a susceptible cell line, 
Madin-Darby Canine Kidney Epithelial Cells (MDCK) were conducted by electron 
microscopy showing IAV pH-independent internalization into coated pits on the 
cell surface and coated vesicles in the cell cytoplasm within 7 minutes after viral 
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binding [95, 97]. These results provide evidence that IAV enter by clathrin-
mediated endocytosis; however, IAV was also observed to be within uncoated 
vesicles inside the cell suggesting an alternative, clathrin-independent, pathway 
of entry [97, 98].  
In clathrin-dependent endocytosis, IAV attachment to its SA receptor 
induces the binding of the adaptor protein clathrin to the cytoplasmic tail. The 
accumulations of clathrin on the inside face of the plasma membrane all the 
receptor. The accumulation of clathrin on the inside face of the plasma 
membrane allows clathrin to multimerize to form characteristic invaginations or 
clathrin-coated pits. These pits are then pinched off from the plasma membrane 
by membrane scission proteins DNM1/Dynamin-1 or DNM2/Dynamin-2 pinch 
which releases the virus inside the cell within the clathrin-coated vesicle (CCV) 
(Figure 4A) [99-103].  
Macropinocytosis or clathrin-independent endocytosis, is characterized by 
actin-dependent reorganizations of the plasma membrane forming protrusions of 
the plasma membrane that bring the virus into the cell through an invagination of 
the plasma membrane (Figure 4B, step 2) [104-106]. Macropinosomes are 
formed after fission events separate the invagination from the extracellular 
space, characterized morphologically as heterogenic vesicles that lack coat 
structures (Figure 4). Characterization of the early events of IAV infection by this 
route are very limited with only a few studies using inhibitors to show these 
viruses can actually enter via this route [104, 107].  Clathrin-coated vesicles and 
macropinosomes traffic and mature in a parallel manner (Figure 4) [108]. Both 
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are transported towards and fuse with early endosomes (EE), regulated by 
associated Rab5 GTPases [109]. Over the course of maturation the endosomes 
are acidified by membrane bound V-type proton ATPases and Rab5 GTPases 
are exchanged for Rab7, which then surrounds the late endosomes (LE) [109]. 
The endosomes travel along microtubules mediated by the motor protein dynein 
and once the pH within the LE undergoes acidification, the IAV virus escapes by 
membrane fusion [92, 110].  
Macropinosomes are formed after fission events separate the invagination from 
the extracellular space, characterized morphologically as heterogenic vesicles 
that lack coat structures. Clathrin-coated vesicles and macropinosomes traffic 
and mature in a parallel manner. Both are transported towards and fuse with 
early endosomes (EE), regulated by associated Rab5 GTPases. Over the course 
of maturation the endosomes are acidified by membrane bound V-type proton 
ATPases and Rab5 GTPases are exchanged for Rab7, which then surrounds the 
late endosomes (LE). The endosomes travel along microtubules mediated by the 
motor protein dynein. When the pH decreases, the virus fuses and its genome is 
released into the cytoplasm. 
ENTRY/FUSION 
In order for the virion to be released from the endosomal vesicle within the 
cell, it must fuse and undergo a pH-induced, conformational change [20]. Fusion 
of the virus particle with endosomal membranes and uncoating of viral 
ribonucleoprotein is mediated by the HA and M2 proteins [20, 111]. As 
mentioned before, once the HA0 is cleaved, the HA1 and HA2 become 
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functional. The HA1 subunit is responsible for binding of sialic acid receptor and 
then, once bound and internalized, the HA2 protein mediates the fusion and 
release of viral nucleic acid into the cellular cytoplasm as the endosomal pH 
drops (Figure 2) [112].  In its native state, the HA2 trimer forms a stem of three 
helical hairpins each fastened by the N-terminal fusion peptide which is buried 
within the core of a coil-coil structure [113]. Transport of virion cargo to the late 
endosome exposes the proteins to pH of ~5.0 which activates the ion channel 
activity of the tetrameric IAV M2 protein. This activation induces a conformation 
change resulting in the opening of the ion channel allowing hydrogen ions to 
diffuse into the interior of the virion. This reduction of the endosomal pH causes 
an irreversible conformational change, resulting in refolding of the HA2 to expose 
the hydrophobic fusion peptide from its buried position allowing extension of the 
fusion peptide toward the target membrane [113, 114]. To maintain its active 
fusion state, the HA2 relies on the structural constraints of the HA1 subunit, 
which acts as a clamp to keep the HA2 in correct orientation [112, 115]. Further, 
the vRNP complex must be functionally separated from the structural M1 protein 
within the endosomal compartment. Acidification weakens the interaction of the 
M1 and vRNP complex. This stimulates the uncoating of IAV RNP and allows the 
release of vRNP into the host cell cytoplasm [116, 117]. Once the viral envelop 
and endosomal membranes fuse, a pore is formed which allows the viral 
contents to be released into the cytoplasm [111]. 
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Early studies demonstrated that IAV envelope fusion was activated in 
acidic media at a pH of 5.0 [97, 118, 119]. Changes in the ability of the virus to 
undergo membrane fusion at slightly lower or higher pH can affect host tropism.   
Specific mutations within the HA1 (N142K) and HA2 (E47K, E374K) of IAV 
strains can confer a higher thermos-stability to these proteins and therefore lower 
the pH required for fusion as compared to those without these mutations [120-
122]. For example, some of the 2009 H1N1pdm viruses have a lysine at the 47 
amino acid position in the HA2 subunit of the stalk region of the HA instead of a 
glutamic acid [121]. This mutation was shown to correlate with a reduction in the 
pH of fusion and increased acid stability of the HA2 [121]. Further this change 
resulted in a higher thermal stability of the HA2 when exposed to high 
temperatures, which was seen to correlate with infectivity in ferrets. Because the 
ferret and human share similar lung physiology and similar sialic acid distribution 
[123], the increase in E47K infectivity in ferrets suggested a fitness advantage for 
the E47K change in humans [121]. Further, studies analyzing differences among 
the HA sequences in their intermolecular interactions found that a residue at 
position 374 (HA0 numbering) of the HA2 is critical for HA trimer stability and that 
a specific mutation, E374K improves the pH stability of those viruses [124].  
For avian IAV, the pH stability can also influence the outcome of 
infectivity. For example, changes of +0.4 and -0.5 units in the pH of activation by 
Y23H and K58I mutations in the HA1 gene reduced weight loss, mortality, 
shedding, and transmission of H5N1 in ducks [125]. Further, studies in vivo in 
mice and ferrets found that an increased tolerance to low pH (increased pH 
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stability) of the HA enhanced H5N1 growth in the upper respiratory tract of ferrets 
and mice [126, 127].  Additionally, Galloway et al. reported that the pH of fusion 
varies among different HA subtypes, and notably, the pH of fusion for most HAs 
from human IAVs ranged from 5.5 - 5.6, whereas HAs from avian IAVs ranged 
from 5.1-5.4 [128]. 
TRANSCRIPTION 
Once the vRNPs are released into the host cytoplasm, they are imported 
to the nucleus via an energy-dependent importin-alpha-importin-beta-dependent 
nuclear import pathway [129] (Figure 2). Briefly, importin protein importin-alpha 
recognizes the nuclear localization signals on IAV NP [130, 131] , PB2 [132, 
133], or PA/PB1 [134, 135], which is then recognized and bound to importin-beta 
transport receptor [136]. This complex diffuses through the nuclear pore complex 
and undergoes active RAN GTPase (RAN-GTP)-induced dissociation with the 
help of cytoplasmic RAN G-proteins, releasing the vRNP into the nucleus where 
transcription and replication take place [137, 138].  
Differences in how IAV strains use importin-alpha within the host cell have 
been shown to control host adaptation [139-141]. Specifically, mutations in PB2 
(D701N) and NP (N319K) alter the binding of vRNPs to importin-alpha in 
mammalian and avian cells, which limits RNP translocation into the nucleus of 
cells of a particular species while enhancing translocation in another [139]. More 
recent studies have shown a differential dependence on a specific importin-alpha 
proteins, with avian IAVs dependent on importin-alpha3 and mammalian IAVs 
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dependent on importin-alpha7 [142]. Regardless, once in the nucleus, mRNA 
and complementary viral RNA (cRNA) are transcribed from the vRNA template 
Viral transcription of the viral mRNAs is mediated by the heterotrimeric 
RdRp (PB1, PB2 and PA), NP and host-derived components (described below) 
[143, 144].  First the RdRp complex recognizes and binds to newly transcribed 
host cellular mRNAs containing a 5’ cap in the nucleus [145, 146]. The PB2 binds 
to the 5’ cap of the host pre-mRNAs followed by the endonuclease activity of the 
PA which cleaves 10-12 nucleotides from the 5’ end. This is commonly referred 
to as “cap snatching” [147]. The 5’-capped RNA serves to prime transcription of 
the viral template to produce viral mRNAs mediated by PB1 [148-150]. PB1 also 
adds a polyadenylated (poly(A)) tail by the ‘stuttering mechanism’ [151] on a 
sequence of uridine residues near the 5’ end of the viral genome [152]. Two of 
the smaller vRNAs, the M segment and NS segment in concert with the 
spliceosome are further processed to yield M1, M2, NS1, and NS2/NEP. These 
splicing events are critical for IAV infection and are regulated by host nuclear 
splicing machinery as well as NS1 IAV protein [153, 154].  Once completed, the 
viral mRNAs are transported  to the cytoplasm where they hijack host cell 
translational machinery to make IAV proteins [155] (Figure 2).  
TRANSLATION 
Once exported into the cytoplasm, viral mRNAs undergo translation on 
free and membrane bound ribosomes. IAV infection drives a selective translation 
of viral mRNAs over cellular mRNAs [156, 157]. This selective translation of viral 
mRNAs over cellular mRNAs has been suggested to be mediated in two ways. 
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First, the “cap snatching” mechanism limits newly synthesized cellular mRNA cap 
structures, resulting in premature degradation before nuclear export [158]. 
Second, viral translation occurs by selective recognition of sequences in the 
5′UTR of viral mRNAs [156]. The NS1 protein of IAV has been shown to bind the 
5′UTR of viral mRNAs and plays a critical role in suppressing the production of 
host mRNAs, including anti-viral host genes, by inhibiting the 3′-end processing 
(post-transcriptional processing) of host mRNAs [159-162]. Eukaryotic translation 
initiation is mediated by eukaryotic initiation factors (eIFs) interacting with the 
ribosomes and the mRNA [163]. IAV NS1 was shown to bind and recruit two of 
those factors, eiF4G and eiF4F, to the 5’UTR of viral mRNA thus increasing viral 
specific translation [164].  
Regulation of eIF phosphorylation can lead to increases or decreases in 
translational events within cells. Phosphorylation of the eIF2 prevents the 
exchange of GDP for GTP by eIF2B, thus preventing the 43S pre-initiation 
complex from forming and ultimately inhibiting protein synthesis [163, 165]. A 
correlation between enhanced phosphorylation of eIF4E and increased rates of 
viral protein synthesis has been reported in a lymphocyte cell line [166]. Within 
an infected cell, activated double-stranded-RNA-dependent protein kinase (PKR) 
blocks cellular and viral protein synthesis by phosphorylating the alpha subunit of 
the eIF2 translation initiation [167, 168]. The NS1 protein of IAV has been shown 
to regulate these phosphorylation events by binding to PKR [169]. Mutant IAVs 
unable to express NS1 displayed high pathogenicity in mice with fully active PKR 
[170-173]. The regulation of host and viral protein production by IAV plays an 
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important role in the viral life cycle as it limits host protein and enhances viral 
protein production.  
After IAV translation occurs proteins PA, PB1, PB2, NS1 and NP, are 
synthesized in the cytoplasm and transported back to the nucleus to perform viral 
genome replication. This occurs via their nuclear localization signals and 
importin-alpha [131, 133, 174, 175].  
REPLICATION 
Viral RNA replication starts with the synthesis of the cRNA from vRNA 
(Figure 2) [20, 176]. This process is mediated by the heterotrimeric RdRp (PB1, 
PB2 and PA), NP and host-derived components [143, 144]. Replication of the 
vRNA from the cRNA or cRNA from vRNA does not require a primer. This is 
possible because the 5’ and 3’ ends of the viral genomes and anti-genomes 
exhibit partial inverse complementarity and are able to base pair with one 
another to form a double-stranded promoter structure or “panhandle” that is 
recognized and bound by the viral RdRp [177-179]. The vRNA is combined with 
PB1, PB2, and PA to form the vRNP complex and shuttled to the cytoplasm for 
assembly at the plasma membrane and release. The mechanism for shuttling 
through the nuclear pore will be discussed in the following section. 
The N-terminus of the  NP protein contains an RNA-binding domain that 
plays a role in controlling the “switching” of RNA polymerase activity from 
transcription to replication [180]. Based on in vitro antibody depletion 
experiments, the NP protein binds the viral RNA template and act as an anti-
termination factor for replication [181]. Shapiro and Krug et al. further confirmed 
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the requirement of NP for IAV replication with experiments with temperature-
sensitive NP mutants which fail to synthesize cRNA, but not mRNA [181]. 
The RdRp has been implicated as a determinant of viral tropism [182]. A 
single residue in the PB2 of avian IAV, amino acid 627, regulates polymerase 
activity in a species-specific fashion [183]. PB2 derived from human viral isolates 
almost exclusively possesses a lysine at position 627 (K627), whereas in avian 
viruses glutamic acid (E627) at this position predominates [184]. The presence of 
an E627 mutation at this position has been shown to drastically reduce 
replication efficiency and pathogenicity in mammalian systems [184, 185]. 
Recently, Mehle et al., reported that the glutamic acid-to-lysine mutation allows 
avian IAV to escape, however, in human cells an amino acid at this position 
restricts replication [186]. Thus, identification and monitoring of emerging 
mutations that increase polymerase activity in species specific cell types are 
important for assessing pandemic potential of IAVs. 
NUCLEAR EXPORT 
In the nucleus, newly synthesized vRNA genomes, bound to NP, are 
joined with newly synthesized PB1, PB2, and PA to form vRNPs which travel to 
the cytoplasm through the CRM1 export pathway [187]. The vRNP complex does 
not interact directly with CRM1 to form an export complex but uses an adaptor 
nuclear export protein (NEP/NS2).  THE NEP/NS2 complex recognizes and 
binds to the export signal [188, 189] on the vRNPs and is followed by binding of 
the viral matrix M1 protein and CRM1, thus linking the viral RNP with CRM1 
[190-192]. Additionally, NS2 interacts with nucleoporins and serves as an 
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adaptor between vRNPs and the nuclear pore complex [187, 191]. The export 
pathway functions in a reverse manner to importin under the control of RAN 
cargo complex [130]. Dissociation of vRNPs from the exportin requires RAN-
GDP which occurs only in the cytoplasm. Mutations within the nuclear export 
protein can also drive  the adaptation of a highly pathogenic avian influenza 
(HPAI) virus such as H5N1 to mammalian cells enabling increased replication 
[193]. Other viral components such as HA, NA, and M2 are transported to the 
plasma membrane via the Golgi network and assemble with RNPs to form 
mature virus particles that are released from the cell via budding [20]. 
ASSEMBLY AND BUDDING 
During the final stage of IAV assembly, all 8 vRNPs are incorporated into 
the virion as it buds from the apical plasma membrane of the cell [194]. Studies 
have identified packaging signals in the 5’ and 3’ non-coding regions of the viral 
segments to mediate assembly [195-198].  IAVs utilize lipid raft domains in the 
plasma membrane of infected cells as sites of virus assembly and budding [199-
203]. Lipid rafts are regions of the plasma membrane that are variable in size and 
enriched with cholesterol [204]. For IAV, HA and NA associate with lipid raft 
domains; the transmembrane domain being a critical component of HA for strong 
affinity for these rafts [199-203, 205]. These raft-associated proteins can cause a 
merging of lipid raft domains which help concentrate proteins in a defined region, 
forming the viral ‘budzone’ [206]. The HA functions as an important piece of the 
budding machinery. However,  budding of the virion can occur without the HA, 
thus making other IAV proteins important to the process as well [207]. M1 has 
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been postulated to be the crosslink between the cytoplasmic portion of the HA 
and NA [202]; however, the domains required for this interaction have not been 
identified. As mentioned before, M1 binds to the newly synthesized vRNPs and 
by linking to the cytoplasmic tails of HA and NA suggests M1 is an important link 
to assemble the necessary viral components as the site of budding. Once 
assembled, budding results from HA induced membrane curving followed by 
detachment of the virion by NA cleavage of the sialic acid residues connecting 
the virion to the cell surface [208-211].  
IAV MORPHOLOGY 
IAVs are highly pleomorphic, showing mostly spherical (80-120nm 
diameter), but other forms have been reported including long filamentous 
particles (up to 400 nm long and 80-120 nm in diameter) (Figure 5) [20, 212]. 
Different strains of IAV vary in their shapes with filamentous forms of IAV being 
reported in the literature for many years [104, 213, 214]. Using a reverse 
genetics approach, the filamentous phenotype has been mapped to amino acids 
within HA, NA, M1, and M2 [39-44]. Changes in influenza  HA and NA have 
result in irregularly shaped virions possibly as a result of clustering of HA and NA 
on lipid rafts prior to viral budding causing membrane deformation; however, 
these mechanisms remain unclear [44, 215]. Recently, several studies have 
linked the ability to form filaments to sequence variations in the M1 protein [40, 
216, 217]. M2 has also been shown to have a role viral morphology [39, 218-
221]. Further, Rossman et al. found an amphipathic helix located within the M2 
cytoplasmic tail that is able to bind cholesterol, which may be necessary for both 
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filament formation and stabilizing the newly formed filamentous virus [39]. Recent 
work utilizing a filamentous strain of influenza virus (H3N2 Udorn) demonstrated 
that a filamentous IAV could  enter cells as efficiently as the spherical forms [92]. 
However, this occurs with slightly delayed kinetics suggesting yet another source 
of variation in IAVs that could affect viral entry and tropism.  
 
HOST IMMUNE RESPONSE TO IAV INFECTION 
CYTOKINE AND CHEMOKINE RESPONSES 
Infection of epithelial cells with IAV leads to the production of inflammatory 
cytokines and chemokines that initiate an innate immune response by recruiting 
monocytes, macrophages, and other leukocytes to the site of infection [222-224]. 
Specifically, in response to IAV infection, respiratory epithelial cells produce 
antiviral interferons alpha and beta (IFNα, IFNβ) [225, 226], leukocyte 
chemoattractants such as CCL5, CCL2, CXCL10, interleukin 8 (IL8), and 
migration inhibitory factor 1-alpha (MIP1α/CCL3) [227-231], and pro-inflammatory 
cytokines such as interleukin 6 (IL6), tumor necrosis factor (TNF) and interleukin 
1-beta (IL1β) [231, 232]. Most studies suggest a positive correlation between 
inflammatory cytokine response and disease severity in human infections [233, 
234]. For example, elevation of IL6 in the blood of humans infected with IAV has 
been linked to a greater number of intensive care hospital admissions and severe 
pneumonia [234]. Secretion of these cytokines and chemokines further activate 
bystander (uninfected) and cells of the immune system. Links between the lung 
microenvironment and disease outcome remain elusive.  
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PATHOGEN RECOGNITION AND INNATE IMMUNE SIGNALING 
Early host responses elicited by IAV within infected and bystander host 
epithelial cells are crucial to controlling the magnitude, duration and lethality 
caused by IAV infection [230, 231]. This initial innate immune response activated 
by IAV is triggered by pattern recognition receptors (PRRs) recognizing pathogen 
associated molecular patterns (PAMPs) within the infected cells (Figure 6, left 
panel) [235-237]. These receptors include Toll-like receptors (TLR), RIG-I-like 
receptors (RLR), NOD-like receptors (NLR) and C-type lectin receptors (CLRs). 
During IAV infection, toll-like receptors 3 and 8 (TLR3 and TLR7) within the 
internal endosome recognize the structural components of IAV viruses, including 
viral single-stranded RNA (ssRNA) and surface glycoproteins [238]. RIG-I-like 
receptors recognize viral RNA during viral replication whereas NOD-like 
receptors recognize both viral RNA and viral induced stress within the infected 
cell [238, 239]. Once activated, the PRR pathways further activate intracellular 
signaling cascades, such as nuclear factor-kappa beta (NFκB), interferon 
regulatory factor 3 and/or 7 (IRF3, IRF7) and mitogen-activate protein kinase 
(MAPK). Activation of these pathways leads to the induction of inflammatory 
cytokines and type I interferon (IFN) secretion from the infected host cells. RIG-I, 
which is known to be the main sensor of IAV infection, is crucial to IFN 
production as demonstrated in cells whose RIG-I has been suppressed resulted 
in an inability to produce IFN in response to IAV [236, 240]. Once secreted, IFNs 
can further stimulate antiviral signals through IFN-stimulated genes (ISGs) in 
infected and uninfected neighbor cells (Figure 6, right panel) [236, 237, 240-244].  
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ANTIVIRAL RESPONSES IN BYSTANDER CELLS 
One strategy the host cell uses to prevent virus proliferation occurs when 
virus-host interactions trigger a potent IFN antiviral response. The secreted IFN 
will activate bystander cells in the induction of IFN-stimulated genes (ISGs) 
whose protein products will assist in fighting off IAV infection and proliferation in 
the lung (Figure 6, right panel).  IFNs mediate their responses by signaling via 
specific receptors that bind to Janus kinases (JAKs) and activate signal 
transducers and activators of transcription (STATs). Activation of these pathways 
results in expression of a broad range of ISGs in the bystander cells, including 
PKR [245], MxA [246], RNaseL [247], and ISG15 [248].These genes serve to 
inhibit protein synthesis (PKR), induce RNA cleavage (RNaseL), or interfere with 
viral replication (MxA) [249, 250]. However, IAV have evolved multiple 
mechanisms to evade the ISGs, allowing the virus to replicate and transmit 
between hosts.   
 Strategies to evade and inhibit the IFN response include increased 
replication speed, inhibiting host protein synthesis, and decreasing the sensitivity 
to host-cell interferon stimulated effectors such as Mx1 [251]. The viral NS1 
protein is widely regarded as the common factor by which all influenza A viruses 
antagonize host immune responses by competing with cellular proteins for RNA 
binding which in turn prevents PKR and OAS activities [252].  
EMERGENCE OF NEW INFLUENZA VIRUSES 
Newly emerging IAV arise through mutations in the antigenic sites of HA 
and NA. Small alterations in these sites are referred to as antigenic drift, whereas 
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larger alterations caused by reassortment are referred to as antigenic shift [253]. 
Once inside the host, IAVs are targeted for clearance by the antiviral, innate, and 
adaptive immune responses. Reassortment of IAV genome segments results 
when two different virus genotypes or species infect the same host, exchange 
segments and undergo immunological selective pressure generating potentially 
novel, more “fit” viral mutants which escape or evade host immunity [253-256]. 
IBVs do not undergo this immunological pressure and, hence, mutate at a lower 
rate [257]. A study by Parvin et al. in 1986 reported the mutation rate for the NS 
gene of IAV A/WSN/33 (H1N1) (WSN) to be 1.5 × 105 mutations per nucleotide 
per infectious cycle [258]. More recent work in MDCK cells have shown the 
mutation rate of the  IAV NS gene is two to three times faster than the NS gene 
in IBV [259].  This variation and how quickly the viruses evolve is depicted using 
a phylogenetic tree for 14 NS gene sequences from IAV, IBV, and ICV (Figure 7).  
Drift and shift may vastly increase the diversity of circulating IAV strains. 
This diversity in turn allows for the survival of variants that escape pre-existing 
immunity in the population that may lead to widespread epidemics and potentially 
pandemics. New epidemics of IAV on average occur in the human population 
every 3 years with a similar process for IBV every 5 years [253]. Reassortment 
between IAV and IBV has not been shown to occur [260-262] despite the ability 
of IBV to cause significant morbidity and mortality every 1 in 3 years [263, 264]. 
This lack of reassortment is somewhat surprising but some studies have 
suggested the incompatibility between IAV and IBV occurs at the protein 
(complex formation) or viral RNA level (encapsidation) [264-266]. 
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At least sixteen HA subtypes and nine NA subtypes exist in animal 
species that humans have little or no prior immunity/exposure to, making them a 
potential source of antigenic shift [2, 253, 254]. When animal IAVs acquire 
mutations directly or by reassortment with human IAVs, the resulting antigenic 
shift can improve viral replication, fitness, and human-to-human transmission [2, 
254, 267, 268]. For example, in 2009, reassortment led to the emergence of an 
H1N1pdm with the capacity for transmission in human populations. This was as a 
result of mixing of influenza viruses from humans, birds and pigs, and will be 
discussed in more detail in the following section [269, 270]. To date, three 
subtypes of HA (H1, H2, H3) and two subtypes of NA (N1, N2) have caused 
pandemics in humans [2, 255, 267, 271] (Table 2).  
IAVs can be further described as low pathogenic (LP) or high pathogenic 
(HP) based on virulence in humans and/or poultry. Highly pathogenic influenza 
(HPAIV) viruses, H5N1 and H7N9, cause mortality and morbidity in millions of 
poultry when outbreaks occur [272-274].  HPAIV emerge from low pathogenic 
avian IAV (LPAIV) within domestic poultry populations. The emergence of HPAIV 
was a result of an insertion of basic amino acids at the HA cleavage site [275] 
that confers a selective advantage by altering the spacing in the cleavage site, 
making it more accessible by ubiquitous proteases [276]. Currently, the 
pandemic potential of HPAIV circulating in wild birds is being closely monitored in 
humans as ongoing phylogenetic analyses have revealed that antigenic drift 
continues to diversify the H5N1 virus [277-279]. 
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LPAIV and HPAIV spillover into human populations, however, they have 
not yet shown the ability to transmit between humans. H5N1 first emerged in 
1997 in Hong Kong where 18 human infections were identified and six of the 
patients died [280, 281]. Since 2003, 650 human infections with highly 
pathogenic H5N1 viruses have been reported to the World Health Organization 
(WHO) by 15 countries. About 60% of these people died from their illness [282]. 
Current concern with HPAIV is the potential for sustained inter-human 
transmission with the potential to cause significant morbidity and mortality.  
EMERGENCE OF THE 2009 PANDEMIC H1N1 
In late March 2009, an outbreak of a respiratory illness emerged in Mexico 
[283]. The causative agent was a novel H1N1 IAV that quickly spread across 
North America in April 2009 and across the world by May 2009 [284]. The 2009 
pandemic arose through a reassortment of two preexisting swine influenza 
viruses (Figure 8), a Eurasian avian-like virus and a North American triple 
reassortant [284, 285]. Epithelial cells of the pig trachea produce both alpha-2,3-
SA and alpha-2,6-SA [78, 284]. This is believed to be the reason why pigs can be 
infected with both avian and human IAV strains and serve as a ‘mixing vessel’ for 
the emergence of new viruses.  
The 2009 H1N1pdm virus initiated the first influenza pandemic of the 21st 
century [285-287]. Most illnesses caused by the H1N1pdm were acute and self-
limiting, with the highest attack rates reported among children, young adults and 
pregnant women. As compared to seasonal IAV, those infected with the 
H1N1pdm shared similar risk factors and common underlying conditions [288].  
26 
However, in contrast to seasonal IAV, most of the severe illnesses occurred in 
those younger than 65 years of age. Sources speculated that adults older than 
60 years of age were spared because of prior exposure to antigenically related 
influenza viruses earlier in life, resulting in the development of protective 
antibodies [289, 290]. In the United States, of the patients who were hospitalized 
with H1N1pdm, 32-45% were under the age of 18 years, with approximately 9-
31% requiring admission to an intensive care unit (ICU) [291] and 25-50% of 
patients were hospitalized or died with no previously reported coexisting medical 
conditions [292-296]. Together this illustrates the impact of viral genotype and 
host phenotype on disease progression. However, early in a new pandemic, it is 
challenging to predict the public health impact of a circulating genotype based on 
sequence alone. Improving our ability to predict the relationship of genotype and 
disease phenotype may provide better strategies for intervention and treatment.   
H1N1 INFLUENZA ISOLATE SPECIFIC DIFFERENCES 
ISOLATE SPECIFIC DIFFERENCES IN MICE 
The immune response to IAV infection in general is highly linked to 
differences in disease outcome [91, 233, 297]. Our laboratory has developed a 
unique panel of closely-related, clinical H1N1pdm isolates enabling hypothesis-
driven investigation into isolate-specific differences in host immune responses 
and viral determinants of the infection processes. Our panel of H1N1pdm clinical 
isolates were obtained from hospitalized patients (nasal swabs) from an on-going 
Severe Influenza Pneumonia Surveillance (SIPS) in the state of Kentucky [298]. 
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Further details of the SIPS project can be found on the study website, 
http://www.kyflu.net.  
Our laboratory isolated a panel of H1N1pdm strains from patients ranging 
in age from 31 to 58 years old with both males and females represented (Table 
3) [298]. The length of hospital stay and clinical outcome varied among this 
population (Table 3). We hypothesized that differences in disease severity of 
hospitalized patients, despite associated comorbidities, may be due to genetic 
variations in the circulating viruses that affect the trajectory of pathogenesis. To 
test this hypothesis, we first screened these 9 isolates in the DBA2 mouse 
model. The following summarizes the major results from Camp et al 2013 [298].  
Specifically, our data suggested that genotypic differences were present among 
these closely related genotypes. 
Using a previously established DBA2 mouse model of IAV infection, we 
observed IAV isolate-specific differences in immune responses among the panel 
of H1N1pdm isolates [298]. We characterized each isolate for viral infection, 
immune response and lethality. Using a principal components analysis based on 
a panel of key cytokine/chemokine responses, immune responses clustered into 
four general groups which correlated with virulence from low (group1) to high 
(group 4). The first group included what we considered a typical non-lethal 
course of disease in mice, and was exemplified by infection with the seasonal 
strain H1N1and H1N1pdm viruses. A second group included those strains with 
moderate lethality in the mouse model, and was similar to the first group in 
course of disease, but had increased inflammatory cytokines (e.g., IL6, KC, and 
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GCSF) and chemokines (e.g., MIG). The third group showed the highest level of 
chemoattractant chemokines, (e.g., MCP1, MIP1α, and CXCL10) and the highest 
levels of inflammatory cytokines late in infection (e.g., IL6, TNF, IL1β), but were 
similar to Group 2 in terms of lethality. The fourth group of isolates represents the 
most lethal, and relative to all other isolates, these were characterized by 
reduced responses of all cytokines and chemokines analyzed.  Most notably, 
these isolates failed to produce any IFNα/β or IL10 [298]. The host and viral 
factors responsible for these differences between isolates and the mechanisms 
of action involved remain unclear. 
As mentioned above, pro-inflammatory cytokine and chemokines are 
critical for recruiting immune cells to the site of infection that are key to clearing 
the virus, as well as activating the adaptive immune response [299-301]. Of 
importance, infection of primary human epithelial cells with H1N1pdm have 
shown a diminished induction of innate immune responses as compared to 
seasonal H1N1 [90]. Notably, recent findings suggest genotype-specific 
differences among H1N1pdm viruses as shown by their ability to induce varying 
degrees of early host antiviral and inflammatory responses in human respiratory 
epithelial cells [91]. Together these findings propelled the objectives of my thesis.  
OBJECTIVE OF DISSERTATION 
HUMAN EPITHELIAL CELL CULTURE MODELS TO STUDY IAV 
Animal models of influenza virus induced pathogenesis are essential for 
research efforts aimed at understanding the viral and host factors that contribute 
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to disease and transmission of influenza virus infection in mammals [63, 72, 302-
305]. These models also allow discovery and preclinical testing of antiviral drugs 
and vaccines aimed at reducing morbidity and mortality in the human population. 
However, these models do not allow specific dissection of human-host influenza 
specific interactions and mechanisms. Culture systems of primary epithelial cells 
from human airways provide valuable in vitro models for characterizing cellular 
tropism and IAV induced cell-specific responses and infectivity and dissecting 
these mechanisms [66, 90].  
Primary epithelial cell cultures offer numerous advantages, including 
greater control of experimental conditions and the ability to study epithelial cell 
function and specific responses in the absence of other cell types. When 
focusing on human disease, it is beneficial to use human cell lines to identify 
host-specific proteins associated with viral infection and replication to establish 
potential new antiviral targets. Information collected from the primary cell model 
can provide valuable information that would otherwise be difficult to obtain in 
vivo.  
The use of polarized/differentiated, primary human cell culture models that 
contains both types of SA receptors represent a more comprehensive model for 
infection and may be important to the advancement of our understanding of 
virus-host interactions such as those that modulate the outcome of IAV infection 
and disease [59, 84, 86, 91, 306]. During the 2009 H1N1 pandemic, pre-existing 
immune status and the existence of underlying chronic conditions definitely 
contributed to patient outcome; however, it is not entirely clear why some 2009 
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H1N1pdm-infected patients developed severe disease but others did not. We 
hypothesized that disease severity of certain hospitalized patients, despite 
associated comorbidities, may be due, additionally, to subtle genotypic variations 
in the circulating viruses that effect cellular tropism and intracellular responses. 
To further test this hypothesis, we compared the responses to two H1N1pdm 
isolates in both undifferentiated and well-differentiated human bronchial epithelial 
cells. 
HUMAN IMMUNE CELL CULTURE MODELS TO STUDY IAV 
In agreement with studies in patient populations, H5N1increases 
inflammatory cytokine in primary human lung epithelial cells [84] and immune 
cells, specifically macrophages [307]. Additionally, excessive recruitment of 
pulmonary macrophages and neutrophils correlates with severe infection with 
pandemic 1918 H1N1 influenza virus in the lungs of mice [222]. 
Immunopathology at the site of influenza infection suggests a role for immune 
cells infiltrates in severe influenza infection [308, 309]. Production of pro-
inflammatory cytokines by virus-infected monocyte/macrophages can potentially 
contribute to lung pathology by inducing the activation and migration of additional 
blood monocytes, as well as T and B cells to the site of infection. Additionally, 
pro-inflammatory cytokines such as IL1β, TNF and IFNα/β promote up-regulation 
of the MCP1, MCP3 and CXCL10 chemokines, resulting in amplification of the 
inflammatory/chemotactic signal and further recruitment of 
monocyte/macrophages and T lymphocytes to the site of infection [299]. 
Together, these data strongly suggest that innate cells and their associated 
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responses may effect influenza disease manifestation. To date there is significant 
gap in our knowledge of innate immune cells and their response to different 
strains of influenza virus and individual clinical isolates. Moreover, most of the 
studies published to date have focused on strains adapted to mouse and specific 
isolates of IAV. Hence my dissertation asks whether different phenotypic 
outcomes would arise from closely-related genotypes using primary cell culture 
models of human epithelial and macrophage cell culture models. 
SPECIFIC AIMS 
The increasing threat of epidemic and pandemic influenza underscores 
the need to better understand the immune response to influenza virus infections 
and to better understand the factors that contribute to different outcomes of 
disease. Epithelial cells and macrophages play central roles in the innate 
immunity and anti-viral defense against IAV. Severe disease outcomes are 
associated with hypercytokenemia and infiltration and response of macrophages 
in the lung [297, 310]. The main goal of this dissertation was to characterize IAV-
host interactions and define the viral determinants involved in the early host 
immune response to infection differentiating two genetically similar 2009 
H1N1pdm isolates from one another. This was examined with the following aims; 
1) To compare the infection of well-differentiated primary human bronchial 
epithelial cells by two H1N1pdm and seasonal IAV isolates in terms of viral titers, 
gene expression profiles by microarray analysis, the integrity of the epithelial cell 
layer, and the dynamics of the host cytokine and chemokine responses.  
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2) To compare infection and dynamics of the host response to genetically 
similar H1N1pdm IAV isolates in human monocyte-derived macrophages (MDM). 
3) To define the mechanism and map the isolate-specific immune 
phenotypes in MDM to specific viral molecular determinants.  
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Table 1.  Description of influenza A virus proteins. Information extracted from 
(Lamb and Krug, 1996 and Palese and Shaw, 2007 Fields Virology). IFN, 
interferon; Nt, nucleotide. 
Genome Segment Protein Name Length (Nt) Amino Acids Copies per virus Function 1 PB2 2341 759 30-60 Internal, virus replication 2 PB1 PB1-F2 2341 757 87 30-60 Internal, virus replication Internal, induction of apoptosis 3 PA 2233 716 30-60 Internal, virus replication 4 HA 1778 566 500 Surface glycoprotein, viral attachment, antigenic determinant, and membrane fusion 5 NP 1565 498 1000 Nucleocapsid protein, genome packaging, RNA transcription, and vRNP nuclear import 6 NA 1413 454 100 Surface glycoprotein, antigenic determinant, viral release from host cells through sialidase activity 7 M1 M2 1027 252 97 3000 20-60 Membrane protein stability Membrance protein, assembly and proton channel 8 NS1 NS2 (NEP) 
890 230 21 unknown 130-200 Internal protein, IFN antagonist Regulation of mRNA transcription and vRNP nuclear export   
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Figure 1.  Schematic of Influenza A virion and nomenclauture. (A) 
Representation of influenza A virion and the associated proteins including both 
structural and non-structural proteins. (B) Description of how the nomenclatures 
of influenza viruses are represented in the literature and in this dissertation. 
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Figure 2.  Life cycle of influenza A virus in cells. The virus binds to sialic acid 
residues on the cell surface and enters the cell by endocytosis. Influenza virsues 
enter through Clathrin-dependent and Clathrin-independent endocytosis and the 
vesicles formed then traffic through the endosomal pathways to the late 
endosome.The low pH in maturing or late endosomes triggers a conformational 
change of HA mediating fusion of viral envelope and endosomal membrane. The 
released genome in form of eight vRNPs translocates into the nucleus, where 
mRNA as well as vRNA synthesis take place. Viral proteins are then translated in 
the cytoplasm on ER-bound ribosomes and transported back into the nucleus to 
assist with viral replication.  New viral proteins (PB1, PB2, PA, NP) assemble into 
vRNPs in the nucleus, and are exported by the help of M1 and NS2 and 
transferred to the budding site. The virus buds presumably by a concerted 
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interaction of the spike proteins and M1 and is finally released by M2-mediated 
membrane scission. SA, sialic acid.  
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Figure 3.  Schematic of the human respiratory tract and distribution of influenza A 
receptors. (A) Shows the distribution and chemical composition of sialic acid 
receptors located in the upper and/or lower respiratory tract. (B) The diversity of 
where Influenza A viruses infect in the respiratory tract is depicted here. 
Seasonal IAVs predominantly infect the upper airways whereas highly 
pathogenic avian influenza infects the lower airways. In 2009, the H1N1 triple 
reassortment emerged with properties of both upper and lower airway tropic 
viruses.  SA, sialic acid; HPAIV, highly pathogenic avian influenza; pdm, 
pandemic; AM, alveolar macrophage  
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Figure 4.  Schematic of two of the known entry pathways utilized by influenza A 
viruses. (A) Clathrin-mediated endocytosis begins by accumulation of clathrin 
adaptor proteins on the inside facing side of the plasma membrane, allowing 
clathrin to multimerize and form clathrin-coated pits. These pits are then pinched 
off from the plasma membrane by membrane scission proteins releasing the 
virus containing vesicle inside the cell within the clathrin-coated vesicle. (B) 
Macropinocytosis is characterized by actin-dependent reorganizations of the 
plasma membrane forming protrusions of the plasma membrane that bring the 
virus into the cell through an invagination of the plasma membrane. Once inside 
the host cell, both macropinosomes and clathrin-coated vesicles traffic from the 
early to late endosome via adaptor proteins Rab 5 and Rab 7. Once in the late 
endosome, a pH drop induces a conformational change in the viral envelope 
causing viral RNP to be released into the cytoplasm.   
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Figure 5.  Cryo-EM micrographs influenza A virus structure. Influenza A viruses 
are pleiomorphic with both spherical (100-150nm) and filamentous viruses (250-
400nm) existing in nature. SEM images were kindly provided by Dr. Jason 




Figure 6.  Current model of the activation of pattern-recognition receptors (PRRs) 
after IAV infection. (A) In infected cells, interaction of PRRs (TLR3, TLR7, RIGI, 
MDA5) with their specific pathogen-associated molecules (PAMPs) induces 
signaling thru NFkB, MAPK, IRF3 and 7 leading ultimately to secretion of 
cytokines, chemokines, and type I Interferon. (B) Type I interferon can further 
bind to IFNAR (interferon receptor) on bystander cell and induce signaling 
through STAT and IRF9 which activates interferon stimulated genes, which 
further block viral translation and replication. Mito, Mitochondria; IFN, Interferon. 
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Table 2. Description of influenza A subtypes resulting from antigenic shift which have historically caused pandemics.  
Influenza A Virus Pandemics (Antigenic Shift) 
Year Subtype Severity of Pandemic 
1889 H3N2 Moderate 
1918 H1N1 Severe 
1957 H2N2 Severe 
1968 H3N2 Moderate 
1977 H1N1 Mild 




Figure 7. Phylogenetic tree demonstrating the variation in NS proteins of IAV, 
IBV, and ICV. The phylogenetic history was inferred by using the Maximum 
Likelihood method based on the Tamura-Nei model [1]. The tree with the highest 
log likelihood (-5152.9524) is shown. The percentage of trees in which the 
associated taxa clustered together is shown next to the branches. Initial tree(s) 
for the heuristic search were obtained automatically by applying Neighbor-Join 
and BioNJ algorithms to a matrix of pairwise distances estimated using the 
Maximum Composite Likelihood (MCL) approach, and then selecting the 
topology with superior log likelihood value. The tree is drawn to scale, with 
branch lengths measured in the number of substitutions per site. The analysis 
involved 20 nucleotide sequences. Codon positions included were 
1st+2nd+3rd+Noncoding. All positions with less than 95% site coverage were 
eliminated. That is, fewer than 5% alignment gaps, missing data, and ambiguous 
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bases were allowed at any position. There were a total of 763 positions in the 
final dataset. Evolutionary analyses were conducted in MEGA5 [2].  
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Figure 8.  Depiction of emergence of 2009 pandemic (reassortment). (Adapted 
from Medina et al. Nature Reviews Microbiology 2011). The 2009 pandemic 
arose through a reassortment of two preexisting swine influenza viruses, a 
Eurasian avian-like virus and a North American triple reassortant. Two segments, 
NA and M, derived from the Eurasian avian-like swine lineage and six gene 
segments originated from the North American triple-reassortant swine lineage. 
Specifically the HA segment of the virus was genetically very similar to the 1918 
H1N1 HA suggesting emergence from an avian source Epithelial cells of the pig 
trachea produce both alpha-2,3-SA and alpha-2,6-SA and could be the potential 
mechanism for the reassortment to occur in pigs. Pigs can be infected with both 
avian and human IAV strains and serve as a ‘mixing vessel’ for the emergence of 




Table 3. Panel of H1N1pdm clinical isolates obtained from hospitalized patients 
(nasal swabs) from an on-going Severe Influenza Pneumonia Surveillance 
(SIPS) program at the University of Louisville, Kentucky. 
Patient ID (Case number) 
Patient Age/Sex Hospital Admission Date 
Nasal Swab Sample Date LOS (Days) Mortality 
80 31/F 9/30/2009 9/30/2009 10 Died 
96 51/M 10/24/2009 10/26/2009 4 Survived 
99 35/F 10/28/2009 10/29/2009 3 Survived 
104 58/M 10/30/2009 11/4/2009 2 Died 
108 57/F 11/2/2009 11/3/2009 19 Survived 
110 54/F 11/3/2009 11/4/2009 3 Survived 
136 46/M 12/10/2009 12/11/2009 8 Survived 
180 53/M 3/24/2010 4/1/2010 19 Died 
190 55/F 4/10/2010 4/15/2010 12 Died 
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CHAPTER 2 
 EARLY HOST RESPONSES OF SEASONAL AND PANDEMIC INFLUENZA A VIRUSES IN PRIMARY WELL-DIFFERENTIATED HUMAN LUNG EPITHELIAL CELLS  
OVERVIEW 
Replication, cell tropism and the magnitude of the host’s antiviral immune 
response each contribute to the resulting pathogenicity of influenza A viruses 
(IAV) in humans. In contrast to seasonal IAV in human cases, the 2009 H1N1 
pandemic IAV (H1N1pdm) shows a greater tropism for infection of the lung 
similar to H5N1. We hypothesized that host responses during infection of well-
differentiated, primary human bronchial epithelial cells (wdNHBE) may differ 
between seasonal (H1N1 A/BN/59/07) and H1N1pdm isolates from a fatal 
(A/KY/180/10) and nonfatal (A/KY/136/09) case. For each virus, the level of 
infectious virus and host response to infection (gene expression and apical/basal 
cytokine/chemokine profiles) were measured in wdNHBE at 8, 24, 36, 48 and 72 
hours post-infection (hpi). At 24 and 36h post-infection, KY180 showed a 
significant, ten-fold higher titer as compared to the other two isolates. Apical 
cytokine/chemokine levels of IL6, IL8 and GRO were similar in wdNHBE cells 
infected by each of these viruses. At 24 and 36 hpi, NHBE cells had greater 
levels of pro-inflammatory cytokines including IFNα, CCL2, TNF, and CCL5, 
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when infected by pandemic viruses as compared with seasonal. Polarization of 
IL6 in wdNHBE cells was greatest at 36 hpi for all isolates.  Differential polarized 
secretion was suggested for CCL5 across isolates. Despite differences in viral 
titer across isolates, no significant differences were observed in KY180 and 
KY136 gene expression intensity profiles. Microarray profiles of wdNHBE cells 
diverged at 36 hpi with 1647 genes commonly shared by wdNHBE cells infected 
by pandemic, but not seasonal isolates. Significant differences were observed in 
cytokine signaling, apoptosis, and cytoskeletal arrangement pathways. Our 
studies revealed differences in temporal dynamics and basal levels of 
cytokine/chemokine responses of wdNHBE cells infected with each isolate; 
however, wdNHBE cell gene intensity profiles were not significantly different 
between the two pandemic isolates suggesting post-transcriptional or later 
differences in viral-host interactions 
INTRODUCTION 
The 2009 pandemic H1N1 influenza virus (H1N1pdm) arose through 
reassortment of two preexisting swine influenza viruses, a Eurasian avian-like 
virus and a North American triple reassortant virus [311, 312].  Epidemiological 
data illustrated the speed of global spread of the 2009 pandemic virus; including 
significantly high infection attack rates in children and an 80% of H1N1pdm 
deaths in people younger than 65 years of age [313]. This was unlike seasonal 
IAV where morbidity and mortality are mainly seen in the elderly [314].  The 
illness associated with H1N1pdm infection was, however, very similar to 
seasonal influenza [315].  The risk factors associated with human cases of 
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H1N1pdm mirrored those of seasonal influenza [313], although in contrast to 
seasonal influenza, a greater proportion of severe and fatal cases had a pre-
existing chronic illness [313, 314, 316].  The most common underlying chronic 
conditions among hospitalized patients were respiratory disease, asthma, cardiac 
disease, and diabetes [292, 313, 315]. Immunohistopathology of patients with 
lethal disease confirmed positive for H1N1pdm identified the major cellular 
targets of infection as being upper respiratory epithelial cells, type II 
pneumocytes, and occasionally macrophages, which is similar to the pattern 
previously observed in H5N1 cases [295]. 
  Most seasonal IAV strains infect primarily the upper respiratory tract with 
limited lower respiratory tract involvement. The ability of H1N1pdm viruses to 
infect the lungs within lower respiratory track has been attributed to a broader 
specificity in the binding of the H1N1pdm surface HA with the alpha-2,3-SA 
(common on ciliated cells) and alpha-2,6-SA (common on non-ciliated secretory 
cells) [66, 74-76].  There are mixed conclusions in the field regarding what cell 
type is "readily" infected by seasonal influenza strains, with data supporting both 
ciliated and non-ciliated cell infections [61, 66]. Seasonal IAV and H1N1pdm 
viruses enter and replicate efficiently into non-ciliated cells which are present in 
the epithelial cell layer in both the large and small airways of the lower respiratory 
tract, while H5N1 enters and replicates more efficiently in ciliated cells within the 
small airways [74, 75, 83-86]. Hence, the spatial distribution and concentration of 
potential receptors associated within different areas of the respiratory tract and/or 
different cell types are integral in the study of IAV infection and disease [75, 88-
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91]. Further, while the lung epithelium is a primary target for infection [46], it is a 
highly complex environment composed of a heterogeneous cell population, 
including secretory (Clara), goblet (secretory/mucus), ciliated, and basal cells 
that differ in frequency and distribution depending on location in the lung [317]. 
The use of polarized, primary cell culture models that contains both types of sialic 
acid receptors and represent a more comprehensive model for infection are 
important to the advancement of our understanding of virus-host interactions 
such as those that modulate the outcome of IAV infection and disease [59, 66, 
84, 86, 306].   
Early host responses elicited by IAV of host epithelial cells likely control the 
magnitude, duration and lethality of infection.  Once infected by IAV, cells 
respond by eliciting antiviral response genes and pro-inflammatory/ chemotactic 
cytokines and chemokines [230, 231]. This initial innate immune response is 
triggered by pattern recognition receptors (PRRs) within the cell. PRR pathways 
further activate intracellular signaling cascades, such as nuclear factor-kappa 
beta (NFκB) and mitogen-activate protein kinase (MAPK). Activation of these 
pathways leads to the induction of inflammatory cytokines and type I interferon 
(IFN) secretion. This further stimulates the antiviral signals through IFN-
stimulated genes (ISGs) [236, 237, 240, 241, 243, 244].  Pro-inflammatory 
cytokine  and chemokine products are critical  responses as they are important 
for recruiting immune cells to the site of infection that are key to clearing the 
virus, as well as activating the adaptive immune response [299, 301].  Of 
importance, infection of human epithelial cells with H1N1pdm virus have shown a 
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diminished induction of innate immune responses as compared to seasonal 
H1N1 [90].  Notably, recent findings suggest isolate-specific differences among 
H1N1pdm viruses as shown by their ability to induce varying degrees of early 
host antiviral and inflammatory responses in human respiratory epithelial cells 
[91].   
To probe potential differences in early infectivity and host responses of cells 
infected with seasonal or pandemic IAVs, we utilized a polarized, model of 
primary, well-differentiated normal human bronchial epithelial (wdNHBE) cells.  
We hypothesized that early stages of infection in the airway epithelium may differ 
in terms of replication and host immune responses between a H1N1 seasonal 
isolate (A/BN/59/07) and two H1N1pdm strains shown to have fatal (A/KY180/10) 
and nonfatal (A/KY/136/09, A/BN/59/2007) outcomes in hospitalized patients 
(Table 4) [298].  The two H1N1pdm clinical isolates (KY180 and KY136) differ in 
their pathogenicity and cytokine/chemokine profiles in a DBA/2 mouse model 
[298].  In this study, we demonstrate a comparison of infection of wdNHBE cells 
with each IAV isolates show differences in virus titers and the dynamics of the 
host cytokine and chemokine responses. We show that infection with the lethal 
H1N1pdm isolate (KY180) alters the structure and cellular integrity of the 
epithelial layer, replicates more efficiently, and results in an increased, polarized 
pro-inflammatory cytokine and chemokine responses.  Interestingly, the 
microarray profiles of the antiviral signaling pathways do not correlate with 
differences in the virus titer of host cytokine and chemokine responses.  This 
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suggests that post-transcriptional events may mediate the isolate-specific nature 
of the host cytokine and chemokine responses.  
METHODS 
Viruses and cells.  The 2009 H1N1pdm IAV strains used herein were 
A/KentucKY180/2010, (KY180), and A/KentucKY136/2009, (KY136), from nasal 
swabs taken from a fatal and non-fatal case, respectively [298].  The GenBank 
accession numbers for KY180 and KY136 are provided in Table S1. The 
seasonal H1N1 IAV vaccine strain A/Brisbane/59/2007 (BN59) was kindly 
provided by the Centers for Disease Control and Prevention, Virus Surveillance 
and Diagnosis Branch, Influenza Division.  Viral seed stocks were prepared as 
previously described [298].  Virus titers were determined by TCID50 (50% tissue 
culture infectious dose) using MDCK (Madin-Darby Canine Kidney Epithelial 
Cells) as described previously [298] and calculated using the method of Reed 
and Muench [318].   
 All cell culture reagents were purchased from Invitrogen unless otherwise 
noted.  The human lung bronchial epithelial (Calu3), human adenocarcinomic 
alveolar basal epithelial (A549), and MDCK epithelial cells (ATCC) were cultured 
in Dulbecco’s minimum essential medium supplemented with 5 mM L- glutamine, 
1% pen-strep and 10% fetal bovine serum at 37°C under 5% CO2.  
Undifferentiated (udNHBE) cells were purchased from Lonza and cultured 
according to the suppliers instructions in serum-free, hormone supplemented 
bronchial epithelial growth media.  
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  Primary wdNHBE cells (EpiAirway PC-12, MatTek Corporation) were 
shipped in 12-well plates with agarose embedded in the basal layer and air 
apically after being maintained for 28 days under an air-liquid interface. Upon 
arrival, the transwell inserts were removed and placed into a 12-well plate with 
media in the basal compartment (AIR 100 complete growth media, MatTek). No 
media was added to the apical layer. Cells were incubated at 37°C, 5% CO2 and 
the basal media was changed after 24 h. At this point the cells were ready for 
infection and this is described in the next section. 
In vitro IAV infection. Infection of continuous and primary cells lines were 
performed in triplicate for measurement of virus production, immune responses 
or microarray studies. Each experiment (except for microarray) was replicated 
three times. Calu3, A549, MDCK and udNHBE cells were infected with KY180, 
KY136, BN59 or mock-infected (using viral growth media as specified in prior 
section) at a multiplicity of infection (MOI) of 3 for 1 h at 37°C, 5% CO2.   IAV 
infection of Calu3, A549 or MDCK included 2 µg/ml of tosylsulfonyl 
phenylalanylchloromethyl ketone-treated trypsin (TPCK, Sigma) and 0.2% BSA 
in the media.  
WdNHBE cells were washed twice with Dubelcco’s phosphate buffered 
saline (DPBS) to remove mucus accumulation and infected at an MOI of 3 in 
triplicate in replicate experiments from a total of three donors. After 1 h, the 
apical layer was washed twice with DPBS to remove unbound virus.  Basal 
medium was removed and replaced with complete medium.  At each time point 
analyzed, the basal media was removed and apical layer washed twice with 0.5 
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ml DPBS supplemented with 0.2% BSA and stored at -80oC until use.  Cells were 
collected in TRIzol and stored at -80°C until used for RNA and protein extraction.   
Quantitative RT-PCR (qRT-PCR). Total RNA from each set of viral-infected 
cells was extracted at designated time points using TRIzol as described by 
Invitrogen. cDNA was synthesized from total RNA with random hexamer primers 
and Superscript III reverse transcriptase (Invitrogen).  Gene specific primers 
were used to amplify the HA genomic RNA using SYBR green select (Invitrogen) 
and detected with a 7900HT Real-time PCR System (Applied Biosystems). The 
amount of HA copy number was determined by extrapolating the Ct of each 
replicate against the standard curve generated using 10-fold dilutions of HA 
plasmid with known copy number. The sequences of the forward primers for 
H1N1pdm were 5`-CACCAGTCCACGATTGCAATA-3` and for BN59 5`-
GAGTAGAGGCTTTGGATCAGGA-3`. The reverse primer was the same for both 
H1N1pdm and seasonal (5`-ATGGGAGGCTGGTGTTTATAGC-3`). 
Quantification of apical and basal levels of virus and immune responses in 
wdNHBE cells.  Virus titers and cytokine/chemokine protein levels were 
measured in basal and apical supernatants in two experiments with two donors.  
Virus titer was measured by TCID50 as discussed above. We measured levels of 
CCL2/MCP-1, CCL5/RANTES, IL6, CXCL8/IL8, G-CSF, GM-CSF, CXCL1/GRO, 
IFN-α, CCL4/MIP-1α, CXCL10/IP-10, IL10,  and TNF using multiplexed arrays 
according to the manufacturer's protocol (Millipore) using a Luminex 100™ 
machine.  Concentrations for each secreted cytokine and chemokine were 
determined using standard curves and Luminex xPONENT® software.   
54 
Microarray studies.  Total RNA was extracted by TRIzol from three replicates of 
virus-infected or mock-infected wdNHBE cells from a single donor and further 
purified using RNeasy kit (Qiagen).  The samples were run in triplicate on 
Affymetrix HG-U133 plus 2.0 chips (Affymetrix) and processed according to the 
manufacturer in the Microarray Core facility at the University of Louisville.  The 
raw data have been deposited in a Gene Express Omnibus (GEO).  The GEO 
accession number is GSE48466.  Prior to statistical analyses, raw data were 
processed by Plier Workflow normalization method using Gene Console software 
(Affymetrix, version 1.3.1).  After normalization, data were log2 transformed and 
differentially expressed genes (DEGs) were identified by one-way analysis of 
variance (ANOVA) using Partek Genomics Suite 6.5 software.  Fold-change and 
p-values were calculated for each virus infection, as compared to the mock-
infected.  Principal component analysis was conducted as a quality control 
measure to ensure the three replicates per viral treatment grouped together with 
limited variation.  The data set was further filtered to select statistically significant 
genes and corrected using a p-value of 0.05 with a 2-fold cut-off.  Data filtering 
and pathway analyses were performed using Ingenuity Pathway Analysis (IPA, 
Ingenuity Systems) software.   
Immunohistochemistry.  Tissues were fixed in 10% buffered formalin, 
processed, and paraffin embedded.  Four-micron thick sections from infected 
wdNHBE cells at 36 hpi were processed by immunohistochemistry (IHC).  
Antigen retrieval and staining of the paraffin-embedded sections of the wdNHBE 
cells were performed as others described [319].  Briefly, paraffin was removed; 
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sections were incubated with pronase and blocked with H2O2 in Tris-buffered 
saline and with avidin/biotin blocking kit (Vector Labs).  The slides were 
incubated with primary antibody specific for NP protein (East Coast Bio), blocked 
with goat serum, and then incubated with VECTASTAIN ABC kit (Vector Labs).  
Development was then performed using either diaminobenzidine (Vector Labs), 
and secretory cells were counterstained with Alcian Blue (Sigma) and mounted 
with Permount (Fisher).  Cell layers were measured using Zeiss software 
measurement tool using a 10X objective. Five pictures with 3-4 measurements 
per picture were taken. Five images per slide were used to quantitate cell layer 
thickness (3-4 segments/image). 
Statistical analysis.  The differences of log10-transformed viral titers among 
different viruses at different time points post-infection and the quantitative 
cytokine and chemokine mRNAs and proteins of influenza virus-infected cells 
were compared by using one-way ANOVA followed by a Bonferroni multiple-
comparison test, unless otherwise stated.  Differences were considered 
statistically significant at a p-value less than or equal to 0.05.  The statistical 
analysis was performed using Graph-Pad Prism 5.04 and Partek Genomics Suite 
6.5 software.   
RESULTS 
Kinetics of viral replication of pandemic and seasonal H1N1 isolates in 
continuous and primary cell lines.  To select a cell type for microarray and 
cytokine studies, we used several cell types (primary and continuous) to screen 
for potential differences in the ability to infect and produce infectious virus among 
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the pandemic (KY180 and KY136) and seasonal (BN59) isolates. We chose 
Calu3, A549, udNHBE, and wdNHBE cells and an MOI of 3 for this study.  We 
included primary cell lines (udNHBE and wdNHBE cells) to ascertain if a more 
complex cell culture model would reveal greater differences. Differences in entry 
were anticipated as the KY180 has a D222G signature in the HA [298].  The 
udNHBE was included to determine the general influence of the alpha-2,3-SA 
(common on ciliated cells) in the wdNHBE cells as compared to the alpha-2,6-SA 
(common on non-ciliated secretory cells) in the udNHBE cells. Supernatant was 
collected over 3 days to measure the kinetics of each virus with the TCID50 
assay.  
All three isolates infected and produced infectious virus in the all cell types 
apically (Figure 9A-D).  No virus was detected in basal supernatant of infected 
cells across all time points (data not shown).  The wdNHBE as compared to the 
udNHBE cells conferred a distinct advantage showing a 2-3 fold higher level 
production of infection virus over time suggesting the importance of the alpha-
2,6-SA (Fig 9A versus 9B). In the primary wdNHBE cells, the titer of all three 
isolates peaked at 24 hours post-infection (hpi) (Figure 9A). KY180 showed 
significantly higher levels of virus at 24 hpi than KY136 and BN59 apically (Figure 
9A).  In udNHBE cells, significant differences occurred between isolates over 
time (Figure 9B). In the A549 cells, viruses peaked at 36-48 hpi at the highest 
levels of any of the cells (Figure 9C). Pandemic isolates replicated more 
efficiently at 24 hpi as compared to the seasonal isolate (Figure 9C). In the Calu3 
cells, no significant differences in replication occurred between isolates over the 
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time course of infection (Figure 9D). Given the greater differences between 
KY180 and the other viruses, the primary wdNHBE cell, a physiologically relevant 
model, was chosen for further analyses. The level of viral RNA as measured by 
the HA was assessed in NHBE to further explore the difference in viral titer. The 
viral RNA levels were similar among all three isolates at 24 hpi suggesting that 
another mechanism was responsible for the higher levels of virus such assembly 
of budding.  
Infection of the wdNHBE cells was confirmed by IHC for each isolate as at 
36 hpi (Figure 10 A-D).  The 36h time point was chosen based on preliminary 
studies measuring the level of IFNβ which peaked at 36 hpi (data not shown) 
coupled with the differences in the viral titer data. Staining for IAV nucleoprotein 
(NP) showed a similar distribution of infected cells for all three isolates (Figure 10 
A-D). 
Cytokines and chemokines elicited in wdNHBE cells by H1N1pdm IAV 
isolates show different trajectories.  Differences in replication among the three 
H1N1 isolates prompted us to ask whether differences occurred in the levels of 
cytokine and chemokine secreted from the infected wdNHBE cells. We analyzed 
the levels of 12 cytokines and chemokines over time in the apical and basal 
medium (Figure 11 and 12).  At 24 and 36 hpi, both H1N1pdm isolates showed 
greater levels of pro-inflammatory markers, apically (CCL5, GM-CSF, CXCL10, 
MCP1, CCL4) and basally (CCL5, IL6, TNF), compared to BN59 (Figure 11 and 
12).  The concentration of apical IL6, IL8 and GRO secreted by cells were similar 
between all isolates (Figure 11).  IFN was secreted apically, and not basally, in 
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cells infected by pandemic or seasonal isolates.  IL10 occurred in trace amounts 
apically and was absent basally in all three isolate infected cultures. Overall, the 
patterns were fairly similar for pandemic isolates in the apical wash. Significant 
differences were seen between isolates in the basal culture supernatants (Figure 
13).  The only notable differences between KY180 and KY136 were the greater 
levels of CCL2, IL8, IL6 and CCL5 in the basal media at 36 and 72 hpi (Figure 
13).  
Microarray analyses of NHBE cells infected with seasonal or pandemic 
isolates.  To complement our cytokine and chemokine studies, we measured 
differences in gene transcription levels at 36 hpi by microarray.  Overall, cells 
infected with KY180 or KY136 had roughly 2,000 genes that were significantly 
up- or down-regulated as compared to mock-infected, whereas the seasonal 
BN59 isolate had only 360 genes significantly up- or down-regulated  (Table 5). A 
Venn diagram shows the agreement between the three lists of genes (Figure 
14A).  There were 355 significant DEGs (p<0.05) in wdNHBE cells common to all 
three isolates at the 2-fold cut-off (Figure 13A); of which, many of the genes were 
from the early innate immune response pathways (Table 6).  For all three IAVs 
the largest category of up-regulated genes was the ISGs (e.g., RSAD2, IFIT2, 
IFI44L, IFIT3, OAS1, OASL, MX2, STAT1) (Tables 6).  Other genes up-regulated 
by all three isolates included interferon-induced chemokines (e.g., CCL5, CXCL9, 
CXCL10, and CXCL11), type III-IFN (e.g., IL29, IL28A and IL1A), PRRs (e.g., 
DDX58, IFIH1, TLR3, MYD88, CASP1), and other regulatory factors (e.g., IDO1, 
SOCS, EIF2AK2).  Surprisingly, when a 2-fold change cut-off with a significance 
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of p<0.05 was applied there were only three genes unique to BN59-infected cells, 
whereas KY180 and KY136 had 279 and 326 unique DEGs respectively.  
We noted 1647 genes that were commonly expressed in KY180 or 
KY136-infected NHBE cells that were not significant in the BN59-infected cells 
(Figure 14).  When comparing global gene expression levels, H1N1pdm-infected 
wdNHBE cells showed greater fold-changes in transcription as compared to 
seasonal IAV (Figure 14B).  Cells infected with H1N1pdm isolates had very 
similar levels of global gene expression with KY136 showing slightly greater up-
regulation at 36 hpi (Figure 14B). Genes common to both KY180 and KY136-
infected cells but not BN59 included transcription factors (cMYC, CDK1, SP1, 
SOX9, and ATF3), keratinocyte factors (KRT24 and KRT6B), defensins (DEFB1), 
and protein folding proteins (HSPA6).  Also significant were genes involved in 
activating signal transduction pathways through toll like (TICAM) and the 
chemokine receptors, CCR4 (Table 7) and apoptosis.  The similarities of KY180 
and KY136 to each other and their differences to BN59 are further revealed upon 
comparison of the raw numbers of genes within the top canonical pathways, IFN 
signaling and communication, that were up- and down-regulated were similar 
between KY136 and KY180-infected NHBE cells (Figure 15A).  Both KY180 and 
KY136 differed with the pattern shown by BN59-infected NHBE cells (Figure 
15A).  
We further conducted pathway analyses using the Ingenuity Pathway 
Analysis (IPA) to identify the intracellular signaling pathways that were most 
significantly represented in seasonal and pandemic infected cells using Fisher’s 
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Exact Test (Table 8).  The top two ranking pathways for all three viruses were the 
same; IFN signaling and communication between innate and adaptive immune 
cells. The remaining three pathways and ranking differed in importance. The role 
of PRRs was shared but greatest for KY136.  The importance of the complement 
system was suggested for only KY180, while antigen presentation was 
suggested for KY136 and BN59. Finally the aryl hydrocarbon pathway was 
significant for KY180 and KY136 but not BN59.  Combined with the individual 
gene analysis, the pathway analysis underscores important similarities but 
resulting gene specific differences. 
wdNHBE cell layer integrity changes overtime after infection.  When 
evaluating the cells by IHC, we observed changes in epithelial layer integrity in 
infected epithelial layers compared to mock-infected wdNHBE cells (Figure 10).  
Cultures infected with KY180 appeared thinner than both mock-infected cells and 
cells infected with the other IAV isolates (Figure 10).  To address this 
observation, we further analyzed paraffin-embedded sections by measuring the 
distance from the collagen layer to the top of the epithelial layer (Figure 16A).  
Significant differences were noted among all isolates compared to the mock-
infected control.  Cells infected with KY180 showed the smallest distance, 
followed by BN59 and KY136 as compared to mock (Figure 16A). 
 Having observed these differences, we turned to the microarray data to 
determine whether the observed changes in epithelial cell layers could be 
explained at the transcriptional level (Figure 16B).  We evaluated expression 
levels of DEGs in bronchial epithelial cells after the air-liquid interface culture 
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process.  These genes include those associated with cell adhesion, transport, 
and cilia formation and function, such as SPRR1A, KRT6B, KRT24, ASAM, 
FOXJ1, MUC5B, AKAP14, and PROM1 (and apoptosis genes CASP7 and 
BAK1).  According to Ross et al. (2007) wdNHBE cells have decreased 
expression of the keratinocyte marker genes and an increased expression of 
genes involved in cell signaling, cilia formation and also cilia function [320].  We 
saw an increase in expression of keratinocyte genes and a decrease in 
expression of cilia genes in wdNHBE cells.  Cells infected with KY180 showed a 
greater difference in gene expression levels over the mock compared to KY136 
and BN59 (Figure 16B).   
DISCUSSION 
The contribution of the early host-virus interactions to the progression of 
disease remains a critical question.  Using in vitro models that closely mimic 
physiological conditions within the lungs in evaluating respiratory infections is an 
important approach in elucidation of potential differences between strains with 
different virulence [321, 322].  For example, recent studies  evaluating the 
pathogenesis of 2009 H1N1pdm in bronchial epithelial cells suggest that 
differentiation status of bronchial epithelial cells has a profound impact on the 
infection efficiency of different influenza strains and the host innate immune 
responses [75].  We sought to compare host responses in a wdNHBE cell culture 
model to determine whether lung epithelial cells infection differed between 
seasonal and pandemic influenza isolates.  
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Recently, Zeng et al. evaluated extracellular inflammatory molecules 
secreted by polarized bronchial epithelial cells (Calu-3) and pharyngeal cells 
(Detroit 562) infected with 2009 H1N1pdm compared to seasonal. They show the 
two isolates are considerably different in terms of inflammatory responses, such 
as type-I IFN, IL6, CXCL10, and TNF, as well as replication efficiency, with 
H1N1pdm being more efficient [90].  Furthermore, a study comparing different 
H1N1pdm isolates in udNHBE cells show critical differences in levels of 
cytokines and chemokines elicited from cells infected with closely-related 
influenza isolates [91].  They show distinct differences in viral infectivity as well 
as differences in IFN levels between 2009 H1N1pdm (CA/08, Mexico/4108, 
TX/15) and the seasonal H1N1 (Solomon/03) [91].  The differences seen in these 
models, prompted us to compare the phenotype induced by our genetically, 
closely-related H1N1pdm and seasonal influenza isolates in wdNHBE cells.  
To select the optimal cell line for microarray and immune response studies 
to probe regulatory differences among pandemic and seasonal isolated, we 
screened several continuous and primary cell lines. We show that H1N1pdm 
isolate KY180, which was previously reported to be lethal in mice and humans 
[298], produced significantly more virus in NHBE cells than the other isolates 
from 24-72 hpi.  The udNHBE cells were less permissive for production of virus 
presumably due to less differentiation and lack of the alpha-2,6-SA. Previous 
reports show productive replication of H1N1pdm in NHBE cells [323].  
Differences in viral titers among strains of the same HA subtype (i.e., H1) in 
wdNHBE cells have not been reported previously.  Interestingly, an examination 
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of the viral genomic HA RNA levels did not suggest that this was due to 
replication levels. Future studies to understand the reason for a higher virus titer 
will focus on the potential of differences in assembly and/or budding. 
Because regulation of innate immunity by viruses is a key determinant of 
the subsequent host immune response and clinical outcome, we evaluated the 
cytokine and chemokine secreted apically and basally in wdNHBE cells.  IAV 
infections lead to a variety of intracellular responses, inducing innate immune 
signaling cascades which serve as the first line of defense against the invading 
virus [324-326].  Cytokines and chemokines produced by these pathways play an 
important role in the production of airway inflammation and recruitment of 
immune cells to the site of infection.  A key finding from our data was the greater 
levels of basolateral secretion of pro-inflammatory cytokines (IL6, CCL5, IL8 and 
CCL2) by wdNHBE infected with the lethal KY180 isolate as compared to KY136 
and BN59.  We are aware of only two studies of IAV infection in primary NHBE 
cells that have looked at secretion of cytokines and chemokines from both the 
apical and basal side of the epithelial culture [327, 328].  However, these studies 
were limited to the earliest time points and did not look at the later time points 
where we saw the greatest differences.   We speculate that differences in 
basolateral signals such as CCL5 from epithelial cells may play a role in the 
recruitment, activation, and responses elicited by monocytes.  Further, the 
magnitude of the CCL5 response may give rise to differences in outcome [328].  
Recently, in mice, apoptosis of virus-infected macrophages was prevented by 
CCR5/CCL5 [329].  CCL5 has been demonstrated to send an anti-apoptotic 
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signal to the cell via the Akt and Erk1/2 pathways, which could support an 
increase in survival and scavenging of recruited and resident macrophages.  
With replication and apical/basal chemokine/cytokine data suggesting 
differences among the isolates, we sought to evaluate the intracellular signals 
gene expression patterns triggered by the virus. These intracellular responses 
include the  double-stranded vRNA recognition by PRRs [330], Nod-like 
receptors, TLR, and the MAPK pathway, which have all been reported to be 
important to control of cellular responses against invading pathogens [331].  
Three different types of MAPKs, the ERKs, the JNKs, and ERKs, contribute to 
the generation of cytokines and chemokines, such as IL8, CCL5, and TNF [312].  
We hypothesized that differences in up- or down- regulation of genes involved in 
these pathways would explain the phenotypic differences observed in replication 
and secretion of cytokines and chemokines in our wdNHBE infection model.  
Strikingly, we saw no significant differences in transcriptional profiles between 
KY180 and KY136 within these pathways; indicating a potential for differences in 
post-transcriptional regulation by KY180.   
IAV have been shown to induce apoptosis in vitro and in vivo [332-336].  
Inducers of apoptosis in epithelial cells include dsRNA signaling through PRRs, 
NS1, and NA. In our wdNHBE model we observed a change in the epithelial cell 
layer structure after infection. We observed a loss of monolayer depth and 
desquamated cells as seen in previous models of infection [336].  We sought to 
explain this change in phenotype using our microarray data. We found factors, 
previously shown to alter the epithelial phenotype of the cell, are differentially 
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regulated in KY180 compared to the other isolates including KRT genes and 
those involved in cilia formation (FOXJ1, AKAP14, and PROM1) (Figure 16B) 
[320].  Furthermore, we looked at apoptosis pathways to determine whether 
these pathways were different between infections. We found that KY180 and 
KY136 significantly up-regulated BAK1 and Caspase 7, an apoptosis inducer, 
and down-regulated the CDK1 gene, a cell division control protein (Figure 15 A-
B). This suggests any differences in phenotype, such as replication and cytokine 
and chemokine secretion, between isolates may be related to cellular integrity 
and state of differentiation.   
Limited research is available providing a comprehensive gene expression 
profile of DEG in response to IAV infection of wdNHBE cells.  In a recent study 
conducted by Lee et al., on type I-like alveolar epithelial cells infected with 
H1N1pdm  (A/Hong Kong/415742/2009) and seasonal H1N1 (A/Hong 
Kong/54/1998), 88 genes were found to be up or down-regulated in response to 
seasonal H1N1 infection while only 18 genes were affected in H1N1pdm infected 
cells [337].  IFN-induced genes, including IL28A, IL28B, IL29, IRF9, ISG15 and 
MX1, were significantly up-regulated in response to both H1N1pdm and seasonal 
H1N1 infections and to a similar degree. Additionally, Ioannidis et al. 
demonstrated that, in IAV infected primary differentiated lung epithelial cells, the 
most represented category of DEGs included the IFN-inducible genes, IFN-
induced cytokines and chemokines, and PRRs  [333].  Our data agree that both 
seasonal and pandemic isolates up-regulate IFN-induced genes; however, in our 
model, the degree of the response was greater in H1N1pdm infected cells 
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compared to seasonal.  We saw similar trends overall in terms of an elevated 
type-I IFN and antiviral responses, and additionally, we show a difference in 
genes involved in cellular differentiation.  
In summary, we demonstrate the value of the wdNHBE cell model in 
understanding the early events of viral infection, and unraveling clues to strain-
specific, and pandemic versus seasonal virus-host interactions. Our studies 
provide preliminary evidence that strain specific differences between closely 
related pandemic viruses during infection of the lung epithelium may contribute to 
the trajectory of host responses and pathogenesis observed in mice and in 
humans [298]. By directly comparing pandemic and seasonal IAV isolates, we 
found unique differences in virus titer and cytokine and chemokine secretion 
between isolates.  Intriguingly, there are only 22 amino acid mostly synonymous 
changes between KY180 and KY136 and of these only one of these so far in the 
HA (D222G) has been suggested to correlate with higher virulence in patients 
[338, 339]. Future studies will evaluate the role of the D222G and other amino 
acids in conferring the greater levels of virus, basal secretion of cytokines and 
apparent epithelial damage noted by KY180. Further, future studies that couple 
in vitro human primary cell culture models with immune cells will be an important 
step in developing a fuller understanding the outcomes of viral-host interactions. 
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Table 4. Seasonal and pandemic IAV isolates used in this study. 
Virus Subtype Source Phenotype  
A/KY/180/2010 H1N1pdm Fatal Case Lethal 
A/KY/136/2009 H1N1pdm Non-fatal Case Non-lethal 
A/BN/59/2007 Seasonal H1N1 CDC Non-lethal 
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 Figure 9. Virus titer detected in supernatant from cells infected seasonal and 
pandemic IAVs. (A) wdNHBE, (B) udNHBE, (C) A549, and (D) Calu3 cells were 
infected with 3 MOI of seasonal (BN59) or pandemic (KY180, KY136) viral 
isolates and apical wash from wdNHBE cells and supernatants from udNHBE, 
A549, and Calu3 cells were collected at 8, 24, 36, 48, and/or 72 hpi. The virus 
titer was determined using a TCID50 assay. In (E), the amount of viral HA RNA in 
cells was quantified by qRT-PCR wdNHBE cells using the Ct method. Data are 
presented as the mean+SEM of the virus titer pooled from 3 replicates from three 
independent experiments with 3 donors (A-D) or 1 donor (E). Asterisks indicate 
significance of p<0.05(*), p<0.01(**), and p<0.001(***) respectively. The dotted 
line indicates the limit of detection of the TCID50 assay.  
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Figure 10.  Immunohistochemical microscopy of wdNHBE cells after IAV 
infection. IHC microscopy of wdNHBE cells stained with Alcian blue and 
evaluated 36 h after infection with (A) MOCK, (B) KY180, (C) KY136, and (D) 
BN59 for localization of influenza nucleoprotein antigen (brown) in the epithelial 
cell nucleus.  
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Figure 11. Apical cytokine and chemokine production by wdNHBE cells infected 
with seasonal and pandemic IAVs.  After infection, the apical side of the culture 
insert was washed twice and harvested for Luminex multiplex analysis. The error 
bars indicate mean+SEM from 3 replicates per isolate per time point from one 
representative experiment. A total of two experiments were conducted with two 
donors.  Letters indicate significant differences between isolates (a- different from 




Figure 12. Basal cytokine and chemokine production by wdNHBE cells infected 
with seasonal and pandemic IAVs.  After infection cell culture supernatants were 
harvested from the basal side of the culture insert and a multiplex analysis was 
performed using Luminex platform. A total of two experiments were conducted 
with two donors.  The error bars indicate mean+SEM from 3 replicates per isolate 
per time point from one representative experiment. Letters indicate significant 
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differences between isolates (a- different from KY180, b- different from KY136, c- 
different from BN59, and d- different from Mock).  
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Figure 13. Apical and basal secretion of cytokines and chemokines in wdNHBE 
cultures infected with seasonal and pandemic IAV at 36hpi. Culture supernatants 
were harvested from the apical and basal side of the culture inserts and 
screened for presence of protein using Luminex platform. The error bars indicate 
mean+SEM from 3 replicates per isolate per time point from one representative 
experiment. The mean and SEM from 3 replicates per isolate per time point are 
shown. Asterisks indicate significance of p<0.05(*), p<0.01(**), and p<0.001(***). 
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Table 5. Differentially expressed genes in IAV–infected wdNHBE cells at 36 hpi. 
Virus No. Differentially Regulated Genes* 
KY180 2281 KY136 2338 BN59 360 *No. significant genes p<0.05, 2-fold cut-off  
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Figure 14. Summary of wdNHBE microarray analysis. Differentially expressed 
genes (DEGs) were identified by one-way ANOVA analysis by comparing mock 
and IAV-induced gene expression intensities in wdNHBE cells. DEGs were 
selected by filtering the genes whose expression changed by at least 2-fold 
relative to the level in the mock infected group with a p<0.05, as outlined in 
Materials and Methods. (A) The Venn diagram illustrates the agreement between 
the lists of DEGs detected by microarray. (B) Overall data are represented in 
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scatter plots of log-2 fold-change expression data of seasonal vs. pandemic 
infected cells at 36 hpi. The diagonal line indicates where the fold change values 
would be equivalent for the compared isolates. (C) Gene expression intensities 
were visualized by means of a heatmap of the 355 differentially expressed genes 
common to all three isolates. Clusters represent types of genes as defined by the 
Ingenuity pathway analysis output.  The error bars indicate mean+SEM from 3 
replicates per isolate per time point from a single donor.  Asterisks indicate 
significance of p<0.05 (*), p<0.01 (**), and p<0.001 (***) respectively. 
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Table 6.  Notable genes upregulated in wdNHBE cells infected with seasonal and 
pandemic IAV isolates at 36 hpi. 
Gene Symbol Affymetrix Probe ID 
Fold Change KY180 
Fold Change KY136 Fold Change BN59 
RSAD2 213797_at 34.23 35.17 22.28 IFIT1 203153_at 25.48 25.28 22.24 IFIT2 226757_at 36.38 37.06 31.47 IFIT3 204747_at 27.81 29.10 18.81 SOCS1 210001_s_at 9.70 13.70 5.30 IFITM2 201315_x_at 8.77 9.13 6.46 IFI35 209417_s_at 16.30 17.24 8.67 IRF1 238725_at 4.18 5.09 3.09 IRF9 203882_at 3.07 3.35 2.64 IFI44L 204439_at 15.81 15.75 14.87 OAS1 205552_s_at 12.21 12.56 7.48 OASL 210797_s_at 57.01 65.33 20.55 MX1 202086_at 17.52 18.42 14.80 MX2 204994_at 22.35 23.55 18.55 JAK2 205842_s_at 4.94 5.65 2.28 STAT1 200887_s_at 4.07 4.16 4.00 STAT2 205170_at 3.14 3.29 2.37 PSMB8 209040_s_at 3.34 3.68 2.76 CCL5 1555759_a_at 15.06 19.06 3.45 CXCL9 203915_at 2.74 2.61 4.29 CXCL10 204533_at 127.36 128.62 77.29 CXCL11 210163_at 140.77 140.60 80.39 IL29 1552917_at 9.91 16.13 2.92 IL28A 1552915_at 12.53 20.10 3.23 IL1A 210118_s_at 4.32 3.98 2.00 DDX58 218943_s_at 21.42 23.25 12.17 IFIH1 219209_at 11.71 12.03 7.72 TLR3 206271_at 5.91 6.32 3.43 CASP1 211367_s_at 4.69 5.16 2.62 MYD88 209124_at 3.54 3.64 2.30 IDO1 210029_at 17.61 19.36 9.83 SOCS2 203373_at 5.73 6.08 2.05 EIF2AK2 204211_x_at 3.55 3.46 3.17 
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*Fold change values obtained by 1-way ANOVA analysis comparing gene 
expression intensities of seasonal and pandemic IAV-infected cells to mock.  
Analysis conducted using Ingenuity core analysis (p<0.05, 2-fold change cut-off). 
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Table 7.  Fold change of significantly differentially expressed genes. 
Gene Symbol Affymetrix Probe ID KY180 KY136 BN59 KRT24 220267_at 31.65 25.90 1.73 
DEFB1 210397_at 8.10 8.41 1.82 
KRT6B 213680_at 6.02 5.12 1.43 
HSPA6 213418_at 5.82 7.17 1.52 
CCR4 208376 _at 3.95 4.00 1.93 
BAK1 203728_at 3.80 4.37 1.89 
IFNB1 208173_at 3.58 6.90 1.69 
TICAM1 213191_at 3.48 3.88 1.77 
IL-6 205207_at 2.78 3.06 1.50 
MYC 202431_s_at 2.73 2.72 1.38 
CDK1 203213_at -2.67 -3.00 -1.61 
ATF3 202672_s_at 2.22 3.30 1.78 
GSTA1 203924_at -12.09 -12.03 -1.21 
SOX9 202936_s_at 4.66 5.38 1.97 
ICAM1 202638_s_at 2.28 2.27 1.67 
SOCS2 200887_s_at 4.07 4.16 4.00 
*Fold change values obtained by 1-way ANOVA analysis comparing  
gene expression intensities of IAV-infected cells to mock.  Analysis  
conducted using Ingenuity (p<0.05, 2-fold change cut-off)  
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Figure 15. Pathways significantly represented by all isolates as compared to 
mock. (A) Graphs represent the number of genes differentially up- or down- 
regulated for each isolate compared to mock. Red represents the number of 
genes up-regulated, green represents the number of genes down-regulated, and 
white represents the number of genes that are not significantly different from 
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mock. (B) Graphs represent the fold change expression of significant DEGs 
within these pathways.  
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Table 8.  Top five significant canonical pathways in IAV-infected wdNHBE cells at 
36hpi relative to mock 
RANK KY180 KY136 BN59 
1 
 
IFN Signaling Pathway (6.47E-07, 0.471) 
IFN Signaling Pathway (3.49E-07, 0.471) 
IFN Signaling Pathway (3.36E-15, 0.412) 
2 
Communication between Immune Cells (3.07E-06, 0.471) 
Communication between Immune Cells (4.70E-06, 0.258) 
Communication between Immune Cells (6.51E-12, 0.172) 
3 Complement System (2.37E-05, 0.424) 
Role of PRRs in Recognition of Viruses (1.15E-05, 0.284) 
Antigen Presentation Pathway (1.13E-10, 0.275) 
4 
Role of PRRs in Recognition of Viruses (2.75E-05, 0.284) 
Aryl Hydrocarbon Receptor Signaling (7.14E-05, 0.234) 
Activation of IRF of Cytosolic PRRs (1.14E-07, 0.175) 
5 
Aryl Hydrocarbon Receptor Signaling (7.65E-05, 0.241) 
Antigen Presentation Pathway (1.04E-04, 0.325) 
Role of PRRs in Recognition of Viruses (1.53E-07, 0.137) 
* Rankings are listed based on statistical significance scored using Fischer’s 
Exact Test (p-value<0.05).  For each canonical pathway we report the p-value of 
Fisher's exact test to measure significance and the proportion of genes in the 
pathway that were actually significantly represented in the brackets.  
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Figure 16: Changes in epithelial layer integrity in infected wdNHBE cells at 36h 
after infection. Cell layers were measured using Zeiss AxioVision version 4.8 
software using a 10 X objective. Five pictures were taken with 3-4 measurements 
per picture. (A) Differences in epithelial layer thickness, as measured by mean 
height of the epithelial layer from the collagen are depicted. The error bars 
indicate SEM from 3 replicates per isolate per time point. Asterisks indicate 
significance of p<0.05 (*), p<0.01 (**), and p<0.001 (***) respectively.  (B) 
Microarray gene expression of genes shown to be associated with differentiation 
of bronchial epithelial cells and apoptosis. Values are shown as fold-change over 








Severe cases of influenza A virus (IAV) infection are associated with 
pneumonia and bacterial co-infection, which predispose patients to a greater risk 
of severe outcomes including acute respiratory distress, sepsis, and death [340, 
341]. The most common comorbidities associated with hospitalized patients 
include asthma, cardiac disease, and diabetes [311, 342]. In the recent 2009 
pandemic influenza A H1N1, influenza-associated pneumonia was also a 
common complication among hospitalized patients within the United States in 
2009, causing excess mortality in children and young adults [340, 343-346]. In 
these younger patients, however, comorbidity was less common. As seasonal 
IAV predominantly target the upper respiratory tract, the epidemiology of 
H1N1pdm suggested it had a broader tropism for the lower respiratory tract 
(Figure 17) [347, 348]. Subsequent research showed the H1N1pdm has tropism 
for the upper and lower respiratory tract [74, 349]. Histopathologic analysis of 
fatal cases of seasonal and pandemic influenza virus infection show a similar 
spectrum of pathologies [295, 350], however, strains vary in their ability to infect 
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and replicate in specific cell types (i.e., respiratory, alveolar, and lung endothelial 
cells) [66, 86, 91, 351-353]. Furthermore, different strains of IAV vary in their 
ability to infect and replicate productively in macrophages which also show 
differences in the magnitude of their pro-inflammatory responses [222, 307, 351, 
354-357]. Given the apparent tropism of the H1N1pdm for the lung and the 
central importance macrophages play in innate immune responses [358], in vitro 
models that permit the study of IAV-macrophage interactions are critical. 
Influenza-associated pneumonia is characterized by an early influx of 
neutrophils followed by the recruitment of large numbers of blood-derived 
monocytes within the first days of infection [309, 359]. Recruitment of neutrophils 
and monocytes to the infected lung relies heavily on early cytokines and 
chemokines (including CXCL10, IFNβ, CCL5 and IL6) produced by infected or 
bystander lung epithelial cells (Figure 17) [223, 232, 360]. An increase in the 
number of these cells and their respective inflammatory responses have been 
linked to severe lung immunopathology after infection [308, 309], suggesting an 
important link between recruited cells and the outcome of IAV infection. However, 
these cells have also been shown to play an important role in protection from 
infection. Animal studies of influenza infection (i.e., mice, ferrets, and pigs) by 
H1N1 and H3N2 viruses reported that alveolar macrophages are critical for 
protection. Clodronate liposome-mediated depletion of macrophages in these 
models resulted in greater virus replication in the lungs, systemic dissemination 
of the virus, and exacerbated disease severity [358, 361-364]. This highlights that 
macrophages, are necessary for protection but can also cause severe 
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immunopathology if dysregulated, thus the need for studies to understand how 
the viruses modulate macrophage responses are needed.   
To date, studies evaluating IAV infection in human macrophages have 
employed tissue-resident alveolar macrophages (AM) and monocyte-derived 
macrophages (MDM) models; however the results of these studies vary as to 
whether IAVs productively replicate in human macrophages [222, 307, 351, 354-
357]. Both models are relevant given that both are required for pathogen 
elimination and restoration of homeostasis following infection and tissue damage 
[365].  All macrophages originate from bone marrow hematopoietic stem cells 
and gain access to the respiratory tract via blood and lymph [366, 367]. MDM 
arrive in the lung after inflammation causes increased vascular permeability, 
permitting extravasation of plasma and blood cells [368]. These recruited cells 
can differentiate into different subsets (pro- and anti-inflammatory) of 
macrophages once they reach the site of infection [369]. 
Differentiation of macrophages to AM occurs through interactions within 
the lung microenvironment, although this is not completely understood. The 
presence of surfactant proteins A (SP-A) and D (SP-D) and the presence 
granulocyte-macrophage colony stimulating factor (GM-CSF) within the lung 
have suggested to influence differentiation [365, 370]. The activation status of the 
AM and their immune responses are critical to balance the epithelial response to 
protect the lung [371].  
Studies to date on the macrophage phenotype induced by IAV infection 
have been limited mostly to in vitro models that pre-treat cells with growth factors 
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such as GM-CSF or M-CSF to drive differentiation and activation of 
macrophages [372-374]. Monocytes and MDM pretreated with GM-CSF result in 
a pro-inflammatory (previously known as M1) macrophage phenotype [375, 376], 
whereas M-CSF induces an anti-inflammatory (previously known as M2) 
macrophage phenotype in vitro [377, 378]. Up-regulation of NFκB is associated 
with the inhibition of M1-polarization in vivo [379], and up-regulation of IRF5 by 
GM-CSF pre-treatment in MDM is associated with activation of M1 markers 
[375]. Influenza viruses have been shown extensively to activate signal 
transduction pathways through pattern recognition receptor activation [325, 380, 
381], suggesting a potential link to IAV infection and macrophage 
activation/polarization.  
There is little known regarding the early events following MDM infiltration 
into the lung during infection. Herein we have developed a resting MDM model of 
seasonal and pandemic H1N1 viruses to uncover early IAV-MDM interactions. To 
characterize this model we first established the culture conditions as previously 
described for differentiating monocytes to macrophages over 7 days and 
confirmed this differentiation by evaluating surface marker and gene expression 
of CD14 and CD11b markers. We then confirmed the MDM cultures were not 
activated after the 7 day maturation. We evaluated the cells via light microscope 
to determine whether the macrophages were in an activated or resting state as 
previously described [382, 383]. This was further confirmed evaluating the 
presence of both anti- and pro-inflammatory activation surface markers on the 
surface of MDM by flow cytometry and RT-PCR. Lastly, to eliminate elements 
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that could prematurely affect the outcome of our experiments on IAV-MDM 
interactions, we optimized the infection culture conditions including infection 
media, multiplicity of infection, and the use of egg- or cell-derived IAV stock virus 
for infection.   
METHODS 
Isolation and differentiation of MDM. Peripheral blood mononuclear cells 
(PBMCs) were obtained from healthy donors and isolated using plasma-percoll 
gradients by the University of Louisville Nephrology Department. MDM were 
generated using a protocol developed by Dr. Suttles laboratory at the University 
of Louisville as previously described with slight modifications [384]. Briefly, 
PBMCs were washed twice in Dulbeccos PBS (DPBS, HyClone with Magnesium 
and Calcium, ThermoFisher) and resuspended with final concentration at 2x106 
cells/ml in R5 media, which contains RPMI 1640 (HyClone, ThermoFisher) 
supplemented with 5% heat inactivated human AB serum (Atlanta Biologics), 
0.01M HEPES (Invitrogen Life Technologies), and 2ml Pen/Strep (Invitrogen Life 
Technologies). Monocytes were plated on 6 well low-attach plates 
(ThermoFisher) at a volume of 4 ml per well. Monocytes were allowed to mature 
for 5 days in a 37ᵒ C incubator with 5% CO2. After the maturation period, cells 
were removed from low-attach plates gently using a cell lifter (Costar, 
ThermoFisher), washed twice with DPBS supplemented with 0.2% human AB 
serum, and resuspended at 4x106 cells/ml in R5 media. Cells were plated 
(4x10^6 cells/ml) and allowed to adhere for two days. Mature MDM were 
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selected by adherence after 2 days by washing with DPBS with 0.2% human AB 
serum. Cells were incubated in R5 media for 1 h prior to infection/treatment.  
Influenza viruses. Viruses used for these experiments included H1N1 IAV 
isolates from human clinical patients during the 2009 pandemic A/KY180/2010 
(KY180) and A/KY136/2009 (KY136) [298, 385]. For comparison, we also 
included a seasonal H1N1 IAV vaccine strain A/Brisbane/59/2007 (BN59) (kindly 
provided by the Centers for Disease Control and Prevention, Virus Surveillance 
and Diagnosis Branch, Influenza Division).  Viral seed stocks were prepared as 
previously described [298] in egg and MDCK cells and stored at -80˚C. Viral titers 
of the stocks were characterized by median tissue culture-infective dose (TCID50) 
assay in MDCK cells and calculated using the method of Reed and Muench 
[386]. 
In vitro infection of MDM. For infection of adherent MDM, cells were washed 2 
times with macrophage serum-free media (Invitrogen Life Technologies) to 
remove serum from the culture. The cells were infected at an MOI of 1.0 unless 
otherwise indicated diluted in viral growth media containing macrophage serum-
free media supplemented with 0.1% BSA (Invitrogen Life Technologies), 
antibiotics, and Trypsin-TPCK (Sigma) for 1 h. After removing the inoculum, the 
cells were washed 3 times with DPBS. Viral growth media was then added to 
each well and cells were incubated at 37°C with 5% CO2 for 1-36 h depending on 
the experiment.  
Evaluation of MDM cells using light microscope. MDM cells were evaluated 
using a light microscope, Eclipse TS100 (Nikon) using the 4X and 40X 
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objectives. Cell pictures were taken using an attached Digital Sight Camera 
(Nikon). Using previously described methods for identifying resting and active 
macrophage phenotype by microscopy, we evaluated MDM after maturation and 
after IAV infection for their shape (spherical or elongated) and presence of 
protrustions (lamellipodia and filopodia) [382, 383].  
RNA isolation and cDNA synthesis. At the designated time point, total cellular 
RNA was extracted from cells using the TRIzol reagent (Invitrogen Life 
Technologies) according to the manufacturer instructions. The quality and 
quantity of the extracted RNA was assessed using an Experion (BioRad), where 
RNA was accepted for downstream reaction with an integrity value greater than 
7. We used 1 ug of extracted RNA, random hexamer primers, and Superscript III 
reverse transcriptase (Invitrogen Life Technologies) to generate complementary 
DNA (cDNA). HA gene sequences were amplified PCR using Taq Polymerase 
(Invitrogen) and products were visualized on a 1% agarose gel. The sequences 
of the forward primers for H1N1pdm isolates were 5′-
CACCAGTCCACGATTGCAATA-3′ and for BN59 5′-
GAGTAGAGGCTTTGGATCAGGA-3′. The reverse primer was the same for both 
H1N1pdm and seasonal (5′-ATGGGAGGCTGGTGTTTATAGC-3′).  
Real-time PCR of cellular and viral genes. To characterize the surface and 
activation markers expressed in the two populations, monocytes and 
macrophages. Half of the monocytes were either collected in Trizol for RNA/DNA 
extraction for RT-PCR or collected using PBS/0.2% EDTA solution for flow 
cytometry. Monocytes were collected after cells were washed in DPBS and 
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before being placed in media with human serum. The other half were allowed to 
mature through the described protocol and at the 7th day, cells were collected for 
RT-PCR and flow cytometry. Total RNA was isolated, and the expression levels 
were determined by RT-PCR.  
For RT-PCR reactions, 100 ng of cDNA, 10 µM of each gene specific 
primers, and Power SYBR® Green Real-Time PCR master mix (Invitrogen Life 
Technologies) were used.  Primers were designed using PrimerBank software 
[387] or determined using previously published primer sets (Table 9) [376, 388-
391]. The RT-PCR consisted of 1 cycle of 50°C for 5 min and 95°C for 2 min and 
40 cycles of 95°C for 3 s, 60°C for 30 s using the 7900 Fast Real-Time System 
(Applied Biosystems) or VIIA7(Invitrogen Life Technologies). The threshold was 
automatically set and Ct (threshold cycle) determined. For all runs, samples were 
assayed in duplicate and non-template controls were included. Samples were 
normalized using β-actin as the reference endogenous control. The average 
threshold cycles of the replicates were used to compare the expression of the 
genes of interest to the endogenous control (β -actin). This was done using 
the)Ct method, where ΔCt= (Ct (target gene) target-ΔCt (β-actin). The greater the 
ΔCt value, indicating a greater difference between the target gene and 
endogenous control Ct value, indicates a lower level of the target gene 
expression. A smaller ΔCt  value indicates a greater expression of the target 
gene.  
Flow cytometry. For assessing extracellular and intracellular markers in 
monocytes and MDM, cells were detached on ice with 2.5 mM EDTA in PBS. For 
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extracellular staining only, cells were washed and incubated with conjugated 
antibodies (abCam) for 1 h and then fixed in 4% paraformaldehyde.  Cells were 
washed and analyzed using a FACSCalibur (Becton-Dickinson) flow cytometer 
with 10,000 events collected. Data were analyzed using FlowJo® software, 
version 10 (Tree Star).     
Cell viability assay. The CellTox™ Green Cytotoxicity Assay (Promega) was 
used to assess changes in membrane integrity that occur as a result of cell death 
during culture. This assay was performed according to the manufacturer’s 
instructions. Briefly, MDM cells were cultures in a 96-well plate and infected at 
the indicated MOI for 24h. After 24h, the supernatant was removed, the cells 
were washed 3 times in DPBS, and a cyanine dye (Promega) was added to each 
well and allowed to incubate for 15 minutes. Viability (fluorescence) was 
assessed using a Synergy HT Multi-Mode Microplate Reader (Biotek). The 
cyanine dye used in this assay is excluded from viable cells but preferentially 
stains the DNA from dead cells. Therefore, the fluorescence signal produced by 
the binding interaction with dead cell DNA is proportional to cytotoxicity (meaning 
a greater fluorescence indicates greater cell death). A positive control (lysis 
buffer) was added to the cells to cause lysis 4h prior to reading, and represents 
cells that are dead.  
Statistics. For the comparison of two sets of values, Student's t test (two-tailed, 
two-sample equal variance) was used. When comparing three or more sets of 
values, data were analyzed by one-way analysis of variance (ANOVA), followed 
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by posthoc analysis using Tukey's multiple-comparison test. A p-value of ≤0.05 
was considered statistically significant. 
RESULTS 
CHARACTERIZATION OF THE RESTING MACROPHAGE AFTER 7 DAY 
MATURATION. Monocytes, as described in the literature, are mostly classical 
monocytes making up 90% of the human monocyte population and are 
characterized as having high CD14 but no CD16 expression on their cell surface 
[392]. Macrophages on the other hand have been described as having CD11b 
surface expression, with low surface expression level of the monocyte marker 
CD14 [393]. In addition, previous studies have shown mRNA expression of the 
CHI3L1 gene to be exclusively present in macrophages and not monocytes 
[394]. To determine if our culture conditions favored the maturation from 
monocyte to macrophage, we evaluated PBMC’s on day 0 to MDMs on day 7 by 
RT-PCR and flow cytometry. We found our MDM population to be CD11b +, 
CD14 –, CD16 –, and CHI3L1+ (Figure 18A,B) validating our protocol to generate 
MDM from monocytes. 
After the 7 day maturation, we evaluated the cultured cells by light 
microscopy to determine if our cells agreed morphologically with previous studies 
using MDMs. Waldo et al., describe the morphology of MDM at different stages 
of differentiation from resting to activated. They found that under GM-CSF 
conditioning, the majority of MDM cells were elongated as compared to the 
resting MDMs which were spherical [383]. Additionally, Kannan et al. found that 
treating AMs with cultured media from bacterially infected alveolar epithelial cells 
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caused them to activate and the morphology of these activated AMs were shown 
to have lamellipodium and filopodium protrusions by confocal microscopy [382]. 
After selecting for adherence, we observed our 7 day matured MDM culture to be 
primarily made up of spherical cells and limited protrusions were noted on the 
MDM cells (Figure 19A) further confirming our resting model. To further confirm 
the inactive state of our MDM cultures, transcriptional analyses were performed 
showing expression levels of CD80, CD64, CD163, HO-1, CD200R, CD36 and 
CD206 to be consistent with low activation or a resting MDM population (Figure 
19B) [376, 395].  
OPTIMIZATION OF THE IAV-MDM INFECTION PROTOCOL  
Media used for MDM infection. As mentioned in previous chapters, IAV 
requires host cell proteases for HA cleavage and entry into the host cell. For 
immortalized and non-epithelial cell lines, TPCK trypsin is added to the culture 
media to mimic that conditions the virus would see inside the human host. The 
concentration of trypsin to add to the culture media must be optimized to ensure 
there is enough to allow infection but also not too much to destroy the cells. For 
MDM, previous studies have used a concentration of 1ug/ml of TPCK trypsin in 
their media. We evaluated 0, 0.5, 1.0, and 1.5 ug/ml TPCK trypsin and evaluated 
toxicity by observing the cells using a light microscope at 8, 24, 48, and 72h after 
addition. We observed significant MDM cell detachment (characteristic of 
adverse effects of TPCK trypsin) when adding 1.5ug/ml starting at 24h after 
addition. We observed no difference in cells detaching for MDM treated with 0, 
0.5, and 1.0 ug/ml across 8, 24, and 48h. However, by 72h we observed all three 
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induced detachment. Because this occurred at the 0 ug/ml TPCK treatment, we 
assumed the cells were dying as a result of serum starvation and not TPCK 
addition. With this information, we decided to evaluate the IAV-MDM interaction 
at the earlier time points when serum starvation did not seem to be a factor. 
Further, we used 1ug/ml of TPCK in our infection culture media as our 
observations showed no toxicity at 8, 24, and 48h after addition. Previous studies 
looking at IAV-MDM interactions used the 1ug/ml TPCK trypsin concentration 
[222, 353, 391] and since we did not see a difference between 0.5 and 1ug/ml we 
decided to move forward using 1ug/ml so we could best compare our results to 
others.  
Influenza virus stock comparison. Influenza stock viruses are produced 
primarily through passage in the allantoic sac of embryonic chicken eggs or 
through passage in a susceptible mammalian cell line [396]. To summarize, the 
egg-derived virus is produced by serial passage of IAV in the allontoic fluid of 
eggs where the virus replicates to high titers in the chorioallantoic membrane 
cells. The amplified virus is then collected in the allontoic fluid and the titer 
confirmed by TCID50 assay. Cell-derived virus is produced by serial passage of 
IAV in confluent, susceptible mammalian cells in cell culture infection media 
containing bovine-serum albumin, HEPES buffer, and TPCK trypsin. Once 
substantial cytopathic effect occurs in these cells, the supernatant is collected, 
spun down and the titer confirmed by TCID50 assay.  
  Here we compared influenza isolates derived in eggs to those derived in 
cell cultures to determine if there was a difference in activation and their ability to 
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infect MDM. Using 1ug/ml of TPCK and an MOI of 1.0 we first looked at the 
cellular morphology 24h post-infection. We saw significant changes in 
morphology in cultures infected with egg-derived viruses compared to cell-
derived viruses (Figure 20A). We then evaluated the amount of virus present in 
the supernatant after 24h by TCID50 assay as an indication of virus infection and 
replication in those cells. We found the egg-derived virus stocks replicated very 
poorly in MDM with the two H1N1pdm isolate titers below the limit of detection 
(Figure 20B).  
 We then asked if this discrepancy could be a result of sequence variations 
selected for after passage in the different systems. Previous studies have shown 
serial passage of human IAVs (H3N2 and H1N1) in eggs create viruses that 
acquire mutations in their HA gene after isolation compared to sequences of 
those isolated in mammalian cells [397-402]. Further, human H3N2 viruses 
isolated in cell culture were reported to bind with a high affinity to alpha-2,6-SA, 
while viruses isolated in eggs often had increased specificity for alpha-2,3-SA 
[403, 404]. According to sequencing analysis, done by Ryan McAllister in our 
laboratory, the egg-derived and MDCK-derived H1N1pdm and seasonal viruses 
shared the same sequence and does not explain the discrepancy in cell changes 
and differences in the viral isolate’s abilities to infect MDM. Therefore suggesting 
a component of the allontoic fluid induces changes in the MDM that decrease 
permissibility to infection. Hence we moved forward to study IAV-MDM 
interactions using MDCK-derived viruses.  
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Multiplicity of infection. Studies on IAV-macrophage interactions have used a 
wide range of MOIs [222, 307, 351, 405].  One study specifically by Hoeve et al. 
showed a significant difference in HA expression in MDM at different MOIs of 
H3N2 [355]. We sought to determine the optimal amount of virus to add that 
permits infection of MDM but that minimizes harm to the cells. To do this we 
performed infections with two H1N1pdm and one seasonal H1N1 isolate in MDM 
at 0, 1, 3, and 5 MOI. We monitored both the cell viability by Cytotoxicity Assay 
and viral titer by TCID50 assay 24h post-infection. For KY180, there was no 
significant difference in cellular cytotoxicity (Figure 21A). By TCID50 assay, the 
viral titers produced from infected MDM were not dose dependent and this was 
shown for both H1N1pdm and seasonal H1N1 isolates (Figure 21B). Thus, our 
question became which MOI to choose.  
The major limitation of our laboratory is that our MDCK-derived virus stock 
titers are low. The current titers of our stocks are roughly 5x106 pfu/ml, meaning 
to obtain an MOI of 1.0 on a culture of 200,000 cells requires 40 µl of virus stock 
per well. This virus is diluted up to 100 µl in macrophage serum-free infection 
media for the 1h duration of the infection. However, if we use an MOI of 5.0, it 
would require us to use 5 times the volume of the stock virus (200 µl). This 
volume is greater than the 100 µl of media generally used for infection which 
could affect the overall infection protocol. Additionally, the MDCK-derived viruses 
may contain cytokines produced from the infected cultures. Diluting these factors 
out during infection likely minimizes their effects on the MDM; however, if we add 
5 times the amount of stock virus, it could potentially alter the MDM activation 
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state and prematurely affect the outcome of our experiment. Thus not allowing us 
to determine whether the effects were viral or culture induced (Figure 21). 
Because we saw no significant difference in titers, we decided to move forward 
with an MOI that would allow us to utilize the standard 100 µl infection conditions.  
Confirmation of infection of MDM with IAV by PCR. To determine whether the 
‘resting’ MDM culture model supported infection of H1N1pdm and seasonal 
isolates, we infected MDM for 8, 12 and 24h and confirmed the presence of 
intracellular viral RNA by PCR amplification of HA. All three isolates were shown 
to infect MDM as demonstrated in figure 3-5. By 24 hpi, MDM showed 
comparable amounts of intracellular HA for all isolates (Figure 22). The ability of 
our viruses to enter into MDM provided us the confidence to move forward to 
compare IAV-MDM interactions using the resting MDM model with our H1N1pdm 
and seasonal isolates.  
DISCUSSION 
To better understand the early events that take place after IAV-infection, 
we have developed a “resting” MDM model of IAV infection. This model 
represents a non-activated macrophage that is recruited to the site of infection 
with no previous exposures to the lung microenvironment. While developing and 
optimizing the conditions this model, careful consideration was taken to obtain a 
resting MDM model that is permissive to IAV infection while minimizing 
confounding factors that could affect our experimental outcome. Taking into 
account the conditions utilized by previous studies, we confirmed that our model 
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was indeed “resting”, that these cells were permissive to IAV infection and that 
the viral infection culture conditions were minimally harmful to the cells.   
Previously published studies suggest that influenza viruses differ in their 
ability to infect and replicate in macrophages [353, 357]. In contrast [405], and in 
support of the work of others [353, 354, 356], we demonstrated that seasonal 
and pandemic (H1N1) viruses are not restricted in their ability to be internalized 
by macrophages. Further, results on the innate immune responses generated in 
infected macrophages differed when comparing low pathogenic IAV (LPIAV) to 
high pathogenic IAV (HPIAV). Specifically, some show greater induction of pro-
inflammatory and anti-viral responses in MDM after HPIAV infection [307, 406] 
whereas others found an impaired induction after HPIAV infection [405]. These 
inconsistencies may be a result of the culture methods used as pre-treating the 
human macrophages with GM-CSF has been shown polarize these cells into 
“activated” phenotypes and represent macrophages in the later stages of 
infection. By minimizing the confounding factors before infection, we have 
established an MDM model that will allow us to uncover the composition and 
magnitude of early influenza-specific responses after infection. This allows us to 
focus on what the virus does to the cell (early events) instead of what the cell 
potentially does to the virus (late events). 
The susceptibility and early functional responses that take place after IAV-
infection in human immune cells remains ill defined. Specifically, there are limited 
reports on infectivity and the phenotype of human blood-derived macrophages 
infected with different IAVs and the induction of PRRs has not been assessed. 
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Our prior studies in mice suggested that the composition of the innate responses 
in macrophages may differ between closely-related clinical isolates of H1N1pdm 
[298]. The next chapter will focus our analysis of isolate specific differences 
within the resting MDM model to determine how the IAV-MDM interactions differ 
between isolates of the same strain.  
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Figure 17. Schematic of recruitment of macrophages to site of infection. 
Monocytes originate from progenitors in the bone marrow and traffic via the 
bloodstream to peripheral tissues. During both homeostasis and inflammation, 
circulating monocytes leave the bloodstream and migrate into tissues where, 
following conditioning by local growth factors and cytokines, they differentiate into 
macrophage or dendritic cell populations. Recruitment of monocytes is essential 
for effective control and clearance of viral infections. An increase in the number 
of these cells and their respective inflammatory responses have been linked to 
severe lung immunopathology after IAV infection with influenza-associated 
pneumonia characterized by an early influx of neutrophils and a large number of 
blood-derived monocytes within the first days of infection. Seasonal IAV 
predominantly targets the upper respiratory tract and severe HPAIV H5N1 
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targets the lower. The epidemiology of H1N1pdm suggested it had a broader 
tropism for both the upper and lower respiratory tracts indicating a range of 
pathologies are possible depending on which lung compartment becomes 
flooded with recruited cells.  
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Table 9. Primers utilized for RT-PCR and cDNA synthesis. 
Primer M1or M2 
Ref Forward Reverse 
TNF M1 4 AACCTCCTCTCTGCCATC ATGTTCGTCCTCCTCACA IL6 M1 6 ACTCACCTCTTCAGAACGAATTG CCATCTTTGGAAGGTTCAGGTTG CXCL11 (IP11) M1 4 CCTGGGGTAAAAGCAGTGAA TGGGATTTAGGCATCGTTGT CXCL10 (IP10) M1 6 GTGGCATTCAAGGAGTACCTC TGATGGCCTTCGATTCTGGATT CCL5 M1 6 CCAGCAGTCGTCTTTGTCAC CTCTGGGTTGGCACACACTT TGFB M2 2 AAGGACCTCGGCTGGAAGTG CCCGGGTTATGCTGGTTGTA IL1B M1 4 GGGCCTCAAGGAAAAGAATC TTCTGCTTGAGAGGTGCTGA IL10 M2 6 GACTTTAAGGGTTACCTGGGTTG TCACATGCGCCTTGATGTCTG IL12p35 M1 4 GATGGCCCTGTGCCTTAGTA TCAAGGGAGGATTTTTGTGG IDO1 M2 4 GCGCTGTTGGAAATAGCTTC CAGGACGTCAAAGCACTGAA PPARy M2 4 TTCAGAAATGCCTTGCAGTG CCAACAGCTTCTCCTTCTCG IFNB M1 6 GCTTGGATTCCTACAAAGAAGCA ATAGATGGTCAATGCGGCGTC IFNA M1 6 TCATGGTGTATATCAGCCTCGT AGTTGGTACAATGGAGTGGTTTT IFNY M1 6 TCGGTAACTGACTTGAATGTCCA TCGCTTCCCTGTTTTAGCTGC RIGI  6 CTGGACCCTACCTACATCCTG GGCATCCAAAAAGCCACGG MDA5  6 GCCCGCTACATGAACCCTG CAGCAATCCGGTTTCTGTCTT TLR3  6 TTGCCTTGTATCTACTTTTGGGG TCAACACTGTTATGTTTGTGGGT TLR7  6 CACATACCAGACATCTCCCCA CCCAGTGGAATAGGTACAGTT MyD88  6 GGCTGCTCTCAACATGCGA CTGTGTCCGCACGTTCAAGA TRIF (TICAM1)  6 CCTGGAATCATCATCGGAACAG TGAGTGGTCTATGGCGTCCT NFKB  6 GAAGCACGAATGACAGAGGC GCTTGGCGGATTAGCTCTTTT IRF3  6 AGAGGCTCGTGATGGTCAAG AGGTCCACAGTATTCTCCAGG 
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IRF7  6 CCCACGCTATACCATCRACCT GATGTCGTCATAGAGGCTGTTG CASP1  6 TTTCCGCAAGGTTCGATTTTCA GGCATCTGCGCTCTACCATC CD11b M, Mo 
5 GCCGGTGAAATCTGCTGTCT GCGGTCCCATATGACAGTCT 
CD36 M, Mo 
4 AGATGCAGCCTCATTTCCAC GCCTTGGATGGAAGAACAAA 
CD80 M, M1 
3 CTGCCTGACCTACTGCTTTG GGCGTACACTTTCCCTTCTC 
CD64 M, Mo 
6 AGCTGTGAAACAAAGTTGCTC GGTCTTGCTGCCCATGTAGA 
CD200R M2 6 TGGTTGTTGAAAGTCAATGGCT CTCAGATGCCTTCACCTTGTTT CD14 M, Mo 
3 AAAGCACTTCCAGAGCCTGT ATCGTCCAGCTCACAAGGTT 
CD163 Mo 3 ACATAGATCATGCATCTGTCATTG ATTCTCCTTGGAATCTCACTTCTA CD16 M 3 CACCATCACTCAAGGTTTGG AGTCCTGTGTCCACCTGCAAA CHI3TL1 M, M1 
4 GATAGCCTCCAACACCCAGA AATTCGGCCTTCATTTCCTT 
HO-1 M, M2 
3 ACTTTCAGAAGGGCCAGGT TTGTTGCGCTCAATCTCCT 
CCR7 M1 3 GTGGTGGCTCTCCTTGTCAT TGTGGTGTTGTCTCCGATGT CCL22 M2 3 ATTACGTCCGTTACCGTCTG TAGGCTCTTCATTGGCTCAG MRC1 (CD206) M, M2 
3 GGCGGTGACCTCACAAGTAT ACGAAGCCATTTGGTAAACG 
Beta Actin  6 ATTGCCGACAGGATGCAGAA GCTGATCCACATCTGCTGGAA Influenza NP mRNA (for PCR) 
 1 CCAGATCGTTCGAGTCGT CGATCGTGCCTTCCTTTG 
Influenza NP vRNA (for PCR) 
 1 GGCCGTCATGGTGGCGAAT CTCAGAATGAGTGCTGACCGTGCC 
Influenza NP cRNA (for PCR) 
 1 GCTAGCTTCAGCTAGGCATC CGATCGTGCCTTCCTTTG 
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Influenza NP mRNA (for cDNA) 
 1 CCAGATCGTTCGAGTCGTTTTTTTTTTTTTTTTTCTTCAACTGTC 
Influenza NP vRNA (for cDNA) 
 1 GGCCGTCATGGTGGCGAATAAATGGACGAAGGACAAGGGTTGC 
Influenza NP cRNA (for cDNA) 
 1 GCTAGCTTCAGCTAGGCATCAGTAGAAACAAGGGTATTTTTCTTC 
M1, pro-inflammatory macrophage marker; M2, anti-inflammatory macrophage marker; Mo, monocyte marker; M macrophage marker.  
Source of primer (Ref): 1 Cline TD, et al. 2013. Journal of virology 87:1411-1419. 
2 Soulitzis N, 2006. International journal of oncology, 29:305-314. 3 Ambarus, C.A., et al., 2012. J Immunol Methods, 375(1-2): p. 196-206;  4Jaguin, M., et al., 2013. Cell Immunol, 281(1): p. 51-61;  5 Moeenrezakhanlou A, et al., 2008. Journal of leukocyte biology 84:519-528.  6 Spandidos A, et al. 2010. Nucleic acids research 38:D792-799.  
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 Figure 18. Schematic of approach used to culture resting MDM and 
characterization of the ‘resting’ human monocyte-derived macrophage model by 
RT-PCR and flow cytometry. (A) Peripheral blood mononuclear cells (PBMCs) 
were obtained from healthy donors and isolated using plasma-percoll gradients 
by the University of Louisville Nephrology Department. MDM were generated as 
previously described with slight modifications. PBMCs were washed twice in 
DPBS and resuspended in culture media containing human serum and plated on 
6 well low-attach plates. Monocytes were allowed to mature for 5 days and 
further removed from low-attach plates gently using a cell lifter, washed twice 
with DPBS supplemented with human serum, and resuspended and plated on an 
adherent cell culture plate for 2 days. MDM were selected by adherence after 2 
days by washing with DPBS with human serum.  RT-PCR and flow cytometry 
were employed to characterize the known monocyte and macrophage surface 
markers expressed in the two populations, monocytes and macrophages. Half of 
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the monocytes were either collected in Trizol for RNA/DNA extraction for RT-
PCR or collected using PBS/0.2% EDTA solution for flow cytometry. Monocytes 
were collected after cells were washed in DPBS and before being placed in 
media with human serum. The other half were allowed to mature through the 
described protocol and at the 7th day, cells were collected for RT-PCR and flow 
cytometry. (B) Total RNA was isolated, and the expression levels were 
determined by RT-PCR. The data shown represent three replicates of 1 
representative donor of 2. RNA levels were normalized to β-actin and presented 
as ΔCt as described in the materials and methods. (C) The percentage of CD14 
and CD11b MDM cells was determined by flow cytometry. Cells were collected in 
PBS/0.2%EDTA, fixed with 4% paraformaldehyde and stained with anti-CD11b 
(FITC-labeled) or anti-CD14 (APC-labeled) antibodies and evaluated on flow 
cytometer. Gates were established with unstained cells where less than 1% were 
FITC or APC positive. Analysis was conducted using FlowJo® software. 
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Figure 19. Characterization of ‘resting’ human monocyte-derived macrophages 
model by microscopy and RT-PCR. Human MDM were cultured as described in 
the Methods section from peripheral blood mononuclear cells (PBMCs). (A) After 
the 7 day maturation process, adherent macrophages were selected for and the 
morphology was assessed using light microscope using the 10X objective. (B) 
Further RT-PCR was employed to characterize the activation markers expressed 
in the adherent macrophages. The cells were collected in Trizol and total RNA 
was isolated, and the expression levels were determined by RT-PCR. The data 
shown represent three replicates of 1 representative donor of 2. Expression 
levels were normalized to β-actin and presented as ΔCt as described in the 
materials and methods.  
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Figure 20. Evaluation cell morphology and permissibility of MDM infection to egg-
derived and cell-derived viral stocks. MDM cells were infected with an MOI of 1 of 
seasonal (BN59) or pandemic (KY180, KY136) isolates. The figure is 
representative of results from 2 donors. (A) Cell morphology was assessed using 
light microscope using the 10X objective. (B) TCID50 assay was performed on 
supernatants from infected MDM cultures pictured in (A) at 24h post-infection. 
Data are presented as the mean+SD from 3 replicates from one donor. Asterisks 
indicate significance of p<0.05(*), p<0.01(**), and p<0.001(***) respectively. The 
dotted line indicates the limit of detection of the TCID50 assay.  
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Figure 21. Cell Viability at different MOIs 24h post-infection. (A) For cell viability 
assay, the CellTox Cytotoxicity assay (Promega) was performed according to 
manufacturer’s instructions. Positive control wells received lysis buffer 
approximately 4 hours before cytotoxicity assay was performed. At 24h post-
infection with KY180 (MDCK-derived virus) cyanine dye (Promega) was added to 
each well and allowed to incubate for 15 minutes. Fluorescence was then 
measured on a multi-well fluorescence plate reader (BioTek). Raw fluorescent 
intensity values were converted to base 10 logarithm values for analysis. (B) 
TCID50 assay was performed on supernatants from MDM infected with 1 MOI of 
seasonal (BN59) or pandemic (KY180, KY136) MDCK-derived viral isolates at 
24h post-infection. Data are presented as the mean+SD from 3 replicates from 
one donor. Asterisks indicate significance of p<0.05(*), p<0.01(**), and 
p<0.001(***) respectively. The dotted line indicates the limit of detection of the 
TCID50 assay.  
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Figure 22. Infection of MDM by H1N1pdm isolates. Cells were infected with and 
MOI of 1.0 and cell lysates were collected at 24h post-infection and vRNA levels 
were determined by PCR using HA gene specific primers. The data shown is 
representative 2 donors tested at 24h post-infection. Primers to amplify 18sRNA 
were used as a control.  
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CHAPTER 4  
ENTRY-DEPENDENT INNATE SIGNALING OF INFLUENZA H1N1 VIRUSES IN HUMAN MACROPHAGES 
OVERVIEW 
Responses to IAV infection are mediated by multiple immune and non-
immune cell populations. Specifically, macrophages play a central role in the 
early innate immune responses and are found in abundance in lungs of patients 
with fatal pneumonia. These macrophages include resident alveolar and also 
infiltrating peripheral blood monocyte-derived macrophages. The precise 
contribution of these individual cell populations to H1N1pdm induced 
inflammation remains to be defined. Using an in vitro model of primary human 
monocyte-derived macrophages (MDM), our laboratory sought to define isolate 
specific differences between 2009 pandemic H1N1 (H1N1pdm) isolates shown to 
have a fatal (A/KY/180/10) and nonfatal (A/KY/136/09) outcome in hospitalized 
patients but share greater than 99% sequence homology. Our previous in vitro 
studies of human well-differentiated epithelial cells infected with these isolates 
identified a differential polarized secretion for CCL5 with greater basal levels in 
cells infected with KY180. Given the role of CCL5 in monocyte recruitment, we 
postulated that differences in virus-host interactions between these two closely-
related isolates may occur in recruited macrophages. To address our hypothesis, 
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the kinetics of infection (plaque assay and gene expression) and innate immune 
responses (gene expression) were assessed in “resting” MDM at 8, 24 and 36 
hours post-infection (hpi). We infected MDM with H1N1pdm (A/KY/180/10, 
A/KY/136/09, A/NL/602/09) or seasonal H1N1 (A/BN/59/07) viruses at an MOI=1. 
All isolates infected macrophages showing increased titers over time. Pro- and 
anti-inflammatory mRNA levels differed markedly between the lethal (KY180) 
isolate compared to the nonlethal (KY136) and seasonal (BN59) H1N1 isolates. 
At 8 HPI, KY136 and BN59-infected MDM showed significantly greater levels of 
IFNy, CCL5, CXCL11, CXCL10, TNF, and IDO as well as pattern-recognition 
receptors RIGI, TLR3, TLR7, IRF3, and IRF7 compared to KY180.  IL10, TGFβ 
and PPARy (all anti-inflammatory) were not elevated by any virus. By 24hpi, all 3 
IAVs showed similar profiles, although the magnitude of the response was lower 
in cells infected by KY/180. This apparent delay in pro-inflammatory response 
and intracellular signaling by KY180 was found to be dependent on the mode of 
viral entry, as determined using inhibitors to macropinocytosis, and were mapped 
to the D222G mutation within the HA1 gene of KY180. We further revealed a 
greater number of KY180 viruses to have a filamentous shape suggesting the 
differences in route of entry may be dependent on the viral shape. This study 
reveals a novel mechanism for differences between the host responses to 
different circulating IAV isolates of the same strain.  
INTRODUCTION 
In response to viral infection, the release of cytokines and chemokines 
from the host shows both beneficial activation of innate and adaptive immunity, 
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and harmful effects, including high fever, shock symptoms, and cell damage.  
[232, 407-409]. The composition, timing, and magnitude of the host response to 
the virus infection is critical to the outcome of infection. The complex nature of 
pathogen-host interactions are reflected in the diverse range of patient outcomes 
such as those observed each year from seasonal influenza A virus (IAV) infection 
[345, 410-412].  Specifically, during the 2009 pandemic, severe clinical cases 
showed a slower decline in nasopharyngeal viral loads and had higher plasma 
levels of pro-inflammatory cytokines and chemokines [413]. Thus suggesting that 
timing and regulation of the host response is critical to the outcome of infection. 
MDM can be categorized into two subsets  including a healing/growth 
promoting anti-inflammatory macrophages (previously known as M2 or 
alternatively activated), to a killing pro-inflammatory macrophage (previously 
known as M1 or classically activated) [414]. Specific markers associated with 
these two phenotypes are summarized in figure 23 [370, 376, 378, 388, 395, 
415-417]. A balance between the pro- and anti- inflammatory conditions in the 
lung is critical for lung homeostasis and limiting immunopathology associated 
with infection (Figure 24) [418]. Hypercytokenemia, a hallmark of HPAIV, is 
characterized by an unusually high pro-inflammatory and low anti-inflammatory 
response in MDM [307]. Further, studies have found AM are less responsive to 
MDM in pro-inflammatory cytokine induction, suggesting the source of 
hypercytokenemia during H5N1 infection are the MDMs [353]. Thus highlighting 
the importance of understanding the IAV-MDM interaction and how this may 
relate to disease.  
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Studies evaluating IAV infection in MDM also show variation between 
IAVs with some studies reporting productive replication in MDM [222, 307, 351, 
353-357, 405] while others show IAV does not replicate productively [353, 357]. 
Further, results on the innate immune responses generated in infected 
macrophages differed when comparing low pathogenic IAV (LPAIV) to high 
pathogenic IAV (HPAIV). Specifically, some show greater induction of pro-
inflammatory and anti-viral responses in MDM after HPAIV infection [307, 406] 
whereas others found an impaired induction after HPAIV infection [405]. One 
possible explanation that may distinguish IAVs within the human macrophage 
models may occur through interactions with pattern recognition receptors 
(PRRs). PRRs that recognize IAV RNA include cytoplasmic RLRs (RIGI and 
MDA5), and endosome-associated TLRs (TLR3, 7) [325, 381]. These recognition 
receptors are important in activating downstream transcription factors resulting in 
activation of gene expression and synthesis of cytokines, chemokines, cell 
adhesion molecules, and immune receptors [325, 381]. Specifically, these early 
host responses to infection represent an important link to the adaptive immune 
response.  
IAVs are highly pleomorphic, showing mostly spherical (80-120nm 
diameter), but other forms have been reported including long filamentous 
particles (up to 400 nm long and 80-120 nm in diameter) [20, 212] (Figure 5). 
Different strains of IAV vary in their shapes with filamentous forms of IAV being 
noted in the literature for many years [104, 213, 214]. The filamentous phenotype 
has been mapped to HA, NA, M1, and M2 [39-44]. Specifically, studies using a 
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reverse genetics approach identified specific viral genes and amino acids within 
those genes that influence filament formation. They were able to link the ability to 
form filaments to sequence variations in the M1 protein and M2 protein [39, 40, 
216-221]. Recent work utilizing a filamentous strain of influenza virus (H3N2 
Udorn) showed that the virus entered cells as efficiently as the spherical forms; 
however, this occurred with slightly delayed kinetics suggesting another source 
of variation that could affect viral tropism [92]. Thus this delayed entry may be 
due to differences in the virus shape and therefore, differences in viral entry 
pathways elicited. IAVs have been shown to enter epithelial cells via both 
clathrin-mediated endocytosis and macropinocytosis [92-96]. No current 
evidence exists that toll-like receptors exist within macropinosomes suggesting a 
potential correlation with mode of viral entry and exposure to the full range of 
recognition receptors [110].  Thus differences in mode of viral entry into 
susceptible macrophages may provide a mechanism for differences in activation 
of inflammatory responses in MDM models.  
Herein we report a delayed expression of activation markers in MDM, 
specifically CD80, CD64, CD200R, and CCR7, by our more lethal H1N1pdm 
isolate KY180. Further, we found a delay in pro-inflammatory responses and 
intracellular signaling by KY180 which was not found to be due to differences in 
apoptosis, requiring a replicating virus to induce a response, the ability of the 
viruses to regulate the intracellular signaling and protein synthesis, or the pH of 
viral fusion and entry. To further determine the mechanism for this delay, we 
evaluated the shape of KY180 and KY136 by electron microscopy. We revealed 
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a greater number of KY180 viruses to have a filamentous shape suggesting the 
route of entry may be different between the two viruses. Using specific inhibitors 
of clathrin-mediated endocytosis and macropinocytosis, we found KY180 to have 
a greater sensitivity to macropinocytosis inhibitors suggesting this to be the main 
route of KY180 entry into MDM. Using reverse genetics and interchanging KY180 
HA gene onto the NL602 virus (another 2009pdm H1N1 virus) background, we 
were able to map the entry phenotype as well as the gene expression of innate 
signaling genes to the HA gene of KY180. Further, we found the D222G mutation 
within the HA1 gene to be strongly associated with the KY180 phenotype. This 
study reveals a novel mechanism for differences between the host responses to 
different circulating IAV isolates of the same strain. 
METHODS 
Isolation and differentiation of MDM. Peripheral blood mononuclear cells 
(PBMCs) were obtained from healthy donors and isolated using plasma-percoll 
gradients by the University of Louisville Nephrology Department. protocol 
developed by Dr. Suttles laboratory at the University of Louisville as previously 
described with slight modifications [384]. Briefly, PBMCs were washed twice in 
Dulbeccos PBS (DPBS, HyClone with Magnesium and Calcium, ThermoFisher) 
and resuspended with final concentration at 2x106 cells/ml in R5 media, which 
contains RPMI 1640 (HyClone, ThermoFisher) supplemented with 5% heat 
inactivated human AB serum (Atlanta Biologics), 0.01M HEPES (Invitrogen Life 
Technologies), and 2ml Pen/Strep (Invitrogen Life Technologies). Monocytes 
were plated on 6 well low-attach plates (ThermoFisher) at a volume of 4 ml per 
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well. Monocytes were allowed to mature for 5 days in a 37ᵒ C incubator with 5% 
CO2. After the maturation period, cells were removed from low-attach plates 
gently using a cell lifter (Costar, ThermoFisher), washed twice with DPBS 
supplemented with 0.2% human AB serum, and resuspended at 4x106 cells/ml in 
R5 media. Cells were plated (4x10^6 cells/ml) and allowed to adhere for two 
days. Mature MDM were selected by adherence after 2 days by washing with 
DPBS with 0.2% human AB serum. Cells were incubated in R5 media for 1 h 
prior to infection/treatment.  
Influenza viruses. Viruses used for these experiments included H1N1 IAV 
isolates from human clinical patients during the 2009 pandemic A/KY180/2010 
(KY180) and A/KY136/2009 (KY136) [298, 385]. For comparison, we also 
included a seasonal H1N1 IAV vaccine strain A/Brisbane/59/2007 (BN59) (kindly 
provided by the Centers for Disease Control and Prevention, Virus Surveillance 
and Diagnosis Branch, Influenza Division).  Viral seed stocks were prepared as 
previously described [298] in MDCK cells and stored at -80˚C. Viral titers of the 
stocks were characterized by median tissue culture-infective dose (TCID50) assay 
in MDCK cells and calculated using the method of Reed and Muench [386]. 
In vitro infection of MDM. For infection of adherent MDM, cells were washed 2 
times with macrophage serum-free media (Invitrogen Life Technologies) to 
remove serum from the culture. The cells were infected at an MOI of 1.0 unless 
otherwise indicated diluted in viral growth media containing macrophage serum-
free media supplemented with 0.1% BSA (Invitrogen Life Technologies), 
antibiotics, and 1µg/ml Trypsin-TPCK (Sigma) for1 h. After removing the 
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inoculum, the cells were washed 3 times with DPBS. Viral growth media was 
then added to each well and cells were incubated at 37°C with 5% CO2 for 1-36 
h depending on the experiment.  
Plaque assay was used to determine viral titers on supernatant from MDM 
after infection. Briefly, MDCK cells were plated in six-well format, viral dilutions 
were added to cell monolayer with 2.5% Avicel, and plates were allowed to 
incubate for 3 days. Cells were fixed in 0.4% paraformaldehyde and visualized 
using crystal violet.  Plaques were counted and the number of plaque forming 
units (pfu) per milliter (pfu/ml) was determined.  
RNA isolation and cDNA synthesis. At the designated timepoint, total cellular 
RNA was extracted from cells using the Trizol reagent (Invitrogen Life 
Technologies) according to the manufacturer instructions. The quality and 
quantity of the extracted RNA was assessed using an Experion (BioRad), where 
RNA was accepted for downstream reaction with an integrity value greater than 
7. For evaluation of cytokine and intracellular signaling genes, we used 1 ug of 
extracted RNA, random hexamer primers, and Superscript III reverse 
transcriptase (Invitrogen Life Technologies) to generate complementary DNA 
(cDNA) for downstream real time-PCR (RT-PCR) reactions.  
For detection of viral RNA (vRNA), messenger RNA (mRNA), and 
complimentary RNA (cRNA) we used 1 µg of RNA along with primers specific for 
amplifying influenza A nucleoprotein vRNA, mRNA, and cRNA to generate 
cDNA. Gene specific primers (10 µM) ([391], primers summarized in Table 9) 
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were combined with RNA and SuperScript III reverse transcriptase for this 
reaction (Invitrogen Life Technologies).  
Real-time PCR of cellular and viral genes. To characterize the surface and 
activation markers expressed in the two populations, monocytes and 
macrophages. Half of the monocytes were either collected in Trizol for RNA/DNA 
extraction for RT-PCR or collected using PBS/0.2% EDTA solution for flow 
cytometry. Monocytes were collected after cells were washed in DPBS and 
before being placed in media with human serum. The other half were allowed to 
mature through the described protocol and at the 7th day, cells were collected for 
RT-PCR and flow cytometry. Total RNA was isolated, and the expression levels 
were determined by RT-PCR.  
For RT-PCR reactions, 100 ng of cDNA, 10 µM of each gene specific 
primers, and Power SYBR® Green Real-Time PCR master mix (Invitrogen Life 
Technologies) were used.  Primers were designed using PrimerBank software 
[387] or determined using previously published primer sets (Table 9) [376, 388-
391]. The RT-PCR consisted of 1 cycle of 50°C for 5 min and 95°C for 2 min and 
40 cycles of 95°C for 3 s, 60°C for 30 s using the 7900 Fast Real-Time System 
(Applied Biosystems) or VIIA7(Invitrogen Life Technologies). The threshold was 
automatically set and Ct (threshold cycle) determined. For all runs, samples were 
assayed in duplicate and non-template controls were included. Samples were 
normalized using β-actin as the reference endogenous control. The average 
threshold cycles of the replicates were used to compare the infected and 
uninfected controls using delta-delta (ΔΔ)Ct method, using the following formula: 
121 
ΔΔCt= (ΔCt (infected) target-ΔCt (infected) reference)- (ΔCt target (uninfected)-
ΔCt (uninfected) reference). The fold change was determined using the following 
formula: 2-ΔΔCt.  
Flow cytometry. For assessing extracellular and intracellular markers in 
monocytes and MDM, cells were detached on ice with 2.5 mM EDTA in PBS. For 
extracellular staining only, cells were washed and incubated with conjugated 
antibodies (abCam) for 1 h and then fixed in 4% paraformaldehyde.  For 
intracellular staining, cells were collected, washed and fixed in 4% 
paraformaldehyde for 15 minutes, followed by permeabilization with 10X 
permeabilization buffer (2% saponin,  4% Goat Serum in DPBS) for 20 minutes. 
1 × 105 cells were incubated with either influenza nucleoprotein fluorescein 
isothiocyanate conjugated antibody (NP-FITC, AbCam #ab20921) or intracellular 
cytokine primary antibodies (BD Biosciences) diluted in 1X permeabilization 
buffer for 1h. Cells were washed and analyzed using a FACSCalibur (Becton-
Dickinson) flow cytometer with 10,000 events collected. Data were analyzed 
using FlowJo® software, version 10 (Tree Star).     
Immunofluorescence. MDM were cultured on hydrogen chloride treated glass 
coverslips (Bioscience Tools) in a 24-well plate (Corning).  Cells were infected at 
an MOI of 1.0 for 1h and washed 3 times with DPBS to remove unbound virus. 
Viral growth media was replaced and incubated for 24h. Cells were fixed with 4% 
paraformaldehyde in DPBS and permeabilized using 0.2% saponin. After 
blocking with 5% FBS/2%BSA in phosphate buffered saline, cells were stained 
with the primary antibodies as indicated (diluted in DPBS containing 5% FBS) 
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followed by incubation with AlexaFluor-conjugated secondary antibodies (diluted 
in DPBS containing 5% FBS). Slides were embedded using Pro-Long anti-fade 
(Molecular Probes), mounted and analyzed using a Zeiss LSM710 Meta confocal 
laser-scanning microscope. 
Kynurenine Assay (Indirect assay for IDO1 enzymatic activity). This assay 
was done on culture supernatants from two donor sets. 100μL of supernatant 
was collected from infected MDM, as described above. The supernatants were 
mixed with 30% trichloroacetic acid (Sigma) and vortexed. Mixture was 
centrifuged for 5 minutes (9000 xg) and supernatant was then mixed in a 1:1 
ratio with Ehrlich reagent (Sigma) in a 96 well plate format. The optical density 
was measured immediately at 492nm on a plate reader. This is an indirect 
method for measuring kynurenines. The reaction of the aromatic amino group of 
kynurenine with p-dimethylaminobenzaldehyde (in the Ehrlich reagent) results in 
an imine product that can be measured at 492nm. This protocol was provided by 
Jessica Zourelias from the University of New York in Buffalo.  
Protein Isolation. Mock- or influenza virus-infected MDM cells were collected in 
Trizol reagent (Invitrogen Life Technologies) and protein isolated according to the 
manufacturer. Briefly, protein was dialyzed using 10,000 molecular weight cut-off 
SnakeSkin® dialysis tubing (ThermoFisher) in 0.1% SDS overnight. Dialyzed 
protein was centrifuged at 10,000xg for 10 min and protein pellets were 
resuspended in 8M Urea/1%SDS and heated to 50oC. Amount of protein in each 
sample was quantitated using Bradford Assay (Thermo Scientific).   
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Western blot. For Western blot analysis, 15 µg of protein from whole-cell lysate 
was heat denatured in cracking buffer (60 mM Tris (pH 6.8), 6M Urea, 1% SDS, 
1% 2-ME, 1% bromophenol blue). Cell lysates were separated by electrophoresis 
on 12% SDS-PAGE gel and transferred to nitrocellulose membranes. The 
membranes were blocked in Tris-buffered saline plus 1% Tween 20 (TBST) 
containing 5% (weight-to-volume ratio) non-fat milk for 1h and immunoblotted 
with mouse primary antibodies to NFkB, Iκκ, phosphor-NFκB, IRF3, phospho-
IRF3, IRF7, phosphor-IRF7, RIGI, MDA5, or rabbit primary antibody GAPDH 
overnight at 4°C. Bound antibodies were visualized by incubation with HRP-
coupled goat anti-rabbit or anti-mouse IgG antibodies (Abcam) and bands were 
detected using Novex® ECL Chemiluminescent reagent (Invitrogen Life 
Technologies) and developed using X-ray film in a dark room. 
Culture of macrophages for TNF production. Macrophages (1x105 cells per 
well of 24-well plate) were infected or mock-infected as previously described by 
exposure at an MOI of 1.0 for 1h in macrophage infection media. After 1h cells 
were washed with DPBS and fresh infection media replaced. At 4h after infection, 
LPS from Escherichia coli 0127:B8 (source) was added to culture media at 
10ng/ml. At 6h after infection, Brefeldin A (eBioscience) was added to LPS 
treated and untreated wells at a 1:1000 dilution. At 8h after infection, the cells 
were detached on ice with 2.5 mM EDTA in PBS, washed and fixed in 4% 
paraformaldehyde for 15 minutes, followed by permeabilization with 10X 
permeabilization buffer (2% saponin,  4% Goat Serum in DPBS) for 20 minutes. 
1 × 105 cells were incubated with influenza nucleoprotein fluorescein 
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isothiocyanate conjugated antibody (NP-FITC, AbCam #ab20921) and BD 
Pharmingen™ TNF allophycocyanin conjugated antibody (clone MAb11, BD 
Biosciences) diluted in 1X permeabilization buffer for 1h. Cells were analyzed as 
stated above. 
Ultra-violet irradiation of IAV before infection. For UV-inactivation, 500 µl of 
virus seed stock was placed in a 4-cm2 well and irradiated for 1h at 4°C on a UV 
Transilluminator (Spectroline). Viral inactivation was demonstrated by plaque 
assay on MDCK cells as described above. On the day of infection, MDM were 
inoculated with live virus at an MOI of 1.0 or with the same amount of UV-
inactivated virus for 1h. After inoculation, cells were washed 3 times with DPBS, 
viral growth media (as above) was added to each well, and cells were incubated 
at 37°C with 5% CO2 for the duration of the experiment.  
Threshold pH of IAV by syncytia assay. Syncytia assay to assess the 
threshold pH for viral fusion for KY180 and KY136 was performed by Jeremy 
Camp at the University Of Louisville Department Of Microbiology. The approach 
is outlined Figure 33. Briefly, MDCK cells were incubated with virus for 1h, 
washed and then incubated for 24h. MDCK cells were then submerged in 
buffered solutions at varying pH for a 3 minute pulse followed by another 24h 
incubation. Cells were then washed, stained with Geimsa, and evaluated under 
light microscope for syncytia formation. Depicted here is an example of MDCK 
cells that have syncytia formation (KY136 with pH 5.3 buffer treatment) and no 
syncytia (KY136 with pH 5.4 buffer treatment). Using a light microscope, the 
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threshold pH was determined by the presence or absence of syncytia at a 
specific pH. 
Pharmacological inhibitors. 5-(N-Ethyl-N-isopropyl) Amiloride (EIPA), 
Chlorpromazine (CPZ), and Ammonium Chloride (NH4Cl) were obtained from 
Sigma-Aldrich and Dynole 2-24 (DYN) from abCam. All inhibitors (except NH4Cl) 
were dissolved in dimethyl sulfoxide (DMSO) and further diluted in serum-free 
macrophage media (Invitrogen Life Technologies). NH4Cl was dissolved in 
serum-free macrophage media. To exclude any cytotoxic effects of the inhibitors 
and DMSO, control cells were included which were incubated in the same 
dilution of the inhibitors.  
Treatment of macrophages with pharmacological entry pathway inhibitors. 
MDM were incubated with specific concentrations of pharmacological inhibitors 
before viral exposure (1h of pre-incubation at 37 °C). Following incubation, MDM 
were infected with IAV diluted to an MOI of 1.0 in viral growth media containing 
the inhibitors. Inhibitor levels were maintained during viral exposure. Cells were 
then washed to remove unbound virus 3 times with DPBS and viral growth media 
with inhibitors was replaced. Twenty four hours later, viral entry was assessed by 
measuring intracellular IAV-NP protein levels by flow cytometry.   
Flow Cytometry. The percentage of infected MDM cells was determined by 
assessing intracellular NP expression following infection with IAVs in the 
presence or absence of inhibitors. Mock infected cells treated with equal 
concentration of inhibitor served as controls. At the 24h time point, the cells were 
removed from the culture plate using PBS/0.2% EDTA, fixed with 4% 
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paraformaldehyde, permeabilized with 2% saponin 4% serum, and stained with 
anti-NP (FITC-labeled) antibody and evaluated by flow cytometry. Gates were 
established with unstained and mock infected controls where less than 1% NP 
positive. Percent inhibition was determined by comparing the percentage of IAV 
positive cells in inhibitor untreated versus treated cultures.  Counts on y-axis of 
the histograms were normalized to mode. Analysis was conducted using 
FlowJo® software.  
Cryo-electron microscopy of influenza A viruses.  3.5 ul of purified and 
concentrated KY136 and KY180 was loaded onto glow discharged Holey Carbon 
grids and plunge frozen on a Cryoplunge™ 3 machine. Grids were loaded on to a 
Titan Krios (FEI) or a CM200 (FEG Phillips) and images were obtained for both 
strains to compare the morphology. 100 to 125 virus particles were imaged for 
both strains to document the morphology. Measurements of virus morphology 
were done using ImageJ. Cryo-EM imaging was conducted at Purdue University 
in collaboration with Dr. Jason Lanman and Amar Parvate.  
Reverse genetics to create recombinant NL602 viruses with KY180 HA gene 
and NL602 virus with specific mutations in the HA gene. This approach is 
outlined in Figure 25.  Briefly, 8 plasmid rescue systems based on pDZ for NL602 
and pDZ for KY180 were used to transfect 293T cells co-cultured with MDCK 
cells. Subsequent passaging of supernatant was performed until a cytopathic 
effect was seen in the culture.  Supernatant was collected, spun down and viral 
stocks made. Stock titers were determined by TCID50 assay.  Cells were also 
collected and RNA extracted for sequencing to confirm recombination occurred. 
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(B) To introduce specific mutations into the NL602 HA pDZ plasmids, primers 
were designed to amplify plasmids containing the mutation, and then treated 
using a kinase-ligase-DpnI enzyme kit (New England Biolabs) to prepare the 
mutant plasmids for transformation. Transfection, viral stock preparation, and 
sequencing were done as described above. The reverse genetics virus recovery 
and preparation of viral stocks was performed by Jeremy Camp, University of 
Louisville Department of Microbiology. Plasmids were kindly provided by Dr. 
Adolfo Garcia-Sastre Mount Sinai School of Medicine New York.  
Statistics. For the comparison of two sets of values, Student's t test (two-tailed, 
two-sample equal variance) was used. When comparing three or more sets of 
values, data were analyzed by one-way analysis of variance (ANOVA), followed 
by posthoc analysis using Tukey's multiple-comparison test. A p-value of ≤0.05 
was considered statistically significant. 
RESULTS  
H1N1pdm and seasonal H1N1 isolates exhibit a low infectivity of MDM but 
an increase in virus production over time. To determine whether the ‘resting’ 
MDM culture model supported infection and replication of pandemic H1N1, we 
infected MDM with seasonal and pandemic H1N1 influenza viral isolates and 
evaluated viral nucleoprotein levels using both flow cytometry and confocal 
microscopy. Surprisingly, there was no significant difference in infectivity 
between different isolates (Figure 26 A,B). Infection of MDM was examined by 
immunofluorescent staining and confocal microscopy of NP. Positive staining for 
the NP in influenza virus infected macrophages was shown at 24hpi (Figure 
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26A). Additionally, the number of NP positive cells by flow cytometry was similar 
with ~20% of cells becoming infected with virus (Figure 26B) 
Considering that all three, KY180, KY136, and BN59 infected resting 
MDM, we next asked whether they permitted replication and release of infectious 
virions. To achieve this we measured the amount of virus produced by plaque 
assay on culture supernatant from infected cells at 8, 24, and 36 hpi. Although 
inefficient, all three isolates showed increased and similar titers overtime by 
plaque assay (~103) (Figure 27A). To further confirm replication was occurring in 
infected MDM, we evaluated the time course of viral RNA synthesis over time by 
RT-PCR using tagged primers specific for NP mRNA (Figure 27B), vRNA (Figure 
27C), and cRNA (Figure 27D). Overtime, accumulation of all three species of 
RNA were consistently detected in MDM. Our observation that viral RNA 
increases overtime, while viral titers remain somewhat low prompted us to 
conclude that the viral isolates studied here infect MDM productively but 
inefficiently.  
H1N1pdm and seasonal H1N1 isolates showed differential activation 
marker profiles after infection.  Because all three isolates infected the resting 
MDM model, we sought to determine whether the cells became activated after 
infection by all three isolates. We infected MDM for 8h and performed RT-PCR 
analysis of macrophage activation markers including CD80, CD64, CD200R, and 
CCR7. Transcriptional analysis showed mRNA expression levels of all our 
markers were lower for KY180 compared to KY136 and BN59. This suggests a 
delayed activation of MDM infected by KY180 (Figure 28). These results warrant 
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further investigation into the interactions between these isolates and the MDM 
cells.  
Differential expression kinetics of immune response genes in MDM among 
H1N1pdm and seasonal H1N1 isolates. Considering that macrophages are a 
major source of cytokine production during infection [358], we compared the 
gene expression profile of pro-inflammatory, anti-inflammatory, and interferon 
genes in IAV-infected MDM by quantitative real-time PCR at 8 and 24 hpi. The 
comparison of ΔΔCt values of infected cultures to mock infected cultures show a 
delayed expression of immune response genes by KY180 (Figure 29). 
Specifically, KY180 induced much less TNF, IL6, CCL5, CXCL10, IFNβ, IFNγ, 
and IDO1 mRNA expression than KY136 and BN59 at 8h post-infection.  By 24 
hpi, all 3 IAVs showed similar innate immune response profiles, although the 
magnitude of the response was lower in cells infected by KY180 (Figure 29). 
Consequently all isolates showed no expression of anti-inflammatory markers 
such as IL10 and TGFβ and PPARγ at 8 or 24 hpi. Next we sought to determine 
whether KY180 had a reduced IDO (Indoleamine 2, 3-dioxygenase) protein level 
and IDO enzymatic activity compared to the other isolates as suggested by RT-
PCR mRNA expression results. We compared intracellular protein levels of IDO1 
by flow cytometry and found no difference in the percentage of IDO1 positive 
cells in the infected and uninfected cells populations (data not shown).   
Delayed expression of PRRs in MDM infected with KY180. Previous studies 
have shown differential induction of cytokines by H5N1 viruses in human 
macrophages, which can be regulated by IRF3 and p38 MAPK [419]. Because 
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IFN-β as well as other pro-inflammatory genes (TNF, CCL5, etc) showed 
differential kinetics of expression between KY180 and KY136 and BN59 in MDM 
at 8hpi (Figure 29) we sought to determine which upstream genes within the Toll-
like receptor, RIG-I-like receptor, and the NOD-like receptor (NLR) pathways 
were contributing to this outcome.  
We compared the gene expression of TLR, RLR, and NLR genes in IAV-
infected MDM by quantitative real-time PCR at 8 and 24 hpi. When comparing 
the ΔΔCt values of infected cultures to mock infected cultures, we again 
observed a delayed expression of a number of genes by KY180 (Figure 30A). At 
8 hpi, a delayed response within the RLR pathway, specifically RIGI and MDA5, 
and the TLR pathway, specifically TLR7 were noted in KY180 but not KY136 
(Figure 30A). The significant differences in gene expression levels of TLR3, 
TLR7, IRF3 and IRF7 at 8 and 24hpi suggest MDM may detect these two viruses 
differently (Figure 30A).To further confirm these findings, we compared the 
protein levels of selected innate immune response genes at 8hpi by western blot 
analysis after infection.  These studies suggest KY136 has greater toll-like 
receptors protein levels than KY180 agreeing with the RT-PCR findings (Figure 
30B). Interestingly, the levels of NFκB and IRF3 did not differ between viruses 
(Figure 30B). This suggests activation of TLRs are important to the delayed 
response by KY180 infected MDMs.  
Differential expression of immune response genes by H1N1pdm viruses 
cannot be attributed to how the viruses regulate the immune response 
within the cell.  Because of the observed delay and significantly different mRNA 
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expression levels of immune response genes, specifically TNF, between the two 
viruses, we sought to compare the regulation and protein production of TNF. 
Elevated mRNA and protein TNF levels have been shown for more pathogenic 
avian influenza viruses in human macrophages [357]. TNF has pleiotropic 
functions by promoting apoptosis [420] , the inflammatory response [421, 422], 
and providing host resistance to pathogens [423]. IAV proteins have been shown 
to interact with cellular machinery and disrupt protein synthesis and inflammatory 
gene pathways affecting mRNA and protein levels within the infected cell [424, 
425]. We hypothesized the delayed TNF response in KY180 infected 
macrophages was due to viral manipulation of cellular machinery.  
To test this we employed a previously published method looking at TNF 
protein production in the presence of a secondary bacterial signal, LPS.  Early 
studies have shown that most phagocytic mononuclear cells support viral 
replication and responded with a high TNF mRNA accumulation accompanied by 
low TNF protein production. Only when small amounts of LPS were co-cultured 
with virus was the TNF protein production detected [426, 427]. Thus, we co-
cultured IAV-infected MDM with LPS to see if there was a difference in activation 
or suppression of the TNF response by the two viruses. Between two donors, no 
difference was observed in the activation and suppression of the TNF response 
between KY180, KY136, and NL602 (Figure 31). Specifically, the percent of IAV 
positive cells, TNF positive cells, and the percent of both IAV and TNF positive 
cells did not differ between viruses (Figure 31). This suggests the delayed 
response by KY180 is not a result of viral protein manipulation of the host cellular 
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machinery but by a different mechanism.  The following series of studies aim to 
identify the mechanism(s) underlying the delayed MDM immune response to 
KY180 compared to KY136. 
H1N1pdm and seasonal H1N1 require a replicating virus to activate immune 
response gene expression.  To investigate whether the responses from 
infected MDM were dependent on a replicating virus, we performed a time-
course infection experiment in MDM from 2 additional donors using both live 
(Figure 32A) and UV-inactivated IAVs (Figure 32B). We examined the mRNA 
expression of cytokine and interferon genes and show UV-irradiated viruses did 
not induce cytokine or chemokine gene expression at 24hpi (Figure 32B).  This 
suggests that the induction of cytokines and chemokines after infection requires 
an intact genome and a replicating virus.  
As discussed previously, KY180 and KY136 replicated at a comparable 
level (Figure 27 A-B). Thus the differential kinetics of MDM up-regulation of 
cytokine expression cannot be explained based on replication. To further 
understand the mechanism we looked at whether the delayed response was due 
to differences in IAV-induced anti-viral response (apoptosis) or simply a 
differences in the isolate’s ability to overcome entry/replication limitations within 
MDMs.  
MDM are equally susceptible to IAV-induced apoptosis. Previous reports 
relate cytokine dysregulation to the variable onset of apoptosis by different 
influenza strains [428, 429]. We hypothesized that the delayed signaling 
response in KY180-infected MDM may be due to differential onset of apoptosis. 
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By flow cytometric quantification of Annexin V positive cells, we found the 
percentage of apoptotic cells increased in IAV-infected compared to mock-
infected MDM (Figure 32C). Consequently, the percentage of apoptotic cells was 
similar between isolates and did not explain differences in innate signaling 
responses of MDM to infection of two isolates.  
Low pH is required for entry of both H1N1pdm into the MDM.  In order for 
IAV to enter a cell, the bound virus must undergo endocytosis. Viral components 
are released into the cell once the IAV hemagglutinin protein encounters a low-
pH to undergo a conformational change and facilitate membrane fusion.  Our first 
question was whether entry of both H1N1pdm viral isolates into MDM requires a 
low pH. To accomplish this, we treated MDM cells with ammonium chloride 
(NH4Cl) and measured viral entry by staining for intracellular nucleoprotein at 
24hpi and evaluated by flow cytometry. Inhibition of endosomal acidification by 
NH4Cl completely blocked the ability of both H1N1pdm viruses to enter MDM 
(Figure 33A). 
H1N1pdm isolates showed similar thresholds of pH for membrane fusion. 
As expected, both viruses require a drop in pH to enter MDM. We next sought to 
determine if the threshold pH of fusion differed between the two viruses. Previous 
studies have found that the presence of the E47K mutation in the HA2 gene of 
H1N1 viruses reduces the threshold pH for membrane fusion from 5.4 to 5.0 
[121]. Through sequencing analysis, one of the 22 mutations that distinguish 
KY180 from KY136 is this E47K mutation in the HA2 gene [298]. We 
hypothesized that the threshold pH of fusion for KY180 within the MDM 
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endosomes occurs at a lower pH than KY136. To address this hypothesis, we 
performed a syncytia formation assay to determine the threshold pH of fusion for 
the two viral isolates. Despite the apparent mutation differences in the HA2, the 
pH of fusion for the two isolates was identical (Figure 33B). This suggests the 
differences in innate signaling may be a result of the two viruses entering the 
MDM by different pathways.  
H1N1pdm (KY180) has greater sensitivity to macropinocytosis inhibitors 
compared to H1N1pdm (KY136) suggesting differences in intracellular 
trafficking. Clathrin-mediated endocytosis is considered the primary route of 
endocytic entry of influenza virus into cells [95, 96]. To determine whether the 
delayed kinetics of cytokine expression observed was a result of an alternate 
route of entry taken by KY180, we inhibited clathrin-mediated endocytosis using 
pharmacological inhibitors and assessed the resulting viral infectivity by staining 
for intracellular nucleoprotein at 24hpi and evaluated by flow cytometry. As with 
previous reports, we observed that blocking clathrin-mediated endocytosis by the 
inhibitor chlorpromazine (CPZ) moderately inhibited both KY180, KY136 and an 
additional H1N1pdm isolate NL602 from infecting human cells (Figure 34 A,C).  
The blockade of dynamin formation by the inhibitor Dynole (DYN), showed 
that KY136 to be slightly more sensitive to the dynamin inhibitor; however, 
cytotoxicity was observed when MDM were treated with 10uM or greater 
concentrations, limiting the sensitivity of our assay to detect any significant 
difference between the isolates. Previous reports have utilized anywhere from 
10µM-80µM of dynamin inhibitors to dissect the entry of influenza viruses in 
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HeLa and MDCK cells [107, 430]; however, based on technical limitations of 
MDM, we were unable to distinguish whether there were differences in 
susceptibility to dynamin inhibitors. No differences were observed at 1 and 5µM 
concentrations. Next we asked whether the delayed kinetics of cytokine 
expression observed was a result of an alternate route of entry taken by KY180. 
Macropinocytosis has recently been identified as an alternate entry 
pathway for influenza viruses [106, 107]. To evaluate whether the two isolates 
relied on alternative pathways of entry into human macrophages, we inhibited 
macropinocytosis using pharmacological inhibitors and assessed the resulting 
viral infectivity 24h post-infection by staining for intracellular NP and evaluating 
by flow cytometry. Interestingly, inhibition of macropinocytosis by EIPA 
significantly reduced KY180 infectivity but not KY136 or NL602 (Figure 34 B,C). 
This suggests KY180 favors macropinocytosis for entry into MDM and further 
explain the differences in innate signaling in MDM. This further confirms 
macropinocytosis as an alternate entry pathway for influenza virus and a 
potential mechanism for differences in intracellular responses in MDM.  
The delayed immune phenotype induced in KY180-infected MDM is 
dependent on mode of entry, specifically macropinocytosis. To confirm 
whether the immune gene expression phenotype was altered in the presence of 
the inhibitors, we compared the gene expression of pro-inflammatory and PRR 
genes in IAV-infected, treated or non-treated MDM by real-time PCR at the 24h 
time point. When comparing the ΔΔCt values of infected cultures to mock 
infected cultures with or without inhibitors, we see a hindered expression of 
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immune response genes by KY180 in the presence of EIPA (Figure 35). This 
hindrance was not as apparent in KY136-infected MDM treated with EIPA, 
specifically TNF, NFκB, and the TLRs. This collectively confirms our conclusion 
that the delayed immune phenotype induced in KY180-infected MDM is 
dependent on mode of entry via macropinocytosis.  
IAV morphology differs between KY180 and KY136. According to recent 
studies, IAV can take on different shapes, which can influence the route of entry 
taken by the virus [104]. To determine if KY180 and KY136 viruses have different 
morphologies, cryo-EM was employed, in collaboration with Purdue University. 
Purified and concentrated viruses were cryo-frozen onto grids and images 
obtained using a Titan Krios (FEI) imager. Roughly 100 to 125 virus particles 
were imaged for both strains to document the morphology and measurements of 
virus morphology were performed. Only a handful of images were chosen to 
highlight the morphological variation (Figure 36 A-H). For KY136, all the particles 
were of round morphology with diameter varying from 80-350 nm. Only 1 particle 
was seen which had elongated morphology (Figure 36 A-D). For KY180, 80 
(~61%) particles were round (80-120 nm diameter), 40 (~31%) particles were 
oblong (100-300 nm) and 10 (<1%) were filamentous (100 nm diameter and 
>300 nm long) (Figure 36 E-H). These images emphasize the different 
morphologies between the two isolates suggesting a potential source of the 
variation in inhibitor susceptibility.    
IAV sensitivity to macropinocytosis inhibitors in MDM was mapped to the 
HA gene. To further delineate the exact mechanism driving differences in 
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sensitivity to macropinocytosis, we used reverse genetics to identify the viral 
determinants responsible for the increased sensitivity of KY180 to 
macropinocytosis inhibitors. We used reverse genetics to swap the HA gene 
segment KY180 into the background of another early pandemic isolate NL602 
and evaluated the susceptibility to EIPA inhibitor. As expected, swapping the HA 
segment of KY180 into the NL602 background made the NL602 virus more 
susceptible to the macropinocytosis inhibitor, acting more like KY180 (Figure 37). 
This demonstrated that a specific mutation within the HA gene of KY180 drives 
the viruses phenotype in MDM. Specifically, two genes within KY180-HA map to 
the sensitivity phenotype, D222G which have previously been reported to 
correlate with increased pathogenicity. 
Interestingly, there are only 22 amino acid (mostly synonymous) changes 
between KY180 and KY136 and of these only one of these so far in the HA 
(D222G) has been suggested to correlate with higher virulence in patients [338, 
339, 431]. This specific mutation in the HA1 shows dual receptor specificity for 
both alpha-2,3- and alpha-2,6-SA, with a particular increase in binding to 
macrophages and type II pneumocytes in the alveoli and to cells in both the 
tracheal and bronchial submucosal glands [79].  
To determine if the D222G mutation and 5 other mutations found in the 
HA gene (Table 10) were responsible for the KY180 phenotype, we generated 
NL602 viruses containing these mutations in the HA gene using site-directed 
mutagenesis (Figure 38). We subjected these viruses to the same experimental 
conditions as before, where we infected MDM for 24h in the presence or absence 
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of macropinocytosis inhibitor, EIPA. We then assessed whether any of these 
mutant viruses became KY180-like in their sensitivity to EIPA. Interestingly, we 
found two specific mutations that mapped to the EIPA sensitivity, D222G and 
S183P in KY180 HA1 (Table 11). The phenotype resulting from these two 
mutations suggests receptor and binding affinity may be a potential mechanism 
(Figure 38, Table 10).  
IAV sensitivity to macropinocytosis inhibitors in MDM are dependent on 
genes previously associated with IAV pathogenicity. To confirm the immune 
gene expression phenotype of KY180 in the presence of EIPA was similar to the 
NL602 HA D222G mutant virus, we performed RT-PCR of inflammatory and PRR 
genes after infection. Gene expression was compared in mutant (D222G and 
S83P) and wild type (KY180 and NL602) infected MDM, treated or non-treated 
MDM by real-time PCR at 24h post infection. When comparing the ΔΔCt values 
of infected cultures to mock infected cultures with or without inhibitors, we see a 
slightly hindered expression of immune response genes, RIGI, TLR3, IRF7 and 
cytokines CCL5 and TNF, by NL602 HA D222G mutant virus in the presence of 
EIPA as was seen with KY180 (Figure 39). This hindrance was not as apparent in 
KY180 infected cultures and hindrance of expression was also seen for the 
NL602 wild-type virus suggesting an earlier time point may be necessary to see 
the true effect.  
The phenotype of KY180-infected MDM was confirmed by a greater 
inhibition of viral infection and PRR and cytokine expression in MDM infected 
with the D222G HA mutant viruses compared to wild type. This study further 
139 
supports that this mutation is responsible for the KY180 phenotype and suggests 
a mechanism for its action.  
DISCUSSION 
 
To better understand the early events that take place after IAV-infection, 
we employed a “resting” human monocyte-derived macrophages (MDM). This 
model represents a non-activated macrophage with no previous exposures. 
Utilizing this model allowed us to uncover the composition and magnitude of 
early influenza-specific responses after infection. Previously published studies 
suggest that influenza viruses differ in their ability to infect and replicate in 
macrophages [353, 357]. In contrast [405], and in support of the work of others 
[353, 354, 356], we demonstrated that seasonal and pandemic (H1N1) viruses 
are not restricted in their ability to be internalized by macrophages.  
Further, our analyses revealed that the seasonal and pandemic (H1N1) 
viruses replicated in MDM and differed temporally in their induction of the innate 
immune responses. Analysis of the replication revealed comparable speeds of 
replication, yet the amount of virus produced was relatively low. Within a couple 
of hours after infection, viral RNA expression was taking place at high levels, and 
no major differences were noted between the viral isolates. This data suggests 
the MDM cells had no inherent resistance to both pandemic and seasonal 
viruses, yet they did not serve as powerful viral factories.  
Previous studies have shown that human influenza viruses infect 
macrophages inducing the release of TNF, IL6, IL10, IL1β, IFN α/β, and 
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chemokines such as CCL5, MIP-1β, CCL2, and CXCL10 [307, 351, 353, 357]. 
The mRNA expression kinetics of cytokines from MDM in response to infection 
with H1N1 viruses in our experiments (Figure 29) were similar to those 
documented previously. However, we found our more lethal H1N1pdm isolate to 
induce a delayed transcription of cytokine and PRR genes (Figure 29 and 30). 
These novel findings may provide clues as to why this virus behaved differently 
in mice [298] and humans compared to other closely related IAV isolates. Similar 
to what was seen in the MDM model, H1N1pdm isolates have been shown 
previously to have a delayed rate of infection compared to seasonal influenza 
virus in differentiated bronchial epithelial cells [91]. However, the mechanism for 
this delay is still undefined.  
Using the resting MDM model, our laboratory was able to identify specific 
molecular determinants associated with different outcomes of IAV infection. IAV 
virus morphology was visualized using cryo-electron microscopy allowing us to 
image the virus particles in their native state. Of the total virus particles imaged 
for the KY180 strain, we observed about 1% particles to be filamentous and 
about 31% particles to have elongated morphology. However, 99% of all the 
virus particles of the KY136 strain had round morphology. While the percentage 
of filamentous as well as elongated particles for the KY180 strain is lower than 
that reported for the Udorn strain [40] the KY136 strain was predominantly found 
to have round particles. This suggests the two viruses may interact and enter 
differently in susceptible cells. Filamentous virus formation has been linked to 
mutations in the M1 and M2 gene of IAV. The only mutation in the M1 gene 
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between KY180 and KY136 is a S30G mutation suggesting another unknown 
mechanism may create the different morphologies of KY180. Regardless, to 
confirm that the filamentous virus is responsible for delayed immune signaling, 
future studies will employ a reverse genetics site-directed mutagenesis of the M1 
gene in NL602 to create a filamentous virus, as previously reported [40]. This 
filamentous virus will be confirmed by cryo-EM and compared to the non-
filamentous virus by measuring temporal expression of PRR and cytokine genes 
after MDM infection.  
Our studies indicate the phenotype of KY180 is dependent on the pathway 
of entry and can be mapped to specific mutations in the HA gene (D222G and 
S183P). These mutations are located within the receptor binding site of the HA 
gene and have been shown to alter binding affinity [432, 433].  The Asp222 in 
IAV HA is predominantly found in human-adapted H1N1 viruses and has been 
shown to create optimal contact with the galactose sugar in glycans terminated 
by alpha-2-6-SA [434]. Consequently, a change from aspartic acid (D) to a 
glycine (G) has been shown to alter the electrostatic potential of the receptor 
binding domain resulting in a higher affinity for alpha-2,3-SA by increasing the 
flexibility of 220-loop within the HA [435]. With this in mind, we can hypothesize 
that differences in receptor-IAV binding affinity between KY180 and KY136 might 
explain phenotypic differences seen in the MDM model.  
A possible explanation for our results is that these mutations promote 
binding to alternative receptors on the macrophage surface, potentially altering 
the timing of entry depending on their affinity. Many cell surface lipids and 
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proteins contain sialic acids making them potential targets for IAV binding. 
Mannose and galactose-type lectins found on the surface of macrophages have 
been shown previously to assist IAV infection murine macrophages; however 
entry through these receptors did not permit replication [436]. However, this 
study was not conducted using primary human macrophages. The presence and 
distribution of these lectins and their role in IAV binding and entry in MDM may 
shed light onto the differences between isolates.  
Alternatively, other studies have found IAV capable of binding to multiple 
host receptor tyrosine kinases (RTKs) on the surface of A549 cells, further 
activating intracellular PI3K and ERK1/2 pathways which enhance IAV uptake 
[437]. Expression and activation of these receptors has been shown to alter the 
uptake of IAV, specifically selecting for clathrin-mediated endocytosis of IAV 
[438, 439] and others selecting for macropinocytosis of IAV [440]. To further 
support the role of RTKs in viral entry, Brindley et al. have shown filamentous 
Ebola-Zaire virus uptake in human tumor cells is promoted by the receptor 
tyrosine kinase Axl [441]. This further suggests entry of our viruses, both 
spherical and filamentous, may rely on different RTK for binding and signaling. It 
is possible that the distribution of RTKs on the surface of resting MDM may favor 
induction of clathrin-mediated endocytosis over macropinocytosis. Future studies 
will be conducted to determine whether our viruses rely on the same receptors 
for entry into MDM and also what the receptor distribution profile is on the resting 
MDM that may isolate specific entry. 
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Our work is the first to determine that the mechanism for viral entry is 
critical to activation of innate signaling and that this distinguishes influenza viral 
isolates showing different pathogenicity in mice and humans. 
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Figure 23. Subsets of macrophages and their associated markers. Macrophages 
derived from monocyte precursors undergo specific differentiation depending on 
the local tissue environment. Two distinct states of polarized activation have 
been identified: M1 pro-inflammatory and M2 anti-inflammatory macrophage 
phenotype.  Pro- and anti-inflammatory phenotypes of macrophages have 
distinct chemokine and surface marker signatures as designated above. 
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Figure 24. Balance of pro-inflammatory and anti-inflammatory response to IAV. In 
response to IAV there is a critical balance between pro- and anti-inflammatory 
immune response. Uncontrolled pro-inflammatory immune responses can result 
in damage to host tissues, whereas anti-inflammatory immune responses 
initiated prematurely can result in the survival of the pathogen which is 
deleterious to the host. It is thought that in a natural healthy immune response, 
there is a homeostatic balance between these two responses, resulting in the 
elimination of IAV and reducing the risk of creating extensive tissue damage. 
(Picture adapted from Rouse, B. T., & Sehrawat, S. (2010). Immunity and 
Immunopathology to viruses: what decides the outcome? Nature Reviews. 
Immunology, 10(7), 514–526).  
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Figure 25. Approach used to recover reverse genetics recombinant NL602 
viruses with KY180 HA gene and NL602 virus with specific mutations in the HA 
gene. (A) Plasmids for IAV proteins were transfected into 293T cells co-cultured 
with MDCK cells. Subsequent passaging of supernatant was performed until a 
cytopathic effect was seen in the culture.  Supernatant was collected, spun down 
and viral stocks made. Stock titers were determined by TCID50 assay.  Cells were 
also collected and RNA extracted for sequencing to confirm recombination 
occurred. (B) To introduce specific mutations into the NL602 HA pDZ plasmids, 
primers were designed to amplify plasmids containing the mutation, then treated 
using a kinase-ligase-DpnI enzyme kit to prepare the mutant plasmids for 
transformation. Transfection, viral stock preparation, and sequencing were done 
as described above. The reverse genetics system and preparation of viral stocks 




Figure 26. Pandemic and seasonal influenza viruses infect primary human 
monocyte-derived macrophages. In three independent experiments, human 
monocyte-derived macrophages were infected with influenza A viruses KY180 
(H1N1pdm), KY136 (H1N1pdm) and BN59 (H1N1) at an MOI of 1. (A) MDM cells 
were fixed, permeabilized, and stained with anti-influenza nucleoprotein (NP)-
FITC antibody conjugate and analyzed by flow cytometry 24h post-infection. 
Error bars show mean +/- standard deviation of percent NP-positive cells 
corresponding to the amount of infected cells. The lower limit of detection is 
indicated by the dotted line.  (B) Immunofluorescence staining of MDM 24 h post-
inoculation with KY180, KY136, and uninfected control (Mock). Influenza virus 
matrix protein was stained red (Alexa flour 633), while actin filaments were 
stained purple (Phalloidin). Image magnifications are at 100X. The slides were 
viewed by confocal microscopy as described in Materials and Methods. 
148 
 
Figure 27. Replication of seasonal and pandemic IAV in MDM cells. (A) 
Replication of pandemic and seasonal influenza A (H1N1) viruses in MDM was 
analyzed by plaque assay performed on supernatants from three independent 
donors. Cells were infected with and MOI of 1.0 and supernatant was collected at 
8, 24, and 36h post-infection. Data represent the mean ± SD of virus titer. 
Further, at the indicated time points, total RNA was isolated, and the levels of 
viral NP (B) mRNA, (C) cRNA, and (D) vRNA were determined by RT-PCR using 
gene specific primers. The data shown is three replicates of 1 representative 
donor of 2 (4h post-infection 1 replicate). RNA levels were normalized to β-actin 
and fold change determined by the ΔΔCt method as described in the materials 
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and methods. Results are expressed as mean ± SD. *, p < 0.05; **, p < 0.01; *** 
p<0.001. The lower limit of detection is indicated by the dotted line.  
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Figure 28. Differential expression of macrophage activation genes in MDM after 
infection by KY180, KY136, and BN59. MDM were infected with influenza viruses 
KY180 (H1N1pdm), KY136 (H1N1pdm) and BN59 (H1N1) at an MOI of 1. Cell 
lysates were collected at 24h post infection and mRNA expression of 
macrophage activation genes were measured by real-time PCR. Results are 
depicted from 3 donors (2 replicates of each treatment for each donor) and are 
expressed as mean ± SD fold change as compared to mock (uninfected) control. 
Fold change of 1, indicative of equal expression between infected and mock 
infected controls is indicated by the dotted line.  Asterisks represent significance 
as related to KY180 expression. Significance as determined by ANOVA *, p < 
0.05; **, p < 0.01; *** p<0.001.  
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Figure 29. Influenza virus-mediated expression of cytokines and chemokines in 
MDM.  MDM cells were infected with influenza viruses KY180 (H1N1pdm), 
KY136 (H1N1pdm) and BN59 (H1N1) at an MOI of 1. Cell lysates were collected 
at 8 and 24 h post-infection, and mRNA expression of pro-inflammatory, anti-
inflammatory, interferon, and metabolic genes were measured by real-time PCR. 
Results are from one representative donor (3 done in total) and are expressed as 
mean ± SD fold change as compared to mock (uninfected) control. Fold change 
of 1, indicative of equal expression between infected and mock infected controls 
is indicated by the dotted line.  IP-10 is also referred to as CXCL10 in the text. 
Significance as determined by ANOVA *, p < 0.05; **, p < 0.01; *** p<0.001. 
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Figure 30. Influenza virus-mediated expression of pattern recognition receptor 
genes.  MDM were infected with influenza viruses KY180 (H1N1pdm), KY136 
(H1N1pdm) and BN59 (H1N1) at an MOI of 1. (A) Cell lysates were collected at 8 
and 24h post-infection, and mRNA expression was measured by real-time PCR 
on two donors. Results expressed as mean ± SD fold change as compared to 
mock (uninfected) control. Fold change of 1, indicative of equal expression 
between infected and mock infected controls is indicated by the dotted line *, p < 
0.05; **, p < 0.01; *** p<0.001.(B) MDM from two donors were infected as 
previously indicated and cell lysates were collected at 8 h post-infection. Protein 
levels were confirmed by western blot.  
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Figure 31. TNF protein production in the presence or absence of secondary 
signal, LPS in IAV-infected cells. The percentage of infected MDM cells was 
determined by assessing intracellular NP and TNF expression following 8h 
infection with 1 MOI of KY180, KY136 or NL602 in the presence or absence of a 
LPS. Mock infected cells treated with equal concentration of LPS served as 
controls.  Cells were treated with LPS (10ng/ml) or equal parts infection media at 
4h after infection followed by Brefeldin A treatment (1:1000) at 6h after infection. 
At the 8h time point, the cells were collected, fixed with 4% paraformaldehyde, 
permeabilized with 2% saponin 4% serum, and stained with anti-NP (FITC-
labeled) and anti-TNF (APC-labeled) antibodies evaluated by flow cytometry. 
Gates (% gated macrophages) were established with unstained and mock 
infected controls where less than 1% NP positive and TNF positive cells. % 
positive cells were determined using FlowJo® software. Significance was 
determined by ANOVA *, p < 0.05; **, p < 0.01; *** p<0.001.  
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Figure 32. Innate immune response gene expression (with UV) and apoptosis.  
MDM were inoculated with live virus at an MOI of 1.0 or with the same amount of 
UV-inactivated virus for 1 h. Cell lysates were collected at 24 h post-infection 
from MDM infected with live (A) or UV-inactive (B) virus and mRNA expression of 
selected pro-inflammatory and anti-inflammatory genes were measured by real-
time PCR. Results expressed as mean ± SD. *, p < 0.05; **, p < 0.01; *** 
p<0.001. IP-9 and IP-10 are referred to as CXCL11 and CXCL10 in the text. (C) 
The percentage of apoptotic MDM cells was determined by flow cytometry. Cell 
were infected with 1 MOI of KY180 or KY136. At the 24h time point, the cells 
were collected, stained with propidium iodide (PI) and AnnexinV, then fixed with 
4% paraformaldehyde, permeabilized with 2%saponin 4% serum, and stained 
with anti-NP (FITC-labeled) antibody and evaluated on flow cytometer. Gates 
were established with unstained and mock infected controls where less than 1% 
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NP positive. As shown above, PI negative populations were assessed for 
Annexin and NP staining. Percentages represent those within the PI negative 
population for each treatment.  Analysis was conducted using FlowJo® software. 
156 
 
Figure 33. Requirement for low pH for entry and determination of the threshold 
pH of fusion for KY180 and KY136 by syncytia assay in MDCK cells. (A) The 
percentage of infected MDM cells was determined by assessing intracellular NP 
expression following 24h infection with 1 MOI of KY180, KY136 or NL602 in the 
presence or absence of NH4Cl (dissolved in serum-free macrophage media). 
Mock infected cells treated with equal concentration of inhibitor served as 
controls. At the 24h time point, the cells were collected, fixed with 4% 
paraformaldehyde, permeabilized with 2% saponin 4% serum, and stained with 
anti-NP (FITC-labeled) antibody and evaluated by flow cytometry. Gates were 
established with unstained and mock infected controls where less than 1% NP 
positive. Percent inhibition was determined by comparing the percentage of IAV 
positive cells in inhibitor untreated versus treated cultures.  Counts on y-axis of 
the histograms were normalized to mode. Analysis was conducted using 
FlowJo® software. NH4Cl (ammonium chloride, prevents endosomal 
157 
acidification). (B) Syncytia assay to assess the threshold pH for viral fusion for 
KY180 and KY136 was performed by Jeremy Camp at the University of Louisville 
Department Of Microbiology. The approach is outlined in the figure. Briefly, 
MDCK cells were incubated with virus for 1h, washed and then incubated for 
24h. MDCK cells were then submerged in buffered solutions at varying pH for a 3 
minute pulse followed by another 24h incubation. Cells were then washed, 
stained with Geimsa, and evaluated under light microscope for syncytia 
formation. Depicted here is an example of MDCK cells that have syncytia 
formation (KY136 with pH 5.3 buffer treatment) and no syncytia (KY136 with pH 
5.4 buffer treatment). Using a light microscope, the threshold pH was determined 
by the presence or absence of syncytia at a specific pH.  
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Figure 34. Effects of macropinocytosis and clathrin-mediated endocytosis 
inhibitors on viral entry into MDM. The percentage of infected MDM cells was 
determined by assessing intracellular NP expression following 24h infection with 
1 MOI of KY180, KY136 or NL602 in the presence or absence of the indicated 
inhibitors. Mock infected cells treated with equal concentration of inhibitor served 
as controls. At the 24h time point, the cells were collected, fixed with 4% 
paraformaldehyde, permeabilized with 2% saponin 4% serum, and stained with 
anti-NP (FITC-labeled) antibody and evaluated by flow cytometry. Gates were 
established with unstained and mock infected controls where less than 1% NP 
positive. Percent inhibition was determined by comparing the percentage of IAV 
positive cells in inhibitor untreated versus treated cultures. Counts on y-axis of 
the histograms were normalized to mode. Analysis was conducted using 
FlowJo® software. EIPA, 5-(N-Ethyl-N-isopropyl) amiloride (macropinocytosis 
inhibitor); CPZ, Chlorpromazine (clathrin-mediated endocytosis inhibitor). 
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Figure 35.  Expression of immune response genes in the presence or absence of 
inhibitor. MDM were infected with influenza viruses KY180 (H1N1pdm) or KY136 
(H1N1pdm) at an MOI of 1 in the presence or absence of EIPA at 25uM 
concentration. mRNA expression of pro-inflammatory and viral recognition genes 
were measured by real-time PCR. Results shown are representative of 1 of 2 
donors tested with 2 replicates per donors and are expressed as mean ± SD. *, p 
< 0.05; **, p < 0.01; *** p<0.001.  Percentages listed are percent inhibition of fold 
expression with inhibitor treatment compared to virus alone. EIPA, 5-(N-Ethyl-N-
isopropyl) amiloride (macropinocytosis inhibitor).  
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Figure 36. Cryo-EM pictures of KY180 and KY136. Representative cryo-EM 
images of KY136 exhibiting mainly round morphology (A to D). Diameter of 
particles ranges from 80-300 nm. Representative images of KY180 showing 
mostly round (E, F, G) and occasionally filamentous morphology (J). Diameter of 
the round particles ranged from 100 – 350 nm. Scale bar 100 nm (E to H). 3.5 ul 
of purified and concentrated KY136 and KY180 was loaded onto glow discharged 
Holey Carbon grids and plunge frozen on a Cryoplunge™ 3 machine. Grids were 
loaded on to a Titan Krios (FEI) or a CM200 (FEG Phillips) and images were 
obtained for both strains to compare the morphology. 100 to 125 virus particles 
were imaged for both strains to document the morphology. Measurements of 
virus morphology were done using ImageJ. Cryo-EM imaging was conducted at 
Purdue University in collaboration with Dr. Jason Lanman and Amar Parvate. 
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Figure 37. Sensitivity to macropinocytosis inhibitors can be mapped to the HA 
protein of KY180. The percentage of infected MDM cells was determined by 
assessing intracellular NP expression following 24h infection with 1 MOI of 
influenza viruses KY180 (H1N1pdm),  NL602 (H1N1pdm), or the NL602 virus 
with a KY180 HA swapped in by reverse genetics. Infection was performed in the 
presence or absence of the EIPA at 25uM concentration. Mock infected cells, 
treated with equal concentration of inhibitor, served as controls.  At the 24h time 
point, the cells were collected, fixed with 4% paraformaldehyde, permeabilized 
with 0.2% saponin 4% serum, and stained with anti-NP (FITC-labeled) antibody 
and evaluated on flow cytometer. Gates were established with unstained and 
mock infected controls where less than 1% NP positive. Counts on y-axis were 
normalized to mode. Analysis was conducted using FlowJo Software. EIPA, 5-
(N-Ethyl-N-isopropyl) amiloride (macropinocytosis inhibitor).  
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Figure 38. Sensitivity to macropinocytosis inhibitors can be mapped to specific 
mutations within the HA1 protein in KY180. MDM were infected with influenza 
viruses KY180 (H1N1pdm),  NL602 (H1N1pdm),  or viruses produced by reverse 
genetics and induction of point mutations in the HA1 gene of  NL602 virus 
including NL602-S83P, S84N, S183P, A186T, S203T, D222G.  Infection was 
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performed at an MOI of 1 in the presence or absence of EIPA at a 25uM 
concentration. Mock infected cells, treated with equal concentration of inhibitor, 
served as controls.  At the 24h time point, the cells were collected, fixed with 4% 
paraformaldehyde, permeabilized with 0.2% saponin 4% serum, and stained with 
anti-NP (FITC-labeled) antibody and evaluated on flow cytometer. Gates were 
established with unstained and mock infected controls where less than 1% NP 
positive. % Inhibition (as indicated) was determined by comparing the % IAV 
positive cells in inhibitor untreated versus treated cultures.   Counts on y-axis 
were normalized to mode. Analysis was conducted using FlowJo Software.  
EIPA, 5-(N-Ethyl-N-isopropyl) amiloride (macropinocytosis inhibitor). Percent 
inhibition is presented in Table 11.  
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Figure 39. Gene expression of innate signaling and pro-inflammatory genes with 
recombinant viruses in the presence of absence of inhibitors. MDM were infected 
with influenza viruses KY180 (H1N1pdm), NL602 (H1N1pdm), or viruses 
produced by reverse genetics and induction of point mutations in the HA gene 
NL602-D222G, and NL602-S83P.  Infection was performed at an MOI of 1 in the 
presence or absence of EIPA at a 25uM concentration. mRNA expression of pro-
inflammatory and viral recognition genes were measured by SYBR green real-
time PCR. Results shown represent the average across 2 donors tested with 1 to 
2 replicates per donors and are expressed as mean ± SD. *, p < 0.05; **, p < 
0.01; *** p<0.001.  EIPA, 5-(N-Ethyl-N-isopropyl) amiloride (macropinocytosis 
inhibitor).  
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Table 10. Description of mutations within the HA gene of KY180. 
Nucleotide location of HA mutation Amino Acid Change Literature Reference 83 S → P Common in 2009 pdm H1N1 viruses circulating in Shanghai [442]; not associated with severe disease. 84 S → N Common in 2009 pdm H1N1 viruses circulating in Brazil [443]; not associated with severe disease. 183 S → P Associated with receptor binding and increased disease severity in humans [431, 444, 445] 186 A → T Associated with improved replication in cell culture and egg [446] 203 S → T Common in 2009 pdm H1N1 viruses circulating in UK [447]; not associated with severe disease. 222 D → G Associated with receptor binding and increased disease severity in humans [338, 339, 431]   
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Table 11.  Percent inhibition of viral entry in the presence of macropinocytosis 
inhibitor EIPA (data from figure 38).  




NL602-HA S83P 59 
NL602-HA S84N 52 
NL602-HA S183P 68 
NL602-HA A186T 57 
NL602-HA S203T 34 
NL602-HA D222G 70 
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CHAPTER 5  
CONCLUSIONS AND FUTURE DIRECTION  
CONCLUSIONS  
 Influenza A viruses (IAV) cause a spectrum of respiratory diseases that 
fall into three general pathologies (Figure 40, left panel).  Seasonal IAV are 
predominantly associated with self-limiting, upper respiratory infections (URI) 
across the globe. In the elderly or as a result of comorbidity, however, seasonal 
IAV infections can progress to lower respiratory infections (LRI) resulting in 
pneumonia and secondary bacterial co-infections. Complications from LRI can 
lead to serious complications such as shock/sepsis and organ failure, resulting in 
an average annual attack rate of influenza-associated death of 2.4 deaths per 
100,000 in the USA [448]. On the opposite side of the spectrum are highly 
pathogenic avian influenza viruses (HPAIV) infections that occur in 
geographically localized cases of few individuals that only target the lower 
respiratory system but show greater fatality (50%) (Figure 40, right panel). These 
viruses of avian-origin are not adapted to humans, do not transmit person to 
person and infected patients present with hypercytokinemia [186, 233, 449]. 
There has been great concern among the public health and scientific community 
that the HPAIV may “jump” to humans and result in a global pandemic of high 
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consequence [450].  Regardless of the origin of the infection, HPAIV or seasonal, 
pulmonary infection leads to very similar pathology within the lung (Figure 40, 
center panel).  
IAV subtypes and even genotypes within subtypes can show differences 
in tropism (host, cell type), magnitude of infection, immune response and 
progression of illness. While we know a great deal about influenza viruses and 
their disease, we are not able to predict accurately the pandemic potential and 
impact of new emerging strains.  My thesis focused on the development and use 
of two in vitro physiologically-relevant human cell culture models of IAV, well-
differentiated normal human bronchial epithelial cells and monocyte-derived 
macrophages. These models have given new insight into early host responses of 
seasonal H1N1 and the pandemic (H1N1) 2009 (referred to as H1N1pdm 
herein). Continued advancement of the in vitro human cell culture models is 
important as they will allow rapid insight into characteristics of new strains as well 
as those circulating annually. 
My dissertation focused on the H1N1pdm, however, because of certain 
clinical observations and outcomes that suggested the pandemic viruses differed 
from seasonal H1N1, we included a recent strain of seasonal H1N1 in my 
studies. We viewed this as critical since the models we were using differed in 
some aspects from others and including strains employed by others provided 
benchmarks to better interpret our data. As discussed in earlier chapters, the 
H1N1pdm strains at the start of the 2009 pandemic caused alarm given the 
attack rate in young children and healthy adults. The sequence of the H1N1pdm 
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revealed it arose as a reassortment from at least three viruses circulating in bird, 
pig and human. At the beginning of any outbreak, it is immensely difficult to 
predict a trajectory of infection and mortality. However given the rapid spread, 
age distribution and the lack of a vaccine with protective efficacy, the H1N1pdm 
was predicted by some to be as potentially as dangerous as the HPAIV for its 
impact on public health. One of the major aspects of H1N1pdm that caused 
concern was the finding of upper and lower respiratory infection. Subsequent 
studies in ferret supported the observation that the H1N1pdm had the ability to 
infect the upper and lower respiratory tract [284, 349, 451, 452]. Secondly, the 
HA and NA had an avian and some genotypes retained avian signatures in 
important function domains. Together, the clinical reports and animal studies 
suggested that during the pandemic, different genotypes may have circulated 
with different pathogenic phenotypes. To address this question, we proposed the 
hypothesis that different clinical isolates with distinct clinical outcomes may 
exhibit diverging early host responses in human cell culture models. The major 
conclusions from my collaborations within the lab and my experiments in these 
models are summarized in the following. 
 H1N1pdm show pro-inflammatory signaling in human bronchial epithelial 
that is not necessarily correlated with viral load. H1N1 viruses are reported to 
cause differential pathogenicity that correlates with viral load [413, 453-456]. In 
my studies with the well-differentiate normal human bronchial epithelial 
(wdNHBE) primary cell culture model, we used two clinical isolates from 
hospitalized patients, A/KY180/2010 and A/KY136/2009 from lethal and nonlethal 
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cases respectively [385]. The pathogenicity of these two isolates was mirrored in 
the DBA2 mouse model [298]. Overall, over a 48 hour time period, the host 
responses in wdNHBE cells to the H1N1pdm isolates showed similar 
transcriptional profiles by microarray analysis (Figure 14). The overall similarity in 
the gene expression pathways were surprising given the different outcomes in 
the mouse model [298]. However, when comparing the temporal dynamics of 
secreted cytokines and chemokines from wdNHBE cells in response to the 
H1N1pdm isolates we saw an increased, polarized pro-inflammatory response by 
KY180 compared to KY136 (Figure 12 and 13).  
When comparing seasonal versus H1N1pdm in wdNHBE, all three 
isolates showed similar up- and down-regulation of genes within the intracellular 
signaling pathways, including IFN signaling and communication between innate 
and adaptive immune cells (Table 8). However, when comparing global gene 
expression levels, H1N1pdm-infected wdNHBE cells showed greater fold-
changes in transcription as compared to seasonal IAV (Figure 14, Table 7). 
These differences, were also reflected in cytokine and chemokine secretion, at 
24 and 36 hpi, both H1N1pdm isolates showed greater levels of pro-inflammatory 
markers, apically (CCL5, GM-CSF, CXCL10, CCL2, CCL4) and basally (CCL5, 
IL6, TNF), compared to BN59.  
My studies of a panel of secreted cytokines and chemokines suggested 
one potential clue. I noted significant differences in the polarization of immune 
signals secreted from the wdNHBE cells from the lethal and nonlethal strains. 
Differences were noted over the time course, however, in the polarity of apical 
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and basal signals of 5 immune proteins, CCL5, IL6, IL8, CCL2, and MIP1β. All of 
these showed polarity toward the basal side in wdNHBE cultures infected with 
KY180, the more pathogenic isolate. This observation suggested the hypothesis 
that infected wdNHBE may differ in their potential to recruit immune cells or 
perhaps in their interactions with those immune cells (Figure 41). Hence we 
discussed development of a co-culture model of human wdNHBE and 
macrophage cells to address IAV-host interactions within the cell that may give 
rise to different outcomes in immune cell recruitment. However given the state of 
the field in macrophage studies discussed in chapter 3, we decide to first address 
and define an optimal in vitro macrophage system for such future efforts. And 
hence my first efforts were in exploring the resting MDM as a model of early 
macrophage infection. 
CHARACTERIZATION OF MDM FOR THE STUDY OF INFLUENZA INFECTION 
I adapted a resting MDM model for the study of seasonal and pandemic H1N1 
viruses to uncover early IAV-MDM interactions. To characterize this model I first 
established the culture conditions as previously described for differentiating 
monocytes to macrophages over 7 days and confirmed this differentiation by 
evaluating surface marker and gene expression of CD14 and CD11b markers. I 
then confirmed the MDM cultures were not activated after the 7 day maturation. I 
evaluated the cells via light microscope to determine whether the macrophages 
were in an activated or resting state as previously described [382, 383]. This was 
further confirmed evaluating the presence of both anti- and pro-inflammatory 
activation surface markers on the surface of MDM by flow cytometry and RT-
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PCR. Lastly, to eliminate elements that could prematurely affect the outcome of 
our experiments on IAV-MDM interactions, I optimized the infection culture 
conditions including infection media, multiplicity of infection, and the use of egg- 
or cell-derived IAV stock virus for infection.  Taking into account the conditions 
utilized by previous studies, I confirmed that our culture MDMs were truly 
“resting” and were permissive to viral infection. By establishing this model, I was 
able to ask our first question; would KY180 and KY136 infect macrophages 
similarly? And more broadly, what is the role of peripheral blood monocyte-
derived macrophages (MDM) recruited to the site of IAV infection in the 
subsequent phenotype of the macrophage?  
 In “recruited” MDM cells, we reported the rate of infection and replication 
by a lethal and nonlethal isolate of H1N1pdm were similar but showed 
differences in the temporal pattern of innate immune response profiles. After a 
series of experiments, our studies indicate the phenotype (delayed innate 
immune response) in KY180-infected MDM is dependent on the pathway of viral 
entry and can be mapped to specific mutations in the HA1 gene (D222G and 
S183P). These mutations are located within the receptor binding site of the HA 
gene and have been shown to alter binding affinity [432, 433].  Thus, differences 
in receptor-IAV binding affinity between KY180 and KY136 might explain 
phenotypic differences seen in this model.  
PRIMARY MODEL LIMITATIONS 
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The main advantage of in vitro models of IAV infection based on one cell 
type is the ability to gain information about a particular cell type’s reaction to an 
infectious virus. Primary cells represent a strong model for studying these 
reactions as we can make direct comparisons between isolates of the same 
strain in cell types that mimic what the virus actually encounters in its host. 
However, limitations within these models do exist, no matter how physiologically 
relevant they are. For example, MDM and dendritic cells which are cultured on 
plastic dishes and selected for adherence have been shown previously to have 
different characteristics from non-adherent cells. Specifically adherent monocytes 
are shown to have higher phagocytic activity compared to non-adherent cells 
[457] as well as having greater viability and a greater ability to induce T-cell 
proliferation [458]. The activity of primary human cells, once extracted and grown 
in culture, may differ from those circulating in the blood and tissues. Hence, my 
studies focused on determining the viral factors that differentiate two genetically 
similar isolates with different clinical outcomes. The experiments do not hold 
necessarily direct relevance to human disease. 
The monoculture in vitro environment of “resting” MDM that we created 
represented a simplistic model containing few cytokines in isolation and may not 
adequately represent the complex cytokine milieu that is present before human 
disease. Because of this, we proposed co-culturing human MDM with epithelial 
cells shown to produce cytokines, chemokines, mucus, and other factors which 
are present in the natural lung. While caution must be taken to approach this as 
completely representative; the co-culture allows for the evaluation of the critical 
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processes that drive immune responses to IAV such as bystander IFN and 
apoptotic responses. With the limitations of each system in mind, caution was 
taken not to make too bold of hypotheses around the cell types themselves. 
However, based on our in vitro results in the wdNHBE and MDM cultures, we 
developed hypotheses specific to how the viruses affect the bystander responses 
and how the microenvironment is affected. 
CO-CULTURE HYPOTHESES 
We hypothesize that the delayed activation of MDM infected by KY180 
may lead to a delayed clearance of virus and a dysregulated microenvironment in 
the infected lung. We speculate this will ultimately affect downstream host 
immune responses to the virus. The long term goal of our laboratory is to look at 
the interactions between epithelial cells and macrophages but the data presented 
thus far has looked at the responses of wdNHBE and MDM to pandemic and 
seasonal isolates in separate systems.  
Thus, we hypothesized that upon contact with infected epithelial cells, the 
immune cells (MDM) would differ in their influence on the lung microenvironment. 
With the delayed response phenotype in MDM, we generated a broad hypothesis 
we term “the Goldilocks” hypothesis after the Goldilocks and the three bears fairy 
tale. Previous reports have demonstrated H5N1 induces a very high (“too hot”) 
cytokine response in macrophages after infection. Further, in MDM we show 
KY180 induces a delayed, weak (“too cold”) cytokine response. Finally, KY136 
induces a response that is “just right” in MDM that may lead to just enough of a 
response to activate the immune system and resolve the IAV infection properly 
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(Figure 42 and 43). Thus we hypothesize that this phenomenon will become 
apparent when macrophages are co-cultured with infected epithelial cells. 
176 
 
Figure 40. Schematic of Influenza Virus in Humans. Influenza A virus causes a 
spectrum of diseases from acute inflammatory response to hypercytokenemia 
that can both lead to diffuse alveolar damage. These diseases are mainly caused 
by seasonal (which circulate in pigs and spill over into humans; characterized as 
having a high incidence and low mortality) and highly pathogenic avian influenza 
viruses (emerge through contact with wildlife or infected poultry; low incidence 
and high mortality). The roadmap to disease is dependent upon the cells the 
virus infects and the responses they induced by those infected cells. In our lab 
we hypothesized that closely related isolates of the same strain may differ in the 






Figure 41. Results and hypothesis generated from wdNHBE studies. A key 
finding from wdNHBE studies was the greater levels of basolateral secretion of 
pro-inflammatory cytokines (IL6, CCL5, IL8 and CCL2) by cells infected with the 
lethal KY180 isolate compared to KY136 and BN59.  We hypothesized that 
differences in basolateral signals such as CCL5 from epithelial cells may play a 
role in the recruitment, and responses elicited by monocytes/macrophages. 
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Figure 42.  Hypothesis generated from MDM studies. We hypothesized that upon 
contact with infected epithelial cells, the difference in magnitude of the immune 
cell responses to KY180 and KY136 may alter viral clearance and anti-viral 
response. With the delayed response phenotype by KY180 in MDM, we 
generated a broad hypothesis we term “the Goldilocks” hypothesis after the 
Goldilocks and the three bears fairy tale. Previous reports have demonstrated 
H5N1 induces a very high (“too hot”) cytokine response in macrophages whereas 
we showed KY180 induces a delayed, weak (“too cold”) cytokine response. Thus 
we hypothesize that the KY136 response is “just right” in MDM that leads to a 
well-balanced response (Figure 24) that optimally activates and resolves the 




Figure 43.  Proposed model of the interaction between macrophages and 
epithelial cells based on data presented in this dissertation. This model depicts 
the hypothesized difference in interaction between epithelial cells and recruited 
macrophages when infected with our pdmH1N1 isolates. We hypothesize that 
the delayed activation of MDM infected by KY180 may lead to a delayed 
clearance of virus and a dysregulated microenvironment within the infected lung. 
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PRELIMINARY STUDIES AND FUTURE DIRECTIONS  
INTERACTIONS BETWEEN MACROPHAGES AND EPITHELIAL CELLS BY 
CO-CULTURE  
For co-culture experiments, we employed an immortalized human 
bronchial epithelial cells 16HBE14o- (16HBE), which were kindly provided by Dr. 
Gruenert from the University of California, San Francisco, CA and the primary 
wdNHBE cell culture system as previously described. For 16HBE cells, culture 
plates, flasks and transwells were coated with a fibronectin coating solution 
containing bovine serum albumin, type-I collagen and human fibronectin. The 
cells were cultured in Minimum essential medium (Invitrogen) containing fetal 
bovine serum, l-glutamine, and penicillin/streptomycin. The primary wdNHBE and 
MDM were cultured as described in the previous chapters. The protocol for co-
culture was modified from the only other study found that looked at responses 
after co-culture of epithelial cells and macrophages [459].  
The timeline for the co-culture is depicted in Figure 44. Briefly, 16HBE and 
wdNHBE cells were differentiated in culture for 28 days. Meanwhile, PBMCs 
were collected and processed to create the MDM cells. On the day before co-
culture, cells were infected as previously described in chapter 2 (wdNHBE) and 
chapter 3 (MDM). On the day of co-culture, basal media was kept in the culture 
plates, and MDM were gently collected (using a cell lifter) and placed on with 
wdNHBE cells in a very small volume of media. The cells were then kept at the 
air-liquid interface for the throughout the rest of the infection time course. At the 
24h time point, basal media was collected and the apical side was washed 2 
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times with DPBS+0.2% BSA. The pooled washes were collected, spun down and 
the supernatant saved. The spun down pellet was combined with the remaining 
cells from the apical side of the transwell collected in Trizol. Four experiments 
were conducted in total, two with 16HBE cells, two with primary wdNHBE cells 
and each one with a separate PBMC donor.  
Within the lung, specific cytokines and chemokines have important 
functions early after IAV infection, including anti-IAV responses and resolution of 
inflammation. During experimental IAV infection in humans, early nasal cytokine 
and chemokine responses have been shown to include type-I Interferons and 
also pro-inflammatory cytokines such as TNF and IL6 [297, 460]. For example, 
infections with highly pathogenic IAVs can sometimes result in the excessive and 
dangerous production of pro-inflammatory cytokines and IFN known as a 
‘cytokine storm’, and may contribute to morbidity and mortality during the 
associated infection [461]. Infection of MDM with more pathogenic isolates, such 
as H5N1, have been shown to amplify those responses [307]. Because TNF and 
IFN have been shown to exert powerful anti-viral effects [462], we sought to 
determine whether infection by our different isolates in a co-cultured setting 
would amplify these pro-inflammatory signals and how the responses to those 
viruses compared to one another. Additionally, anti-inflammatory mechanisms 
following acute IAV infection may be a result of phagocytic APCs attempting to 
clear apoptotic epithelial cells, also known as ‘efferocytosis’. This mechanism of 
apoptotic cells being consumed by macrophages is associated with TGFβ and 
IL10 secretion, which are linked to reducing pro-inflammatory cytokines and 
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inflammation resolution after influenza infection [463, 464]. We sought to 
determine whether infection by our different isolates would amplify the anti-
inflammatory signals how this related to the pro-inflammatory TNF and IFN 
responses.  
Preliminary studies were done to compare the pro- and anti-inflammatory 
responses using 16HBE and MDM cells. After co-culture and infection, cells were 
collected in Trizol and total RNA was isolated and converted to cDNA, and the 
expression levels were determined by real time-PCR as described in the 
previous chapters. The ratio of pro- to anti-inflammatory cytokines in co-cultured 
16NHBE with MDM cells was determined by comparing the fold change over 
mock of the pro-inflammatory gene expression (TNF and IFNβ) to the anti-
inflammatory gene expression (IL10 and TGFβ). The ratios revealed a greater 
anti-inflammatory gene expression by KY136 compared to KY180 (Figure 45). 
The ratio for KY180 was 3.02 whereas for KY136 was 1.02 suggesting that 
KY136 has a more balanced response 24 h after co-culture compared to KY180. 
This preliminary data supports our hypothesis that KY136 may be better at 
resolving the infection in a co-culture setting. This experiment lacked the 
necessary controls, including infected macrophages and infected NHBE cells 
only. 
With these preliminary results, we moved forward with the more costly and 
technically challenging protocol to conduct the co-culture experiment with the 
necessary controls using primary human wdNHBE cells. The co-culture 
experiments have been done and the results of the ELISA and viral titers are still 
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pending. Briefly, cell culture supernatants were collected 24h after co-culture and 
the levels of TNF and IL10 will be compared by enzyme-linked immunosorbent 
assay (ELISA) using Ready-set-go ELISA kits (eBiosciences) as recommended 
by the manufacturer. Ratios of pro-inflammatory (TNF) to anti-inflammatory 
(IL10) will be determined by comparing concentrations of TNF to IL10 in 
supernatants for each condition.  
Our expected results for the primary cell co-culture experiment:  
1. KY136- greater clearance; lower ratio of TNF:IL10 (indicating an anti-
inflammatory, infection resolution state); lower virus compared to NHBE 
and macrophage alone 
2. KY180- delayed clearance of virus resulting in greater amplification of 
virus; greater ratio of TNF:IL10 (indicating a pro-inflammatory state, 
delayed viral resolution); higher virus compared to NHBE and MDM alone 
To broaden this model to become more translational, preliminary studies 
as described below have been conducted in our laboratory using a “diseased” 
epithelial cell culture model. During the 2009 pandemic, the most common 
underlying chronic conditions among hospitalized patients were respiratory 
disease, asthma, cardiac disease, and diabetes with a greater proportion of fatal 
cases occurring in those with these pre-existing conditions [288]. Future studies 
will employ this co-culture model to explore the interactions between infected 
wdNHBE (with pre-existing condition) and “recruited” MDM. We will evaluate how 
differences in epithelial condition may alter the MDM response to IAV and how 
this may relate to disease outcome.  
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Figure 44.  Timeline of co-culture experiment including description of all 
treatment and control groups. To evaluate the interactions between epithelial 
cells and macrophages we followed this experimental timeline.  
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Figure 45. Preliminary results from co-culture of infected 16HBE cells with MDM. 
(A) 16HBE cells were cultured for 21 days to create differentiated cells on 
transwell inserts. 16HBE cells were infected at an MOI of 3.0 with KY180, KY136 
or mock. 24h after infection, MDM were gently removed from their culture dish 
and placed on the apical side of the infected or un-infected 16HBE cells. At 24h 
and 48h time points, the cells were collected in Trizol. (B) RNA was extracted 
and expression of two anti-inflammatory (TGFB and IL10) and two pro-
inflammatory (IFNB and TNF) cytokines were evaluated by RT-PCR. Results 
reflect 2 replicates from one representative donor (1 done in total) and are 
expressed as mean ± SD fold change as compared to mock (uninfected) control. 
Fold change of 1, indicative of equal expression between infected and mock 
infected controls is indicated by the dotted line.  Significance as determined by 
ANOVA *, p < 0.05; **, p < 0.01; *** p<0.001.  
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ENVIRONMENTAL EXPOSURE AND SUSCEPTIBILITY TO IAV INFECTION  
For years, investigators have wrestled with the concept that 
environmentally-driven events during embryogenesis and early childhood could 
set the stage for the development of asthma and other obstructive airways 
disease. Epidemiological data strongly support this notion and highlights 
associations between smoking, respiratory infections, and impaired wound 
healing [465, 466]. However, the factors responsible for these events and the 
mechanisms of action involved are unclear and few studies have been published 
that examine this question for respiratory infections. Thus a pilot study was 
conceived in collaboration with Dr. Roman.  Dr. Roman has studied mechanisms 
by which nicotine effects airway development and the development of obstructive 
airways disease in mice [467]. Specifically, we hypothesized that nicotine may 
promote influenza infection by: (i) up-regulation of the receptors used for entry, 
(ii) increasing the levels of endogenous host trypsin-like serine proteases and 
thereby enhancing the proteolytic cleavage of viral HA and entry, (iii) modulating 
the innate immune defense molecules that inhibit replication, and/or (iv) 
modulating the antiviral mediators that limit viral replication and 
budding/shedding of virus particles [468, 469]. These pilot studies will provide 
guidance to future studies about the effects of chronic nicotine exposure and 
Influenza A infection as they relate to chronic airways dysfunction. We 
hypothesized that cigarette smoke (nicotine) suppresses anti-viral responses 
allowing for increased replication and increased susceptibility to infection.  
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Nicotine enhances influenza A infection in primary small airway epithelial 
cells. To ask whether nicotine enhanced influenza virus infection, we used 
primary human small airway epithelial cells (SAEC). Cells were purchased from 
Lonza and differentiated according to the manufacturer’s instructions. Cells were 
differentiated (wd) using the transwell system as previously described for 16HBE 
and wdNHBE. For infection studies, wdSAEC cells were pretreated with Nicotine 
(Sigma) for 4 hr at the following concentrations (0, 10, and 50 ug/ml).  The 
untreated and nicotine-treated cells were mock infected or infected with H1N1 
(BN59), H1N1pdm (KY136 and KY180) at an MOI of 3.0. At 24h post-infection 
apical washes were obtained to determine viral titers as described in Chapter 2 
by TCID50 assay. The addition of nicotine to SAEC is seen to create a cell type 
that is more permissive to infection by KY180 as compared to KY136 and BN59 
(Figure 46). These results suggest that the mechanisms by which nicotine may 
enhance KY180 infection may be virus specific.  
Future work may focus on how nicotine may affect host cell-dependent 
factors that control influenza virus attachment, uptake or PRR activation. Nicotine 
from cigarette smoke can suppress RIGI activation [468]. As discussed in 
Chapter 1, RIGI is an important PRR that activates downstream anti-viral 
responses such as type-I interferons. Without these signals, infected cells may 
not know they are infected and the virus could replicate uncontrollably.  
Based on our preliminary data, I show that KY180 replicated more 
efficiently in nicotine-treated cells suggesting it may escape the antiviral 
responses of the host. Based on our studies using entry inhibitors, we found that 
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KY180 enters through macropinocytosis whereas KY136 enters primarily through 
clathrin-mediated endocytosis. If viruses trafficking in macropinosomes escape 
TLR PRR recognition, then the suppression of RIGI by nicotine would lead to a 
complete evasion of recognition by KY180 in SAECs leading to increased viral 
replication. Future studies may utilize inhibitors to determine the mechanism of 
entry of these viruses in both nicotine treated and untreated cells as well as the 
expression of the PRRs within those cell types (before and after infection). We 
suspect differences in the mode of entry and PRR activation would explain the 
differences in infection in nicotine treated cells.  
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Figure 46. Human airway nicotine (environmental) exposure and susceptibility to 
IAV infection. Well-differentiated primary human small airway epithelial cells 
(SAEC) were pretreated with Nicotine (Sigma) for 4hr at the following 
concentrations (0, 10, and 50 ug/ml).  The untreated and nicotine-treated cells 
were mock infected or infected with H1N1 (BN59), H1N1pdm (KY136 and 
KY180) at an MOI of 3.0. At 24h post-infection apical washes were obtained to 
determine viral titers by TCID50 assay.  
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